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Abstract 
Dietary obesity, insulin resistance (IR) and type-2 diabetes mellitus (T2DM) are the 
major risk factors for the development of cardiovascular diseases (CVDs). Recent 
studies have shown that reactive oxygen species (ROS)-generating enzyme, NADPH 
oxidase (Nox), causes endothelial oxidative stress and is a prominent feature 
underlying vascular abnormalities of patients with IR and T2DM. The Nox2 has been 
found to be constitutively expressed in endothelial cells (ECs) and can be activated in 
diabetic condition. It is known that short chain fatty acids (SCFAs) i.e. acetate (NaA), 
propionate (NaP) and butyrate (NaB) are byproducts of bacterial fermentation of 
resistant starch in the colon and exert beneficial effects in improving insulin sensitivity, 
colonic cancer and reducing CVDs development. However, the effects of SCFAs in 
reducing endothelial oxidative stress and dysfunction are still unknown. In this project, 
I have investigated high glucose (0-30 mM for 24 h)-induced ROS production, Nox2 
activation levels, endothelial function (in terms of cell cycle regulation and capillary 
formation on matrigels), G protein-coupled receptor 43 levels (GPCR43, a SCFAs 
receptor) and the potential therapeutic effect of SCFAs in diabetes using cultured 
human pulmonary microvascular ECs (HPMEC). My results have shown that high 
glucose (30 mM) induced endothelial Nox2 activation and ROS production, which 
causes ECs cycle deregulation, cell apoptosis and capillaries broken down on 
matrigels. High glucose increases the levels of cyclin D, E, A and B, p53 and p16 
protein expression which lead to abnormal ECs cell cycle regulation, apoptosis and 
cell death. Adding NaA (5 mM, GPCR43 agonist) into the culture medium can increase 
the GPCR43 expression on ECs under high glucose conditions, inhibits Nox2-induced 
ROS production and activation as well as improves ECs function. In short, high 
glucose causes endothelial oxidative stress and dysfunction via Nox2-induced ROS 
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production. NaA activated GPCR43 inhibits Nox2 activation which reversed high 
glucose-induced damage on the ECs. SCFAs such as NaA may have the therapeutic 
potential for treating oxidative stress-related vascular complications in patients with 
IR, obesity and diabetes. 
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Chapter 1: General Introduction 
 
1.1 Cardiovascular Diseases and Their Consequences  
In 2008 an estimated 17.3 million people in the population died from CVDs which 
accounts for 30% of all deaths globally. Based on a recent report released by the 
World Health Organisation (WHO; global status report on non-communicable diseases 
2011), cardiovascular diseases (CVDs) are currently the major leading cause of death. 
In 2010/2011 the British Heart Foundation (BHF) reported that 1.6 million people were 
in-patients and CVDs attributed to 180,000 deaths in Britain (Coronary heart disease 
statistics 2012). Moreover, BHF also discovered that in the United Kingdom (UK) 
alone, more than 161,000 people died each year (http://www.bhf.org.uk/heart-
health/heart-statistics.aspx) due to this. These organisations also expected the 
percentage of total population morbidity caused by CVDs to increase yearly. The latest 
survey found that  in 2013, CVDs accounted for 31% of total death worldwide (figure 
1.1 – next page) (Cannon, 2013). Moreover, the financial healthcare burden 
associated with the CVD group of diseases had cost the NHS about £18.9 billion in 
2009 alone (http://www.bhfactive.org.uk/userfiles/Documents/economiccosts.pdf). 
This on its own shows how CVDs hugely affect society and the damage they have on 
the population as a whole. 
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Figure 1.1: Contribution of CVDs towards total deaths in the world (2013). CVDs account for 31% 
of the total deaths worldwide. This shows that CVDs are an important area to improve survivability and 
more research is needed in this area to treat and improve the overall disease and wellbeing of the 
population. Among others, out of the total deaths, 35% are caused by cerebrovascular diseases and 
42% die from ischemic heart diseases. These numbers are increasing yearly and more urgent treatment 
and solutions are needed to decrease this incidence.  
 
The majority of the mortality in the world’s population is caused by cardiovascular 
diseases (CVDs) and this is a growing medical problem worldwide. It is well known 
that the development of cardiovascular diseases (CVDs), for example atherosclerosis, 
involves the coexistence of several risk factors including hyperglycaemia, 
dyslipidaemia, and hypertension in the same individual. CVDs include all diseases 
related to the heart such as coronary heart disease (angina and heart attack), 
congenital heart disease, heart failure and stroke. It is also known as heart and 
circulatory diseases. CVDs are often related to multiple risk factors such as physical 
inactivity, poor diet consumption (high fat (hyperlipidaemia)), carbohydrate, sugar 
((hyperglycaemia) and salt), high intake of alcohol, smoking (poor lifestyle), lack of 
exercise (sedentary lifestyle) as well as genetic inheritance, and have an impact on 
life (Lakka and Bouchard, 2005). Other than these risk factors CVDs are also directly 
linked to a well-known chronic metabolic disorder known as diabetes mellitus (DM). It 
is divided into several categories and type-2 diabetes mellitus (T2DM) is the most 
common and dominant metabolic syndrome affecting approximately 200 million 
3 
 
people in the population and estimate to increase to 366 million by 2030 (Kalofoutis et 
al., 2007). Apart from these metabolic syndromes, another risk factor that contributes 
to the worsening of existing metabolic disorders and CVDs is obesity (Furukawa et al., 
2004). Obesity, especially visceral adiposity, is closely associated with increase of the 
presence of pro-inflammatory cytokines and chemokines in the blood circulation and 
thus can be considered as an inflammatory condition (Boden et al., 2005). Organs 
such as liver, skeletal muscle, pancreas and adipose tissue play an important role in 
regulating and maintaining normal metabolic function of the body (Jensen, 2006). 
Interruption in the regulation and cross-talk between these organs may lead to 
disruption of glucose homeostasis, insulin resistance (IR) and T2DM (Scheen, 2003). 
Thus, this study is designed to focus on a small fraction within this larger disease 
group. Our group is dedicated and aimed at treating T2DM, a known risk factor for the 
development and worsening of CVDs and we aim to seek possible treatment by using 
natural products available in our daily food intake. 
 
1.2 Diabetes Mellitus: The Chronic Metabolic Syndrome, glucose metabolism and 
insulin resistance 
DM is defined as seeing constant elevation of blood glucose (hyperglycaemia) 
chronically (fasting blood glucose more than 7.0 mmol/l) and if it is not well controlled, 
in the long run this will cause multiple organ damage including the blood vessels, and 
death is the main end point for this disease (Expert Committee on the and 
Classification of Diabetes, 2003). Mainly, it is one of many chronic metabolic diseases 
affecting middle age onwards for the population in a society. This chronic metabolic 
syndrome is often accompanied by peripheral organs insulin resistance (IR) at some 
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point during the progression of the disease. Commonly, organs such as the liver, 
pancreas, adipose tissue and skeletal muscle are affected in the development of this 
metabolic disorder. In the long run, it is either the body is not responsive towards 
insulin action or there is a defect in the responsiveness of insulin receptor towards its 
ligand thus these conditions often lead to IR (Scheen, 2003). Risk factors other than 
genetic inheritance such as, inactive lifestyle, unhealthy diets, ageing and T2DM often 
have a linear link towards another metabolic disorder known as obesity. Obesity is a 
state where the body mass index (BMI) is 30kg/m2 or more (Haslam and James, 2005).  
Combined, all these risk factors lead to the contribution and worsening of T2DM. DM 
is one of the key risk factors for the development of CVDs, for example atherosclerotic 
vascular disease, coronary heart disease (CHD), cerebrovascular disease and 
peripheral vascular disease which is a major concern of the world at the moment 
(figure 1.2 – next page)  (Laakso and Lehto, 1998). 
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Figure 1.2: Vascular damage and the worsening of CVDs development through metabolic 
disorders. The increase in unhealthy diets consisting of high salt, carbohydrate (includes various 
sugars) and fat added together with a sedentary lifestyle and age as another risk factor in the long term 
leads to the development of metabolic diseases such as T2DM, atherosclerosis and others that 
damages the vascular system in the body and eventually enhance the development of cardiovascular 
diseases. 
 
T2DM is a bipolar disease characterised by a defect in both insulin secretion and 
function; the combined effect accelerates the increase of plasma glucose level 
(Scheen, 2003). The causes for T2DM are varied and include both genetic and 
environmental elements that effect both beta-cell function in the pancreas and other 
insulin sensitive tissues (e.g. skeletal muscle, liver and adipose tissue) (Delbin and 
Trask, 2014, Scheen, 2003). On the other hand, because of the defects of insulin 
action on insulin targeted tissues, T2DM is also commonly associated with abnormal 
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carbohydrate, fat and protein metabolism (Boden and Laakso, 2004). Most obese with 
central visceral adiposity individuals are positively associated with T2DM (Scheen, 
2003). Together, insufficient amount of insulin and or combination of IR, causes 
uncontrolled hepatic glucose output and reduced uptake of glucose by skeletal muscle 
with reduced glycogen synthesis and thus leads to hyperglycaemia (Roden, 2006, 
Wilcox, 2005). However, at a chronic stage of IR in T2DM patients, most of them 
experienced unexplained weight loss (Kelley, 2003). Later, this unexplained weight 
loss was found to have a direct link with insulin signalling and the control of skeletal 
muscle mass. It was thought to be the increase of insulin in the circulation has the 
ability to suppress proteolysis and decrease skeletal muscle protein degradation and 
when insulin sensitivity is compromised this has an adverse effects on the skeletal 
muscle mass (Honors and Kinzig, 2012). Causes of death and disability in people with 
DM are principally from vascular diseases. Chronically the negative manifestation 
affects microvasculature and includes atherosclerosis and medial calcification as well 
as defects in the microvasculature such as retinopathy and nephropathy (Creager et 
al., 2003). In the early onset of diabetes, intracellular hyperglycemia causes abnormal 
vascular blood flow, reduced blood vessel vasodilators and an increase in vascular 
vasoconstrictors as well as an increase in permeability between cells of the circulatory 
system (Brownlee, 2001). This initiates endothelial dysfunction, microvascular cell 
loss, programmed cell death and progressive occlusion of the capillary due to 
extracellular matrix overproduction induced by growth factors such as transforming 
growth factor-β (TGF-β) and deposition of plasma proteins. With time, these changes 
lead to oedema, atherosclerosis progression, ischemia and hypoxia-induced 
neovascularization in the retina, proteinuria, glomerulosclerosis in the kidney and 
degeneration of peripheral nerves (Banerjee and Vats, 2014).   
7 
 
1.2.1 Glucose Metabolism  
Glucose (C6H12O6) is a polar, water soluble small monosaccharide molecule. It is used 
to provide energy in the form of ATP by various living cells. It is carried by the blood 
arterial system to the capillaries which supplies it to various tissues in the body. There 
are at least three and up to six types of Na+–dependent  glucose transporters (SGLT–
1 to 6) and thirteen members of facultative sugar transporters (GLUT–1 to 12 and H+–
coupled myo–inositol transporter (HMIT)) have been identified (Wood and Trayhurn, 
2003). To date, there are two major types of glucose transporters reported expressed 
in endothelial cells (ECs); GLUT–1 and GLUT–4 where GLUT–1 have been found to 
be abundantly expressed in ECs (McCall et al., 1997, Lee and Klip, 2012, Alpert et al., 
2005). A study by Alpert et al. found that high glucose at 23 mM significantly 
downregulated glucose transport and GLUT–1 transporter mRNA expression in 
vascular ECs for up to 48 hours of exposure. It was suggested that the explanation for 
the high glucose–dependent downregulation of glucose transport in vascular ECs is 
due to its low rate of glucose uptake that may lead to slow accumulation of glucose 
metabolites which transduce the downregulatory response and this downregulatory 
response may also be a protective mechanism by cells against deleterious effects of 
high glucose influx during a long term or chronic hyperglycemia state (Alpert et al., 
2005). Similarly, a study by Rajah et al. also found a similar result where exposure of 
30 mM high glucose significantly downregulated GLUT–1 expression in bovine brain– 
and rat heart–derived ECs. It is suggested that the slow development of glucose-
induced downregulation in vascular ECs is linked to slow basal rate of glucose 
transport in cells (Rajah et al., 2001). Meanwhile, under hypoxic–induced stress, Yeh 
et al. found that GLUT-1 expression was upregulated through glioma–induced 
secretion of vascular endothelial growth factor (VEGF) in rat brain ECs (Yeh et al., 
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2008). These data showed that the GLUT–1 glucose transporter may be one of the 
main transporters involved in glucose metabolism in the vasculature and the 
downregulation under the hyperglycemia condition pointed out its involvement in the 
DM state. Translocation of glucose transporters to the plasma membrane to facilitate 
glucose uptake by cells from the blood circulation was led by the action of insulin 
(Bryant et al., 2002). After glucose being transported into cells, glucose undergoes 
oxidation also known as the breakdown of glucose through the glycolysis pathway to 
form Glucose–6–phosphate, which is a phosphorylated molecule that is unable to 
cross the cell membrane and ends up trapped in cells. Thereby, this molecule is 
committed as the initial substrate to further subsequent actions down the metabolic 
pathways depending on the current needs of the body. For example, when the cells 
are in excess of glucose, this excess will be converted into other forms of storage such 
as glycogen in the liver and muscle through the glycogenesis pathway, or converted 
into pyruvate then to acetyl-CoA into triglycerides which are stored in adipose tissue 
through the lipogenesis pathway into the lipid metabolism downstream (Nussey and 
Whitehead, 2001). Alternatively, when the body is in need of energy, other substances 
can be converted into glucose through the process known as gluconeogenesis. After 
glucose has run out of supply, the initial form of storage that will be broken down and 
used as an energy supply is glycogen through glycogenolysis and when this storage 
has run out, the body turns to breaking down fat cells through lipolysis and finally at 
the end stage if energy is still insufficient, the body will breakdown muscle cells (protein 
degradation) into amino acids as another alternative energy source. Furthermore, 
these amino acids are converted into pyruvate or ketoacids that can be further used 
within the glucose metabolism pathway to generate energy for the cells (Nussey and 
Whitehead, 2001).   
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1.2.2 Diabetes Mellitus and Insulin Resistance  
In the fed stage, ingestion of food in the forms of carbohydrates and fat into the colon 
get processed and absorbed into the blood circulation that flow to all parts of the 
organs in the body including metabolic activity related organs such as digestive 
organs, liver, pancreas, adipose tissue and skeletal muscle (Delbin and Trask, 2014). 
Normally, the pancreas senses the increase of glucose or amino acids (ketones) in 
the circulation and secretes insulin which has an anabolic actions on glucose 
metabolism that triggers tissues to take up glucose from the circulation and break it 
down either for energy usage or to store the excess of glucose in the form of glycogen 
or as fat through pathways including glycolysis, glycogenolysis or the lipolysis 
processes respectively (Nussey and Whitehead, 2001, Wilcox, 2005). Meanwhile, 
glycogen is made from many glucose molecules that are joined together to form a 
compact and highly branched spherical structure that is stored at two major sites, the 
liver and skeletal muscle (Kreitzman et al., 1992). On the other hand, when the body 
is in need of energy, the body will switch to the catabolic phase by stimulation of 
pancreas α–cells to secrete glucagon and obtain energy from glycogen storage 
through the glycogenolysis pathway and if still necessarily in need of energy then by 
the gluconeogenesis pathway breakingdown other storage such as fat or protein 
(proteolysis) to gain energy in the form of ATP. This is the normal process of the body 
in metabolising glucose (figure 1.2.1). 
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Figure 1.2.1: Uptake of glucose and glucose metabolism by cells. During the fed state, glucose 
level is increased in the blood circulation and the pancreas senses this increase and thus stimulates 
the release of insulin molecules into the circulation. Insulin binds to insulin receptor on cells to enhance 
the uptake of glucose from the circulation into cells through glucose transporters. Cells take up glucose 
either to use it to produce energy in the form of ATP through glycolysis or to store this excess of glucose 
in the form of glycogen in the liver or skeletal muscle or fat in adipose tissue. 
 
In the DM state, the defects often occur when there is not enough insulin supply 
(insulin deficient) to compensate with the uptake of high levels of glucose or there are 
defects on the insulin receptor at peripheral tissues that don’t response to insulin 
action which is also known as IR. This is a state where cells are no longer responding 
to the normal actions of the hormone insulin. It happens when insulin levels are 
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sufficiently high over a prolonged period of time, causing the body’s own sensitivity to 
the hormone to be reduced. Obesity is one of the risks in developing IR and T2DM. 
Under normal conditions, pancreatic β-cells increase insulin secretion sufficiently to 
maintain normal blood glucose tolerance. In the obese state, adipose tissue releases 
a high amount of circulating free fatty acids (NEFA), glycerol, hormones, pro-
inflammatory cytokines and other substances which are factors that contribute to the 
development of  DM and IR (Al-Goblan et al., 2014, Kahn et al., 2006). Adipocytes 
also release pro-inflammatory factors such as tumour necrosis factor-a (TNFa), 
interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and additional 
products of macrophages and other cells within the adipose tissue that may have a 
role in the development of IR (Kahn et al., 2006). Several researchers have proposed 
that increased non-esterified fatty acid (NEFA) in the circulation causes an increased 
intracellular content of fatty acid metabolites such as diacylglycerol (DAG), fatty acyl-
co-enzyme A (fatty acyl-CoA), and ceramides. Overload of these intracellular fatty acid 
metabolites will diminish the downstream event of insulin receptor signalling thus 
leading to IR (Kahn et al., 2006). This state is often accompanied by dysfunction of 
pancreatic β-cells and thus results in the failure to control blood glucose to a normal 
level. Metabolic disorders are often associated with increased levels of low–grade 
inflammation molecules including interleukin (IL) 6, IL-1 and tumor necrosis factor–
alpha (TNF–α) at various insulin target tissues such as the liver, adipose tissue and 
the skeletal muscle that further enhance IR in T2DM (Puddu et al., 2014). In time, the 
combination of insulin deficiency, IR and various inflammatory molecules circulating in 
the blood circulation can lead to various defects in the body such as increase in the 
release of hepatic and renal glucose production and the breakdown of adipose tissue 
into free fatty acids that release into the circulation through lipolysis and cause the 
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liver to oxidise fatty acid into ketone bodies that further result in ketonemia and 
metabolic acidosis. However, when the level of glucose is extremely high and the 
insulin produced is not enough to compensate high levels of glucose in the circulation, 
the body is in a state of glucotocixity and ketoacidosis by fatty acid oxidation that 
eventually can cause various symptoms in patients including polyuria, polydipsia, 
polyphagia, weight loss, dehydration, tachycardia, hypotension, alteration in mental 
status, shock and ultimately coma (Kitabchi et al., 2004).  
 
 
1.3 Vascular Oxidative Stress and Damage: Insight of the Role of NADPH Oxidase 2 
(Nox2)-Induced ROS Generation and Endothelial Cell Dysfunction 
The development and the worsening of metabolic disorders especially in T2DM that 
normally leads to atherosclerosis plague formation and other pathogenesis of 
cardiovascular diseases normally involve defects and stress mechanisms which 
interplay between several organs in the body including the liver, pancreas, adipose 
tissue, skeletal muscle, immune cells and ECs in the vasculature. Of course, all of 
these organs are connected to each other through another important organ which is 
the vascular circulatory system. Within this vasculature system, which consists of a 
single layer of cells known as the ECs that line and cover the walls within the lumen 
of every blood vessel. In this study we only focus on the effects of high glucose-
induced oxidative stress on the vascular ECs that trigger the development of 
endothelial cell dysfunction and its subsequent complications in T2DM.  
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1.3.1 Risk Factors for Cardiovascular Diseases  
Risk factors in the pathogenesis of CVDs for example obesity, IR and T2DM are 
commonly linked to the increase in ROS production in affected organs and cells. 
Pathophysiology of disorders such as hyperglycaemia, hypercholesterolemia and 
dyslipidemia causes the increase of ROS production in various organs (Cade, 2008, 
Wu and Wu, 2006, Hsu et al., 2011). Moreover, metabolic disorders are often 
associated with increased levels of low–grade inflammation molecules including 
interleukin (IL) 6, IL-1 and tumor necrosis factor–alpha (TNF–α) at various insulin 
target tissues such as the liver, adipose tissue and the skeletal muscle that further 
enhance IR in T2DM (Puddu et al., 2014). These inflammatory molecules further 
activate the resting state of ROS producing enzymes such as NADPH oxidase subunit 
2 (Nox2) which is mainly expressed in ECs to overly produce ROS and further worsen 
the disease condition (figure 1.3 – next page) (Fan et al., 2014, Jiang et al., 2011).   
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Figure 1.3: The resting state and activated state of NADPH oxidase 2 (Nox2) enzyme molecule 
structure. In the unstimulated state, cytosolic subunits remain uncoupled in the cytoplasm. However, 
under the activated state, cytosolic regulatory subunits assemble with each other, migrate and then 
bind to the membrane subunits to form a functional NADPH enzyme. This functional enzyme utilises 
the electron from NADPH in the cytoplasm as a substrate to generate superoxide at the extracellular 
membrane (Li and Shah, 2004). 
 
Oxidative stress plays critical roles in the pathogenesis of various diseases. In the 
diabetic condition, oxidative stress impairs glucose uptake in muscle and fat cells at 
the same time decreases insulin secretion from pancreatic β–cells. Increased 
oxidative stress also underlies the pathophysiology of hypertension and 
atherosclerosis by directly affecting the ECs on the vascular wall (Furukawa et al., 
2004). Metabolic stresses from intracellular and extracellular signalling molecules can 
be activated from inflammatory signalling pathways and the increase in glucose 
metabolism can also lead to a rise in ROS production which further enhances 
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activation of inflammatory pathways (Wellen and Hotamisligil, 2005, Zhang et al., 
2011).  
 
1.3.2 Endothelial Cell Function  
ECs play a huge range of roles in regulating vascular function. Now with accumulating 
knowledge on their structure and functional properties, they are not just known as 
being a passive membrane or barrier but a complex tissue with a complex functions 
depending on the specific needs, time and location (Michiels, 2003). The ECs are main 
regulator of vascular homeostasis but also in physiological or pathological processes 
for example thrombosis, inflammation, vascular wall remodelling or vascular tone. 
Since they are the interface between blood and tissue, they are mostly susceptible to 
changes in blood composition and blood flow. Thus, ECs are the main responder to 
all of these changes and play a central role in the mechanisms underlying the 
development of vascular disorders (Michiels, 2003). The endothelium is known as one 
of the critical organs that has an enormous impact on the effects of increased ROS 
production that can lead to pathophysiology of several metabolic disorders and CVDs 
(Hadi and Suwaidi, 2007). In these disease states, it often causes endothelium 
dysfunction (Xu and Zou, 2009, Li and Shah, 2001). ECs produce ROS for example 
O2.- and H2O2 that can modulate redox-sensitive signalling pathways and gene 
expression. A low level of ROS is important in maintaining normal physiological 
activities since ROS acts as a secondary messenger (Thakur et al., 2010). However, 
in the long term, high levels of ROS exceed the antioxidant level and may lead to 
disease setting commonly known in CVDs. 
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1.3.3 Vascular Oxidative Stress: Reactive Oxygen Species and Antioxidants Available 
ROS is important for both physiological and pathogenesis of various CVDs. It was first 
discovered in phagocytes and the production of ROS can be triggered by certain 
stimulants or during an infection. Phagocytes use ROS to fight infections (e.g. 
oxidative burst) and non-phagocytes cells use it as a signalling molecule to maintain 
normal cellular homeostasis (Brandes et al., 2010). A low level of ROS is essential to 
regulate normal cellular functions (Li and Shah, 2004). When there is an imbalance in 
ROS production and it overwhelms the antioxidant level in the body, this causes stress 
to the body known as oxidative stress as shown in figure 1.3.3. In the long term, excess 
oxidative stress can cause damage and modify biologic macromolecules for example 
proteins, DNA, lipids and carbohydrates and in the long run may leads to pathogenesis 
of CVDs (Li and Shah, 2004). Endothelial dysfunction is one of the key factors in the 
initiation of cellular events that lead to the development of vascular complications in 
diabetes and hypertension. Increased production of pro-inflammatory cytokines and 
vasoconstrictors leads to endothelial dysfunction, which in turn increase vascular tone 
which contributes to hypertension, vascular and cardiac remodelling, culminating in 
microvascular, macrovascular, as well as renal damage (Wong et al., 2010). Chronic 
exposure to certain factors such as high glucose, elevated lipid (e.g. LDL) 
concentration, mechanical or chemical sheer, abnormal blood flow and rate causes 
endothelial stress and dysfunction in the bloodstream (Hartge et al., 2006). These 
stresses are highly associated with impairment of physiologic nitric oxide (NO) 
production and cause chronic inflammation to ECs lining the blood vessels. Increase 
in fatty acid adiposity as well as high glucose both activate NADPH oxidase reactive 
oxygen species (ROS) production in ECs. In the diabetes condition, hyperlipidaemia 
and hyperglycaemia increase ROS production and thus leads to endothelial 
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dysfunction as well as atheroma accumulation, thrombus formation and platelet 
aggregation, which enhances atherosclerosis development and may lead to other 
CVDs (Xu and Zou, 2009). 
 
 
Figure 1.3.3: Pathophysiological state of ROS in cells. ROS in normal and abnormal state. Under 
physiological conditions, ROS is used as host defence in cellular signalling, regulation of gene 
expression and cell growth. In pathological conditions where ROS level is increased and overwhelms 
the antioxidant level it can lead to increased oxidative stress and this condition in the long run 
contributes to disease development particularly CVDs (Li and Shah, 2004). 
 
Numerous reactive molecules and free radicals derived from molecular oxygen are 
known as ROS. All aerobic species produce oxygen based radicals as by-products 
during aerobic respiration in the mitochondrial electron transport chain, 
oxidoreductase enzymes, and breakdown or oxidation of metals. The oxygen atom 
has two unpaired electrons in separate orbitals in its outer electron shell. Radical 
formation is more susceptible with this electron structure and through the additional of 
electrons leads to the formation of numerous ROS molecules including superoxide 
(O2-.), hydrogen peroxide (H2O2), peroxynitrate (ONOO-), hydroxyl radicals (.OH) and 
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NO (Li and Shah, 2004). Phagocytic and non-phagocytic cells produce ROS. 
Phagocytic cells use ROS to protect and fight against infection and non-phagocytic 
cells use ROS as signalling molecules to modulate normal function of the body for 
example proliferation, apoptosis, and ECs activation and adhesion (Ray and Shah, 
2005, Li and Shah, 2004). ROS can be generated by several sources and these 
include NADPH oxidase, xanthine oxidase, cytochrome P450, uncoupled nitric oxide 
synthase (NOS) and mitochondria (Li and Shah, 2004). Increase in activation of these 
enzymes increases the oxidative state (oxidative stress) in the cells and in long term 
can contribute to the development of CVDs.  
 
Oxidative stress is an imbalance between oxidant production and the antioxidant 
system with their capacity to prevent ROS from causing oxidative injury. This 
antioxidant system is important as a protective system against damaging oxidant. It 
converts harmful oxidant into a less harmful state for example O2.- to H2O2 and in the 
latter state it is further degraded into water (figure 1.3.4) (Rada and Leto, 2008). 
Antioxidants are categorised into two groups; non-enzymatic and enzymatic 
antioxidant. Enzymatic antioxidants include superoxide dismutase (SOD), catalase, 
thioredoxin system, glutathione peroxidase and heme oxygenase. The non-enzymatic 
molecules are for example uric acid, ascorbic acid (vitamin C), α-tocopherol (vitamin 
E) and glutathione (GSH) (Thannickal and Fanburg, 2000, Li and Shah, 2004). The 
outcome of failing to maintain the balance between the production of ROS and the 
removal of ROS by the antioxidant system can be severe. Over production of ROS 
may cause damage to macromolecules for example by damaging genetic material, 
causing lipid peroxidation in cell membranes and inactivating membrane bound 
enzymes (Thannickal and Fanburg, 2000, Li and Shah, 2004). This can lead to 
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pathogenesis of disease such as atherosclerosis, hypertension, diabetes 
vasculopathy, aging, cancer and heart failure. These diseases have been related to 
the markedly increased activity of ROS generation in various organs (Thannickal and 
Fanburg, 2000, Li and Shah, 2004). 
 
1.3.4 Vascular NADPH Oxidases and Endothelium Nox2 
The NADPH oxidase enzyme was first discovered in phagocytes that utilised ROS to 
fight against infection through the oxidative burst. A rare genetic disorder in patients 
with deficiency in NADPH oxidase is known as chronic granulomatous disease (CGD) 
where the respiratory burst was diminished in phagocytes and the patient was unable 
to fight against infection and kept having recurrent pyogenic infection, 
lymphadenopathy, and hypergammaglobulinemia (Bedard and Krause, 2007). ROS 
contributes to numerous aspects of cardiovascular diseases including ischemia 
reperfusion injury, scavenging of NO or stimulation of inflammatory and hypertrophy. 
In the cardiovascular system, NADPH oxidases of the Nox family are differentially 
expressed, induced or activated by cardiovascular risk factors and significantly 
contribute to the oxidative burden of vascular diseases. Depending on the type of 
ROS, their concentration, cellular environment, and the susceptibility of the individual 
cell, in high levels, ROS can be toxic, activate stress responses, elicit specific 
signalling reactions or can even be tolerated (Brandes et al., 2010).  
 
In mammalian cells, NADPH oxidase consists of seven family members: Nox1, Nox2, 
Nox3, Nox4, Nox5 and Duox1 and Duox2. These Nox proteins differ in their mode of 
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activation, expression, and/ or interaction with other proteins as well as in the type of 
ROS being produced. Nox-type NADPH oxidase may need to interact with at least two 
proteins  including GTPases, cytosolic phox proteins, and proteins of the cytoskeleton 
to activate (Brandes et al., 2010). In the cardiovascular system, Nox1, Nox2, Nox4 
and Nox5 have been reported to be significantly expressed. The Nox enzymes are 
expressed in a small number of tissues at high levels but show intermediate to low 
level expression in many other tissues (Bedard and Krause, 2007). Nox3 expression 
is only high in the inner ear and the expression of Doux proteins is restricted to 
epithelial cells, whereas in disease conditions such as diabetes, hypertension, 
atherosclerosis, and IR aberrant expressions may occur (Brandes et al., 2010, Bedard 
and Krause, 2007).  
 
Proteins that are responsible for ROS production in phagocytes were identified and 
these comprised of two compartments, the membrane subunits and the cytosolic 
subunits. The integral membrane subunits consisted of heterodimer gp91phox (Nox2) 
and p22phox that makes up cytochrome b558 that constitute the catalytic core of the 
enzyme and it exists in a dormant state in the absence of other subunits. The 
regulatory cytosolic subunit is comprised of GTP-binding proteins Rac, p47phox, 
p67phox, and p40phox (Bedard and Krause, 2007, Brandes et al., 2010). During the 
resting state, the cytosolic compartment remains associated with each other. 
However, upon stimulation, p47phox becomes phosphorylated and binds to other 
cytosolic subunits (p67phox, and p40phox and Rac) which then translocate to the 
membrane and activate the catalytic subunits (Nox2 and p22phox) to form a functional 
NADPH oxidase enzyme. This active enzyme complex utilises the electron from 
cytoplasmic NADPH to form superoxide in the extracellular membrane as previously 
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shown in figure 1.3.4 (Groemping and Rittinger, 2005, Brandes et al., 2010, Bedard 
and Krause, 2007). 
 
 
 
 
 
 
Figure 1.3.4: the production of superoxide and its degradation by antioxidant enzymes. Activated 
NADPH oxidase enzyme in ECs in this case is the Nox2 enzyme as it is the major contributor to 
superoxide production during the disease state. The activated enzyme converts cytoplasmic NADPH 
into NADP+ and emits electrons that are transported through the plasma membrane and bind to oxygen 
molecules resulting in the formation of superoxide anions at the extracellular space. The main 
component of the complex is the flavocytochrome b558 which is an embedded heterodimer that consists 
of the entire electron transport machinery. This complex consists of a large glycoprotein containing the 
Nox2 subunit (also known as gp91phox) and a smaller protein known as p22phox. Superoxide or 
hydrogen peroxide are immediately transformed into other derivatives either spontaneously or are 
catalysed by antioxidant enzymes for example superoxide dismutase (SOD) and catalase so that the 
reactive molecule of oxygen does not cause harm to the cells as oxygen can react with a wide range of 
elements and organic compounds (Rada and Leto, 2008, Li and Shah, 2004).  
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A large number of studies on the role of NADPH oxidases in the cardiovascular 
disease condition have been conducted. Evidence shows that in particular endothelial 
dysfunction, β-cell destruction, hypertension, hypertrophy, angiogenesis, and 
remodelling processes involve Nox2 proteins that contribute to diseases such as 
atherosclerosis, IR and T2DM (Gao and Mann, 2009, Kolluru et al., 2012). A study 
from Edward et al. looking at the effect of endothelium specific IR on endothelial 
function in vivo shows that transgenic mice with over expression of mutant human 
insulin receptor have increased superoxide generation as well as increased mRNA 
expression of NADPH oxidase Nox2 and Nox4 isoforms (Duncan et al., 2008). Another 
study by Bendall et al. found that Nox2 transgenic mice have increased total Nox2 and 
p22phox mRNA, and protein levels as well as elevated superoxide production in the 
aortas as compared to wild type mice upon acute and chronic angiotensin II 
administration (Bendall et al., 2007). The risk factors for cardiovascular diseases are 
known to provoke certain degree of systemic oxidative stress per se. The risk factors, 
hypercholesterolemia and hyperglycemia, have been shown to increase the vascular 
ROS production by activating endothelial Nox2 (Brandes et al., 2010, Li and Shah, 
2004). High glucose and free fatty acids have been shown to activate NADPH oxidase 
activity on ECs and vascular smooth muscle cells (VSMC) through protein kinase-C 
(PKC) activation (Brandes et al., 2010, Kolluru et al., 2012, Cohen, 2004). Moreover, 
high glucose–induced ROS is frequently linked to β-cell dysfunction. Sprague-Dawley 
rats were fed a high fat diet for 24 weeks to induce diabetes and showed increased 
glucose levels with concomitant increased ROS production in the blood (Yuan et al., 
2010). A high concentration of glucose (33.3 mM) was used to look at ROS generation 
with NIT-1 cells and Nox2 expression was found to be elevated in these cells (Yuan 
et al., 2010). Importantly, glucose-induced insulin expression and the secretion in NIT-
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1 cells can be saved through siRNA-mediated knockdown of Nox2. High glucose 
concentration led to apoptosis of β-cells through the activation of p38 MAPK and p53. 
High glucose also activates JNK and protein kinase B (Akt/PKB) inhibition that led to 
β-cell dysfunction (Yuan et al., 2010). It is suggested that Nox2-derived ROS could 
play a crucial role in high glucose-induced β-cell dysfunction through PTEN-dependent 
JNK activation and Akt inhibition (Yuan et al., 2010). Major research on this area 
suggested that NADPH oxidase Nox2 activation caused an increase in ROS 
production and by inhibiting the Nox2 activation it is possible to significantly reverse 
the effects of ROS in diabetes, IR and CVDs (Judkins et al., 2010, Xiang et al., 2010, 
Jiao et al., 2012, Li et al., 2012, Jiang et al., 2011). 
 
Nox-2 derived ROS plays a key role in damaging insulin receptor and endothelial 
function in metabolic related diseases such as dietary obesity in middle age and 
above. Targeting Nox2 could represent a valuable therapeutic strategy in preventing 
and improving metabolic syndrome.  
 
1.4 ROS and Cell Cycle Progression 
Cell proliferation is regulated by the cell cycle process which is divided into a series of 
phases. The process within the cell cycle phases is a highly regulated sequence of 
events that leads to the reproduction of a cell. Usually, cells proliferate to increase the 
number of cells and repair any faults within cells as a result of growth and division. 
This process occurs depending on the surrounding conditions and it is a requirement 
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for the cell to proceed down this process and this includes nutrients level, stress or if 
the cell is in a starvation state.  
 
1.4.1 Cell cycle Progression and Its Mechanisms 
Cell cycle progression is divided into a series of distinct and more easily managed 
events; first, duplication of the cell’s contents, and second, equal distribution of the 
contents, by division, into a pair of daughter cells (Albert B, 2002, Shen et al., 2008). 
The first part of the cycle and generally by far the longest is devoted to duplication of 
cell’s components. During this event, cell components such as cytoplasmic organelles, 
membranes, structural proteins and RNAs are replicated continuously throughout the 
cell cycle process which results in the gradual doubling of cell size by the end of the 
cycle (Albert B, 2002). Duplication and division of cellular components must be 
achieved with extreme precision and reliability over countless generations. To ensure 
the correct order of events, the eukaryotic cell contains a complex regulatory network 
known as the cell cycle control system that controls their timing and coordination. This 
control system is essentially a robust and reliable biochemical timer that is activated 
at the beginning of a new cell cycle and is programmed to switch on cell cycle events 
at the correct time and in the correct order. The cell has its own mechanism of 
monitoring the progress of cell cycle events and transmitting this information to the cell 
cycle control system (Murray, 2004).  
 
The complex mechanisms of the cell cycle process have been widely studied in 
treating cancer cases. This extreme precision in cell cycle progression relies on the 
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cell’s ability to translate extracellular signals in order to efficiently replicate DNA and 
divide. This process is divided into several phases where G1 and G2 phases are the 
restriction checkpoint “gaps” in the cell cycle that occur between two phases, the DNA 
synthesis and the mitosis phase. In the G1 phase, the cell is preparing for DNA 
synthesis and drives into the S phase to synthesis DNA where cells will have an 
aneuploidy DNA content between 2N and 4N. The cell then goes into the G2 
checkpoint phase where cells are preparing for mitosis in the next phase (M phase). 
Cells in the G0 phase are normally not active and stay senescent however cells in this 
phase have the potential for division when the conditions are right (figure 1.4.1A) 
(Schafer, 1998, Bresnahan et al., 1996). Furthermore, this process is positively 
governed by cyclins (D, E, A and B) and cyclin-dependent kinases (CDKs) (4, 6, 2 and 
1) and negatively inhibited by CDK inhibitors (CDKIs) (figure 1.4.1A – next page) 
(Vermeulen et al., 2003, Bertoli et al., 2013).  
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Figure 1.4.1A: Normal cell cycle progression within a cell. The normal cell cycle progression within 
a cell consists of several phases including G0 (senescence), G1 (checkpoint 1), S (synthesis), G2 
(checkpoint 2) and M (mitosis) phase. This process is positively governed by the interactions between 
cyclins (D, E, A and B) and cyclin–dependent kinases (CDK) (4, 6, 2 and 1) to form an active complex 
to drive the process. Nonetheless, this process is inhibited by the presence of CDK inhibitors (CDKIs) 
that will inhibit cyclin and CDK complex formation thus abandon cell progression (Braun-Dullaeus et al., 
1998).  
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Cyclins are CDK binding partners which are required for kinase activity where CDKs 
respond to the extracellular signals and are responsible for driving cells through the 
cell cycle stages (McDonald and El-Deiry, 2000, Neganova and Lako, 2008). Both of 
these elements are crucial for DNA synthesis and cell division. Disruption and 
alterations in their function may cause disruption of normal cell growth and apoptosis 
and to the later extent result in carcinogenesis (Johansson and Persson, 2008). To 
maintain normal and efficient progress in place, proteins such as p53, p21, p16 and 
cdc25 will be upregulated if there are abnormalities within the cell cycle process and 
these proteins will inhibit the cyclin-CDK complexes and cause discontinuation of cell 
cycle progression throughout various stages (Schafer, 1998, Stein et al., 1999). The 
most investigated cyclin-CDK complexes inhibitors are the p16 and p21 families. The 
family of p16 consist of p15, p16, p18 and p19 which inactivate only G1 CDKs, CDK4 
and CDK6 (Schafer, 1998, Stein et al., 1999).  
 
On the other hand, the p21 family consists of waf1 (also known as p21, cip1 and pic1), 
p27 (kip1) and p57 (kip2). This family of proteins are also important in the regulation 
of the G1 cell cycle phase (Schafer, 1998, Braun-Dullaeus et al., 1998). Both of these 
families of proteins bind to cyclins thereby preventing CDK from phosphorylating 
retinoblastoma protein (pRb) and induce the release of E2F for protein translation. In 
contrast to p16, p21 but not p27 and p57 also binds and inhibits proliferating cell 
nuclear antigen (PCNA), a DNA polymerase δ subunit, which is responsible for DNA 
repair and replication (Schafer, 1998, Braun-Dullaeus et al., 1998). The protein PCNA 
being produced primarily during the S phase and its expression and level is the highest 
during the S phase with little to no expression in the G1 phase, intermediate levels in 
the G2 and M phase (Schafer, 1998).  Another cell cycle inhibitor protein, p53, 
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transcriptionally induces p21 expression and induces inhibition of cell cycle 
progression (Schafer, 1998, Braun-Dullaeus et al., 1998). Importantly, most of these 
cell cycle events are determined by the state of protein phosphorylation and 
dephosphorylation of the active protein within these phases. A cycling cell enters and 
leaves the cell cycle phases depending on the synthesis and degradation of specific 
cyclins. Commonly, a cell can only enter the next phase when the appropriate cyclin 
of the previous phase is degraded and the cyclin of the next phase is synthesised 
(figure 1.4.1B) (Schafer, 1998, Braun-Dullaeus et al., 1998).  
 
Figure 1.4.1B: Schematic of the cell cycle–dependent cyclins levels. Cell cycle–dependent cyclin 
levels depend on the activation and degradation of the cyclins that are important to drive the cell cycle 
progression smoothly. Cells from the previous phase passage into another phase is closely linked to 
the synthesis and degradation of cyclins. The thickness of the hashed bars shows the relative 
intracellular concentration of cyclins within various cell cycle phases (adapted from Schafer, 1998) 
(Schafer, 1998). 
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Cell cycle arrest is an event referred to delay or withdrawal from the cell cycle process. 
It is influenced by many factors that can be intrinsic (cell size, DNA content and 
structure) or extrinsic (nutrition, ionizing radiation, viruses, bacteria, growth factors, 
stress, hyperglycemia and dyslipidemia) that may affect several different checkpoints. 
Both factors are important to determine the rate of the cell progress through the cell 
cycle process (Schafer, 1998, De Veylder et al., 2007). Cells exposed to DNA 
damaging agents trigger checkpoints to cause arrest in the G1 and G2 phase during 
the cell cycle (Lee et al., 2009). During the proliferation process, cells can also arrest 
in the S phase which causes a delay and a prolonged S phase with slow DNA 
synthesis (Schafer, 1998, Orren et al., 1997). Cells arrested in the G1 phase, which is 
a p53–dependent event, allows DNA repair before DNA replication and cells arrested 
in the G2 phase allows repair before chromosome separation in the next phase 
(mitosis) (Schafer, 1998, Orren et al., 1997). The p53 tumor suppressor protein has 
multiple functions that are tightly linked to the G1 stage arrest. It binds to several types 
of DNA damage, this includes single–stranded DNA, insertion/deletion mismatches 
and free DNA ends. Following damage, p21 transcription is stimulated by p53 to inhibit 
CDKs in the G1 phase (Schafer, 1998, Levine, 1997). Another function of p53 is the 
ability to stimulate apoptosis following severe DNA damage. However, the p53 protein 
has a different role in the G2 phase. Cells with the p53 knockout gene do not arrest in 
the G1 phase however cells arrest in the G2 phase which suggests that the p53 protein 
does not have a role in the G2 checkpoint (Schafer, 1998). Then again, p53 has been 
associated with the G2/M phases where it was found that the G2 phase was blocked 
when wild type p53 cells were exposed to mitotic spindle inhibitors. This suggested  
that p53 may be a part of the G2/M checkpoint to prevent premature cells entering the 
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S phase (Levine, 1997). Nonetheless, whether or not p53 protein is involved in the G2 
phase is yet to be discovered.  
 
The expression of cell cycle markers happens exclusively in this process. 
Furthermore, cyclins are expressed in only a particular portion as cycling cells undergo 
the cell cycle. As a result, the limitation and short life span of the cell cycle cyclins and 
CDKs represent valuable markers for cellular proliferation and cell growth. The cell 
cycle process is also closely linked to the level of ROS within the process. ROS play 
an important role in regulating the strength and duration of signalling through the redox 
dependent signal transduction pathway. This pathway works via cyclic 
oxidation/reduction of cysteine residues in kinases, phosphatases as well as other 
regulatory factors (Burhans and Heintz, 2009, Jiang et al., 2011). The signalling 
circuits may be separated within the cytoplasm such as in the organelles or subcellular 
domains with diverse redox states to allow them to respond independently based on 
the oxidative state of two major thiol reductants, the glutathione and thioredoxin 
reductive system. Oscillation in oxygen consumption, energy metabolism and redox 
state are closely incorporated with cell cycle progression (Burhans and Heintz, 2009, 
Jiang et al., 2011, Tickner et al., 2011). The effects of ROS vary within the cell cycle 
progression. This is because its signalling pathways play specific roles in different 
phases in the cell cycle process as well as the order of redox-dependant regulatory 
checkpoints always changes during the cell cycle process (Burhans and Heintz, 2009). 
In the early phase of G1, ROS stimulate mitogenic pathways which control the activity 
of CDKs that leads to the phosphorylation of pRb and result in the release of E2F for 
transcription and thereby regulate an entry into the S phase (Burhans and Heintz, 
2009, Pucci et al., 2000). Additionally, overproduction of Nox2–derived ROS 
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production was found to modulate the expression of p21 and p53 expression in 
endothelial cell cycle regulation (Li et al., 2007). Inflammatory–induced ROS 
production by Nox in response to cytokines such as TNFα are regulated by NF–κB 
that modulates promoter cyclin D which provides a link to cell cycle progression 
(Guttridge et al., 1999). However, in response to oxidative stress, in order to promote 
cell survival, Nrf2 and Foxo3a induce the expression of antioxidant enzymes and 
factors involved in cell cycle withdrawal such as CDKIs including p27 and induce 
dephosphorylation of pRb in the S phase (Burhans and Heintz, 2009). It was found 
that cyclin D and A were downregulated by the increase of CDKIs p21 and p27 
expression to induce apoptosis (Levkau et al., 2001). Nonetheless, it was reported 
that cells treated with various antioxidants undergo transient arrest and fail to progress 
from the G1 phase into the S phase in the cell cycle progression (McCrann et al., 
2009). There is still a lot to explore in this area involving ROS and cell cycle 
progression as the link between them and its mechanism is far from clear. 
 
1.4.2 High Glucose–Induced ROS and Endothelial Cell Cycle Deregulation  
ROS contribute to cell and tissue damage and dysfunction caused by glucolipotoxicity 
in DM. It is also proved that the source of ROS comes from NADPH oxidase –
dependent ROS generation both in pancreatic β-cells and in insulin sensitive cells 
(Newsholme et al., 2007). High glucose is known to enhance the production of ROS 
that will lead to generation of a proapoptotic state and pro-inflammatory factors in ECs 
that result in ECs and pericyte apoptosis leading to the early stage of diabetic 
retinopathy (Ponugoti et al., 2012). A study by Luo et al. reported that high glucose 
facilitates the inhibition of cell cycle progression through upregulation of p21 protein 
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expression in bone marrow multipotent adult progenitor cells (Luo et al., 2012). 
Furthermore, hyperglycemia and hyperinsulinemia were found to increase the 
intracellular level of cyclins (A, B and D) and significantly increase p21 protein 
expression throughout the myoblast proliferation process (Grabiec et al., 2014). 
Moreover, a study by Lorenzi et al. found that human ECs exposed to high glucose 
(20 mM) for 7 to 8 days have a retarded S and G2 phase as compared to the controls 
in normal glucose concentration. It was suggested that this outcome may be related 
to DNA damage caused by the high level of glucose (Lorenzi et al., 1987). Another 
research by Sun Lin and colleagues found that high glucose ambience increased the 
contents of cells in G0/G1 cell cycle phase as well as the expression of p21 and p27 
with a decreased activity of CDK4 in human proximal tubular cells (HK-2 cells) (Sun 
et al., 2011). Furthermore, Soo–Hyun Park and colleagues found that high glucose 
level at 25 and 50 mM decreased cell number, inhibited DNA synthesis and growth. In 
addition, high glucose also caused an increase in G1 contents and lower S phase 
contents in renal proximal tubule cells (Park et al., 2001). Additionally, high glucose at 
28 mM was found to cause cell cycle arrest through perturbation in protooncogene 
expression with diminished DNA synthesis in HuH7 cells (Prathibha S. Rao, 1999). 
Furthermore, insulin is also known as a mitogenic signal in proliferative cells and it 
was reported that insulin is able to activate the cyclin D–CDK4 complex that leads to 
suppression of internal hepatic glucose production independent of cell cycle 
progression (Lee et al., 2014). Insulin signalling induces stability on cyclin D protein 
by isolating cyclin D in the nucleus. The activated cyclin D leads to leads to inhibition 
of gluconeogenic genes and the loss of hepatic cyclin D causes an increase in 
gluconeogenesis and hyperglycemia. It was suggested that insulin uses components 
within the cell cycle system in post-mitotic cells to control glucose homeostasis 
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independently of cell cycle process (Lee et al., 2014). It was suggested that NADPH 
oxidase associated ROS production play an important role in altering the parameters 
of signal transduction, insulin action and secretion as well as cell proliferation and cell 
death (Newsholme et al., 2007). However, the downstream mechanism is far from 
clear. 
 
In the present, it is challenging to identify redox–dependent targets important to each 
cell cycle phase and more knowledge is needed to understand how these targets 
control cell fate decisions and its mechanisms that link metabolism to cell cycle 
progression. It is because ROS is tightly associated with the cell cycle and with 
hyperglycemia induced by the overproduction of ROS and this caused the damage in 
cells, hence this may be a useful area to reverse the adverse impact of glucolipotoxicity 
by targeting ROS sensitive molecules to treat the diabetic condition. 
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1.5 New Potential Target: Dietary Fiber and its by-products – short chain fatty acids  
Dietary fiber naturally arise from whole grains, nuts, fruits, wheat, corn, vegetables 
and brans which consists of polysaccharides which consist of starch and non-starch 
polysaccharides that are able to escape from the hydrolysis process within the 
digestive system in the human small intestine and get broken down in the large bowel 
by the anaerobic bacteria that reside in the caecum and colon (Theuwissen and 
Mensink, 2008, Slavin, 2003, Haralampu, 2000).  
 
1.5.1 Dietary Fiber and Short Chain Fatty Acids  
Dietary fiber consists of various components that are resistant to colonic enzymatic 
digestion. The components include resistant starch, non-starch polysaccharides such 
as cellulose, hemicellulose, pectic substances, gums, mucilages, lignin, non-digestible 
oligosaccharides and sugar alcohols (Dhingra et al., 2012, Slavin, 2013). The 
breakdown of carbohydrate in an anaerobic process is known as fermentation. This 
process yields short chain fatty acids (SCFAs) as one of the final by-products (figure 
1.5.1 – next page) (Sajilata et al., 2006, Fuentes-Zaragoza et al., 2010).  
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Figure 1.5.1: The basic content of fiber. Resistant starch has been classified into four different sub-
types names RS1, RS2, RS3 and RS4. Food classified as RS1 are a group of starch which is physically 
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inaccessible that is trapped within whole or partially milled grains or seeds; RS2 are food classified as 
raw starch granules (e.g. banana and potato) and consist of high amylose starches (e.g. corn); RS3 are 
a group of retrograded starch either processed from unmodified starch or resulting from food processing 
applications; and RS4 are a group of starch that are chemically modified (e.g. starch ethers, starch 
esters and cross-linked starches) to obtain resistance to enzymatic digestion in the small intestine. 
Starches that escape the enzymatic digestion in the small intestine will be broken-down in the large 
intestine by the anaerobes residing in the lumen of the colon and yield SCFAs as one of the byproducts 
where acetate (C2), propionate (C3) and butyrate (C4) are the major SCFAs produced (Sajilata et al., 
2006, Fuentes-Zaragoza et al., 2010). 
 
It has been known for decades that SCFAs produced by bacterial fermentation of 
dietary fiber are the mediators of beneficial effects of colonic bacteria on the host 
(Ganapathy et al., 2013). During and after birth, the human neonate becomes exposed 
to and colonised by large numbers of commensal bacteria or organisms along the 
intestinal tract. These rapidly growing, facultative bacteria metabolise lactose present 
in the breast milk to acetate and other SCFAs (also known as volatile fatty acids), 
creating a reduced pH and acidic environment to favour a slower growing anaerobic 
bacteria such as the acidophile Bifidobacterium. In the human colon, most of the area 
is occupied by an acidophilic anaerobe, a slow growing organism known as acidophile 
bifidobacterium that metabolises most of the sugar available into acetate (Wolfe, 
2005). Organisms from the genera Bifidobacterium and bacteroides ferment dietary 
fiber which consist of resistant and undigested complex polysaccharides into simple 
sugar and SCFAs. These fatty acids are in the group of carboxylic acids with aliphatic 
tails less than 6 carbons (Layden et al., 2013). They are derived from the fermentation 
of mainly non-absorbed fibres by anaerobic bacteria in the large intestine (Mortensen 
and Clausen, 1996). They are found at a concentration of ~13 mM in the terminal 
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ileum, 130 mM in the caecum and ~80 mM in the descending colon (Vinolo et al., 
2011). However, others found that the normal physiological concentration of total 
SCFAs in human range from 70 to 140 mM in the proximal colon to 20 – 70 mM in the 
distal colon (Nafday et al., 2005). In addition, in molar fractions of SCFAs in the hepatic 
portal veins concentrations were found to be 69: 23: 8 for acetate: propionate: butyrate 
(den Besten et al., 2013). However, Xiong at al. stated that the total SCFAs in human 
is ~ 50–100 μM in peripheral blood and ~ 300–450 μM in portal blood (Xiong et al., 
2004). 
 
1.5.2 Metabolisms of SCFAs in the Human Body 
In the colon, SCFAs constitute approximately two-third of the colonic anion 
concentration (70 to 130 mM) and largely consist of acetate, propionate and butyrate 
where acetate is the predominant by-product. Also, Ganapathy et al. roughly 
concluded that the relative proportions of these three bacterial metabolites (acetate, 
propionate and butyrate) in the colonic lumen is ratio 6:3:1 respectively and the total 
concentration is approximately 100 mM (Ganapathy et al., 2013). Furthermore, 
monocarboxylate transporters (MCTs) are the specific transporters that are 
responsible for the absorption of SCFAs into the colonocytes and out into the blood 
vessels (Gill et al., 2005). After production, these SCFAs are rapidly absorbed by the 
colonic mucosa epithelial cells as the primary energy source for the colonocytes, 
hepatic cells, fat cells and muscle cells (Wolfe, 2005). These SCFAs, especially 
butyrate, that are being produced in the colon are rapidly absorbed by the colonocytes 
and serve as the preferential source of energy (Gill et al., 2005). However, propionate 
and acetate get absorbed and travel via the portal vein into the liver. Propionate mainly 
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gets metabolised in the liver and acetate gets passed through the liver into the 
peripheral circulation (figure 1.5.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.2: SCFAs production and the peripheral tissues. Consumption of dietary fiber yield 
SCFAs as one of the by-products of colonic bacterial fermentation in the colon. Butyrate being absorbed 
as the main energy source for the colonocytes where propionate and acetate travel into the hepatic 
portal circulation to the liver. Propionate gets metabolised in the liver and acetate travel out to the 
peripheral tissues. In metabolic diseases such as T2DM and IR, we often see there is an increase in 
lipolysis, defects on insulin signalling pathways, hyperglycemia and dyslipidemia. However, SCFAs 
have been shown to inhibit these negative effects and improve insulin sensitivity and glucose level in 
metabolic defects models (Ichimura et al., 2014, den Besten et al., 2013, Cummings et al., 1987, Puddu 
et al., 2014). 
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Various cellular functions are being influenced by these SCFAs for example, butyrate 
has been shown to induce cell differentiation and regulate the growth and proliferation 
of colonic mucosa (Bugaut, 1987). Consumption of dietary fiber is often associated 
with SCFAs profile that may increase the anti-inflammatory responses within the body. 
Moreover, high fiber intake has been associated with increased beneficial effects and 
decreased the risk of IBD ulcerative colitis and Crohn’s disease (Ulven, 2012). The 
production of SCFAs acetate, propionate and butyrate generated by the bacterial 
fermentation of dietary fiber in the colon serve as the secondary messengers between 
colonic bacteria and the host. There are many beneficial effects of these bacterial 
metabolites in the colon such as suppression of inflammation and prevention of cancer 
(Ganapathy et al., 2013). Other than being an energy source for the colonocytes and 
other tissues such as the liver and skeletal muscle, SCFAs also exert other important 
functions such as leukocyte recruitment and chemotaxis, chemokine production, 
adhesion molecule expression and many more (Vinolo et al., 2011). Research by Al-
Lahham et al. found that acetate supplemented in drinking water for gem-free wild type 
mice reduced inflammation in disease such as colitis, arthritis and asthma (Al-Lahham 
et al., 2010). Acetate and propionate have also been linked to influence cholesterol 
production and propionate is thought to be gluconeogenic (Miller and Wolin, 1996). 
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1.5.3 SCFAs and Its Receptors: Effects of SCFAs in the Human Body 
These SCFAs byproducts are designed to bind to specific free fatty acid receptors; 
GPCR41 (FFAR3) and GPCR43 (FFAR2) and leads to various effects on cell 
physiology (Ulven, 2012). These receptors, GPCR41 and GPCR43, have 52 % 
similarity and 43% identical structure and activated by similar ligands however with 
different specificity for carbon chain length (Brown et al., 2003). GPCR41 and 
GPCR43 were found on the same gene location which is on chromosome 19q13.1 but 
both have a different length of amino acids, each with 346 and 330 amino acids 
respectively. GPCR43 was found to be coupled to both Gαi/o and Gαq/11 however, 
GPCR41 was only found coupled to G αi/o downstream pathway (Stoddart et al., 2008, 
Lee et al., 2008, Brown et al., 2003, Le Poul et al., 2003). Activation of Gαq/11 leads to 
downstream signalling that involves the activation of phospholipase C (PLC) that will 
further activate cell’s calcium mobilisation, phosphokinase C (PKC), and hydrolysis of 
phosphoinositide. These activate further downstream pathways such as MAP kinase, 
granule secretion, platelets aggregation and PI3K inhibition (Mizuno and Itoh, 2009). 
On the other hand, the activation of Gαi/0 caused a decrease in cAMP level through 
the inhibition of PKA. This leads to a further downstream cascade that involves cell 
survival, proliferation and differentiation (figure 1.5.3 – next page) (Mangmool and 
Kurose, 2011).  
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Figure 1.5.3: GPCR43 downstream signalling.  SCFAs receptors are membrane bound receptors 
that bind to its agonists. They activate various downstream signalling pathways that will lead to 
numerous different effects on cells or organs. SCFAs activated GPCR43 coupled to Gq and Gi 
downstream pathways. Activation of Gq pathway leads to activation of PLC–β and subsequently leads 
to calcium mobilization, PKC activation and phosphoinositde hydrolysis. These will further lead to MAP 
kinase activation, granule secretion, integrin activation, platelets aggregation and PI3K inhibition. In 
addition, Gi downstream signalling involve the inhibition of cAMP–dependent protein kinase (PKA) 
pathway by inhibiting adenylate cyclase. Reduced production of cAMP from ATP leads to a decrease 
activity cAMP–dependent protein kinases. Gene expression by cAMP is important in controlling cell 
proliferation, survival and differentiation in variety of cells (Mizuno and Itoh, 2009, Mangmool and 
Kurose, 2011).  
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In addition, GPCR43 have been reported to be expressed on adipose tissue, 
pancreatic islets, immune cells, ECs and in the colon however, GPCR41 have been 
shown to be expressed in the spleen, lymph node and bone marrow other than in the 
adipose tissue, pancreatic islets and in the immune cells (Stoddart et al., 2008, 
Schmidt et al., 2011, Blad et al., 2012, Voltolini et al., 2012). In addition, Hua et al. 
suggested that FFAR3 is unessential for normal energy homeostasis and glucose 
metabolism as they found that FFAR3 knockout mice on normal chow and high fat diet 
(HFD) showed normal body weight, plasma leptin and adiposity compared to wild-type 
mice. HFD-fed FFAR3 knockout mice also showed normal glycemia, insulin tolerance 
and oral glucose tolerance level (Lin et al., 2012). The list of beneficial effects of 
SCFAs were not only related to their ability to inhibit the histone deacetylase protein 
but also through the activation of the transmembrane cognate G protein–coupled 
receptors that leads to its subsequent activation of downstream signalling pathway 
(Puddu et al., 2014). Binding of agonist e.g. SCFAs to these receptors activates 
several intracellular pathways for example activated GPCR43 receptor will lead to the 
activation of downstream signalling of MAPK, PKC and transcriptional factors such as 
activating transcriptional factor-2 (ATF-2) (Vinolo et al., 2011). However, SCFAs 
receptor GPCR43 and GPCR41 show a difference in SCFAs specificity, intracellular 
signalling and tissue localisation (Lee et al., 2008). These receptors are activated by 
high micromolar or milimolar concentration of SCFAs anions, mostly by acetate, 
propionate and butyrate, which are produced in concentrations of more than 100 mM 
by colonic fermentation of dietary fiber (Topping and Clifton, 2001). Acetate has the 
highest potency binding to GPRC43 nevertheless this receptor also binds to the other 
two major SCFAs (propionate and butyrate) in the preference scale of acetate > 
propionate > butyrate where propionate and butyrate are preferable to activate 
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GPCR41 (Ulven, 2012, Lin et al., 2012, Le Poul et al., 2003, Stoddart et al., 2008, Blad 
et al., 2012, Maslowski et al., 2009). Importantly, SCFAs have been reported to exert 
beneficial effects to treat metabolic disease linked complications in human, animal and 
In vivo cell models (Puddu et al., 2014). Moreover, it was found that GPCR43 receptor 
knockout mice had shown reduced inflammatory response to colitis-induced condition 
with reduced PMNs infiltration (Sina et al., 2009). High fiber diets are known to 
associate with increased levels of peptide YY (PYY), a hormone to decrease appetite 
(Karra and Batterham, 2010). This receptor also had been found to be expressed in 
enteroendocrine L cells of the intestinal tract that are responsible for the secretion of 
PYY hormone (Karaki et al., 2006). The L cells are also responsible for the secretion 
of GLP-1, a potent anorectic incretin hormone which also regulates insulin secretion 
from the pancreatic β-cells and increases insulin sensitivity on target tissue (Tolhurst 
et al., 2012). Furthermore, Kimura et al. has demonstrated that mice with deficient 
GPR43 receptor are obese on a normal diet, while overexpression of GPCR43 
receptor mice especially in adipose tissue stay lean even when they were fed with a 
high fat diet. They also showed that SCFAs–mediated activation of GPCR43 
suppresses insulin signalling in adipocytes, which leads to inhibition of fat 
accumulation in adipose tissue and also promotes the metabolism of unincorporated 
lipids and glucose into other tissues (Kimura et al., 2013). Conversely, Maslowski et 
al. reported that there was an increase in inflammatory cells migration and recruitment 
in GPCR43 receptor knockout mice and they found un-resolving inflammation in 
animal models of colitis, arthritis and asthma (Maslowski et al., 2009). 
 
 
44 
 
Poor diet and physical inactivity are the main factors for the pathogenesis of metabolic 
syndrome and cardiovascular diseases (James et al., 2004). Prolonged consumption 
of high fat and highly refined sugar are commonly associated with diet induced obesity, 
IR, dyslipidaemia and hypertension in wild type rodents (Barnard et al., 1998). 
However, not just by using available drugs on the market to try to treat and better 
control metabolic diseases such as T2DM, researchers are also trying to find an 
alternative treatment and potential drugs to treat metabolic diseases. Recently, many 
of beneficial effects against metabolic related complications has been suggested to be 
linked to the levels and activities of short chain fatty acids from fiber fermentation. 
SCFAs have been found to have an anti-inflammatory response on cells for example, 
down regulation of the expression of CXC chemokine receptor 2 (CXCR2) as well as 
inhibiting neutrophil migration, downregulation ECs adhesion molecules e.g. VCAM–
1 that further prevent leukocyte migration to the inflammatory sites and furthermore, 
butyrate was shown to inhibit LPS–induced macrophage migration. These abilities of 
SCFAs are crucial in preventing the initial step for the development of metabolic 
disorders-linked complications that will lead to the formation of cardiovascular 
diseases in the long run (Puddu et al., 2014). Furthermore, it was also hypothesised 
that the beneficial effect of SCFAs on the interaction between immune cells and the 
ECs is due to their effects mainly on ECs functions and mechanisms rather than on 
the immune cells (Vinolo et al., 2011). Also, all three SCFAs have been found to have 
a protective effect against metabolic diseases such as diet-induced obesity and 
especially acetate has shown an inhibitory effects on weight gain independent of food 
intake suppression and had no acute effects on gut hormone productions (Lin et al., 
2012). Another study by Qureshi et al. found that water soluble rice bran fiber and rice 
bran fiber concentrates (consisting of β-glucan, pectin and gums) reduced significantly 
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the level of glycosylated haemoglobin, fasting blood glucose and serum insulin levels 
were increased (4%) with water soluble fiber which indicate that ingesting water 
soluble fiber rice bran can control blood glucose levels of diabetic humans. His group 
also found that serum triglycerides, apolipoprotein B, low density lipoproteins (LDL) – 
cholesterol and total overall serum cholesterol levels were reduced with the intake of 
concentrate fiber of rice bran in both type 1 and 2 diabetic patients. In conclusion, 
these natural products can be used as nutritional supplements for the control of both 
types of DM in humans and to overcome hyperglycemia, hyperlipidemia and glycation/ 
glycoxidation as well as the development of atherosclerotic plague which are the 
common features of DM  (Qureshi et al., 2002). Furthermore, another study by Zaibi 
et al. found that SCFAs stimulated wild type mice increase leptin secretion through the 
GPCR43 receptor and they also found that acetate but not butyrate stimulated leptin 
secretion in wild type mesenteric adipocytes acts down the GPCR43-induced Gαi/o 
signalling pathway rather than mediating the GPCR41 response (Zaibi et al., 2010). 
Research has shown that individuals consuming increased fibre in daily food intake 
have a significantly lower risk for pathogenesis of developing coronary heart disease, 
stroke, hypertension, diabetes, obesity and colorectal cancer (Anderson et al., 2009). 
Increased dietary fibre improves serum lipid concentration, decreases blood pressure, 
increases insulin sensitivity in diabetic patients and improves weight loss (Anderson 
et al., 2009, Wright et al., 1990). 
 
Adipose tissue (AT) is important for daily buffering of fatty acids in the body. However, 
in disease states such as diabetes, IR as well as obesity, there is an increase in the 
AT lipolysis rate, thus leading to increase in fatty acids release into the blood 
circulation and as a result these excess fatty acids get taken up into peripheral tissue 
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for example the skeletal muscle, pancreas and liver. This causes an increase in the 
lipid storage as well as increase in fatty acids oxidation. Fatty acids compete with 
glucose for substrate oxidation and this in turn reduces glucose transport and 
phosphorylation thus impairing insulin action through the accumulation of intracellular 
lipid metabolites. Increase in fatty acid adiposity as well as high glucose both activate 
NADPH oxidase ROS production in ECs. AT size correlates with whole body insulin 
sensitivity. The bigger AT have more macrophage infiltration and thus leads to an 
increase of cytokines and chemokines flow in the blood vessels (Robertson, 2007). In 
human, GPCR43 receptor is expressed in adipose tissue as well as in mouse where 
activation of GPCR43 receptor leads to adipogenesis and inhibition of lipolysis (Al-
Lahham et al., 2010). Recent research shows that SCFAs from anaerobic bacterial 
fermentation are able to increase insulin sensitivity by suppressing hepatic 
gluconeogenesis (Gao et al., 2009). These fatty acids also show anti-inflammatory 
effects where they modulate leukocyte function and have the potency to prevent 
infiltration of the immune cells from the bloodstream into peripheral tissues for example 
adipose tissue and regulate energy expenditure from adipose tissue and leads to a 
smaller adipose tissue size as well as improve the whole body insulin sensitivity, lower 
triglycerides and HDL, and increase satiety (Robertson, 2007, Gao et al., 2009, Meijer 
et al., 2010). 
 
There are many factors influencing chronic metabolic disease and diet is one of the 
key links to the development of these diseases. These non-viscous fibres after 
fermentation produce SCFAs and these fatty acids have been suggested to have a 
direct effect in metabolic function on peripheral tissues. In a study by Menzel et al., it 
is shown that butyrate at 4 mM inhibits TNF-a induced VCAM-1 expression by 
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inhibiting NF-kB activation on human umbilical endothelial cells (HUVEC) (Menzel et 
al., 2004). In a study by Downar et al., they found that butyrate at 10 mM has an anti-
inflammatory effect on colonocytes but is also able to inhibit TNF-α-induced activation 
of NF-kβ and enhanced PPARα expression in HUVEC (Zapolska-Downar et al., 2004). 
Another study by Downer shows that propionate at 10 mM is able to inhibit TNF-α 
induced activation of NF-kβ and significantly increased PPARα expression in HUVEC 
as well as decreased TNF-α induced VCAM-1 and ICAM-1 mRNA expression 
(Zapolska-Downar and Naruszewicz, 2009). Studies by Yamashita et al. have shown 
that rodents treated with acetate have a significant reduction in lipid accumulation in 
adipose tissue, improved glucose tolerance as well as protection against accumulation 
of fat in the liver (Yamashita et al., 2007). All the results from these researches are 
pointing towards the beneficial effects of short chain fatty acids in protecting against 
metabolic syndromes and the development of CVDs. A study from Zhao et al. shows 
that exposure of HUVEC to high glucose (40 mM) for 72 hours stimulated endothelial 
injury in a dose-dependent manner together with reducing cell viability, increasing 
intracellular ROS, and increasing the production of NO in cell and medium as well as 
generating protein tyrosine nitration (Zhao et al., 2008). The dysfunction and damage 
of ECs by ROS account for an important role in the development and progression of 
diabetic vascular complications. Diets with high glucose as well as high in fat 
contribute to the increase of ROS production in the vasculature and in the long run 
leads to metabolic diseases and CVDs. It is important to look at the beneficial 
properties of resistant starch and their role in the prevention of metabolic disorders 
and CVDs. 
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Thus, in this project I focus on SCFAs receptor GPCR43 and its agonists especially 
acetate as this agonist has a higher potency on this receptor. Moreover, acetate has 
been found to have the highest concentration circulating in the blood circulation and 
its mechanisms of actions on the cells in the vasculature are still unclear. In the context 
of metabolic disorders, DM in particular, it is well known that there is an increase in 
inflammation, IR, hyperglycemia, oxidative stress and endothelial dysfunction which 
progressively occur deteriorating the function of cells and organs affected. However, 
studies have found beneficial effects through the activation of GPCR43 by SCFAs and 
through this interaction it exerts anti-inflammatory properties, regulates cell 
proliferation and differentiation, blood glucose regulation and lipid metabolism. This 
receptor is also expressed in ECs and it has been suggested that this receptor plays 
a critical role in modulating inflammation. Currently, through the given knowledge on 
SCFAs and the GPCR43 receptor, their interaction is particularly important at aiming 
to treat metabolic disorder especially in T2DM, IR and obesity. 
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1.6 Study Hypothesis and Aims 
Previous research has demonstrated that IR, DM and obesity enhanced the 
development of vascular endothelial dysfunction. Hyperglycaemia may induce 
endothelial dysfunction in diabetic patients and animal models by increased production 
of free radicals. Intake of resistant starch (RS) from fiber seems to decrease 
postprandial glycemic index and insulin responses, lower plasma cholesterol and 
triglyceride concentrations, improve whole body insulin sensitivity, increase satiety, 
and reduce fat storage. No one knows for certain why this was so and the effects of 
SCFAs under high glucose stimulation are still relatively new to research. These 
properties of RS make it an attractive dietary target for the prevention of diseases 
associated with dyslipidemia and IR as well as a dietary treatment for T2DM and 
coronary heart disease. In consideration of all the research that has been discussed, 
it seems fair to conclude that short chain fatty acids (SCFAs) are able to reduce high 
glucose-induced endothelial cell oxidative stress and improve endothelial cell function 
under DM-induced dysfunctions. If dietary fiber from natural food sources can be used 
to revert and treat metabolic disorder related complications and cardiovascular 
diseases, it would seem logical to promote changes in the diet to increase dietary fiber 
levels. The hypothesis of this project is SCFAs can reduce high glucose-induced 
oxidative stress and improve endothelial dysfunction thus treat diabetes mellitus 
condition.  
 
Therefore, the aim of this study was to expend our current knowledge of dietary fiber 
and its effects under high glucose conditions as well as to investigate the effects that 
fiber byproducts – SCFAs have on ECs under normal glucose concentration (5 mM) 
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and high glucose concentration (30 mM) to mimic the diabetic mellitus condition. The 
primary objective is to investigate the potential inhibitory effect of SCFAs on high 
glucose-induced ROS production on ECs. Secondly, the objective is to examine the 
effect of SCFAs on endothelial cell function such as in cell cycle progression and 
apoptosis.   
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Chapter 2: Materials and Methodology 
 
 
For a detailed list of materials and reagents used in this study please refer to the tables 
in the Appendix. All chemical reagents were purchased from Sigma-Aldrich (Poole, 
UK) unless otherwise mentioned in the text. Most antibodies were purchased from 
Santa Cruz Biotech (InsightBiotech, Cambridge) unless stated otherwise. 
 
2.1 Cell Culture 
Human Pulmonary microvascular endothelial cells 
Human pulmonary microvascular endothelial cells (HPMEC) were a gift kindly given 
by Professor C. James Kirkpatrick (Johannes Gutenberg University, Germany). 
HPMEC were generated from human pulmonary microvascular ECs isolated from 
lungs of adult donors. Cells were co-transfected with a plasmid encoding the catalytic 
component of telomerase (hTERT) and a plasmid encoding the simian virus 40 (SV40) 
large T-antigen. HPMEC were grown in M199 medium consisting 100 mg/L glucose 
(5.5 mM) and supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 
100 U/ml ampicillin, 100 μg/ml streptomycin,1 mM L-glutamine, 20 μg/ml endothelial 
cell growth supplement (ECGS) and 25 μg/ml heparin. Cells were grown on pre-coated 
flask with 1% w/v Gelatine (Sigma) and continuously cultured in a humidified 
atmosphere at 37ºC, 95% O2 and 5% CO2. HPMEC from passage 2-10 were used for 
all experiments (Krump-Konvalinkova et al., 2001). Below are the layout and 
summaries for all experiments done in this PhD research thesis (figure 2.1 – next 
page). 
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Figure 2.1: Project experimental design using HPMEC. Cells were cultured to 85-90% confluence 
on a gelatine pre-coated tissue culture flasks or dish. After confluence, cells were subsequently pre-
incubated with SCFAs for 1 hour and stimulated with high glucose for 24 hours at 370C. The next day, 
cells were schedule for harvest accordingly as above. 
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2.1.1 Thawing Cells  
Cells preserved in liquid nitrogen cryo-storage facility were removed and thawed at 
370C in a water bath until small ice crystals were observed. Cryovials were 
decontaminated with 70% alcohol and placed in a class II tissue culture cabinet. Cells 
were then transferred to a 15 ml falcon tube and washed with 9 ml phosphate buffered 
saline (PBS; Sigma), followed by centrifugal collection at 800 rpm for 5 minutes. After 
discarding the supernatant, cells were thoroughly re-suspended in 1 ml complete cell 
culture medium and transferred into a cap-vented T75 cell cultured flask containing 7 
ml complete cell culture medium. Cells were cultured and maintained in an incubator 
with 5% CO2, at 370C for minimum 3 days to reach 90% confluence.   
 
2.1.2 Passaging Cells  
After cells had reached 85 – 90% confluence, culture medium was discarded from the 
cell culture flask and the remaining cells were washed with 5 ml PBS. Next, 3 ml of 
Trypsin (0.5 g/l)-EDTA (0.2 g/l; Sigma) was added to coat the whole flask (for T25 
flask: 1 ml of Trypsin-EDTA, for 10cm culture dishes; 1.5 ml of Trypsin-EDTA) and 
cells were incubated with the presence of Trypsin-EDTA at 370C for 1 – 2 minutes. 
Trypsin-EDTA has the function to detach cells by inhibiting cell to cell contact and it 
also dislodges cells from the surface of the tissue culture flask. 5 ml of 10% FBS cell 
culture medium was immediately added into the flask and mixed well to neutralise the 
trypsin action. Cell suspension from the flask was transferred into a 15 ml falcon tube 
and cells were pelleted at 800 rpm for 5 minutes. 20 µl of suspended cell aliquot was 
taken to determine cell number and cell viability and processed as in section 2.1.3.   
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2.1.3 Cell Count and Cell Viability  
To determine cell number, viability and structure, cells were counted using a 
haemocytometer with trypan blue (0.4% w/v; Sigma), a negatively charged 
impermeable dye which enters the cells upon loss of membrane integrity. Trypan blue 
stained cells are considered dead or non-viable cells.  After 1 minute, diluted cells 
were loaded onto the haemocytometer counting chamber and immobilised by using a 
coverslip. Cells in their physical state (alive, dying or dead) were identified by their 
uptake of the dye. Observation and counting were done under a Zeiss light microscope 
at 20x magnification. The ratio of dead and alive cells as well as total number of cells 
was taken from all four corners of a 4x4, 1/25 mm2 quadrant. Cell viability was 
determined by the percentage of dead cells in the total cell count. Cells with a total 
viability of >95% were used in all experiments. The structure of cells were also 
observed and captured by EVOS light microscope. 
 
2.1.4 Freezing Cells  
Both primary and immortalised cells can be frozen, preserved and stored in liquid 
nitrogen for stocks and long-term storage. To preserve quality frozen cells, a freezing 
mixture containing sterilized DMSO and FBS was initially prepared by adding one 
volume of DMSO into four volumes of FBS (20% DMSO/ 80% FBS solution). The 
mixture was thoroughly mixed by inversion and was cooled down and placed on ice 
for a minimum of 20 minutes before use (maximum 2 hours). Cultured cells were 
processed as previously described in section 2.1.2 and 2.1.3 respectively. A 0.5 ml 
(containing 1 x 106 or 2 x 106 cells) aliquot of cell suspension in complete (10% FBS) 
culture medium was transferred to a 2 ml cryovial followed by the addition of an equal 
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volume of pre-cooled 20% DMSO/FBS freezing mixture drop-wise using a 1 ml pipette 
with constant agitation. Finally, the cryovial was placed in a room temperature cryo-
freezing container containing isopropanol and immediately placed at -800C. 
Isopropanol has a valuable property for freezing cells, it enables temperature to 
decrease by 10C per minute to prevent cell damage by rapid freezing and formation of 
large ice crystals. After 24 hours, the frozen cells were removed and stored in a liquid 
nitrogen cryo-storage facility. 
 
2.2 Short Chain Fatty Acids Treatment  
SCFAs have been found to have anti-inflammatory effects and other effects such as 
reversing metabolic diseases in human. However, its effect on high glucose induced-
endothelial oxidative stress are still unclear. Therefore to investigate the role and effect 
of SCFAs on endothelial cell function, HPMEC and other primary cells were used in 
this experiment. After cells had reached 85-90% confluence, the medium was replaced 
with 5 ml of 5% FBS M199 medium and adherent cells were exposed to SCFAs for 1 
hour by directly adding 25 µl of 1 M NaA into the medium with gentle agitation and 
continued to use for downstream experiments in the presence of SCFAs.  
 
2.3 High Glucose Treatment 
High glucose is a potent activator of the Nox family NADPH-oxidase enzymes and the 
consequent ROS production contributes to the formation of pathophysiological 
complications of diabetes in the macro- and micro-vasculature. Therefore to 
investigate the effects of high glucose-induced ROS production in ECs, HPMEC cells 
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and other primary cells were used in various experiments. After cells were exposed to 
SCFAs for 1 hour, adherent cells were stimulated with 30 mM of high glucose (Sigma) 
for another 24 hours by directly adding 150 µl of 1 M glucose into the medium with 
gentle agitation in the presence or absence of SCFAs.  
 
After 24 hours post stimulation, supernatant was collected for marker-related 
experiments or it is discarded. To harvest the cells, PBS was used twice to wash the 
cells followed by detaching the cells with trypsin-EDTA (section 2.1.2) to ensure the 
cells remained intact without a loss of membrane integrity.  
 
2.4 Cell Lysis and Bradford Assay 
To acquire cellular constituents, cells were re-suspended in an appropriate volume of 
harvesting buffer (lucigenin and lysis) and homogenised for 30 seconds on ice using 
a hand held homogeniser (Polytron, Germany) followed by 2 pulses of 10 seconds 
sonication on ice using VC130PB ultrasonic processor at half of maximal amplitude. 
Cell homogenates were then analysed for their protein concentration.  
 
To determine total protein concentration in cellular homogenates, Bradford assay was 
performed according to manufacturer’s guidelines. First, 1 x Bio-Rad protein assay 
dye was prepared by diluting 5-fold with H2O in a total volume of 1 ml. Next, 2 µl of 
cellular homogenate was added to the 1 x Bio-Rad dye and thoroughly mixed by 
vortex. This sample mixture was added to a 1.5 ml plastic cuvette and the optical 
density (OD) at 595 nm was calculated using a spectrophotometer or the NanoDrop 
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ND-1000 spectrophotometer (Thermo Scientific, UK). Then, protein concentration was 
subsequently calculated according to a standard curve (OD595) generated from known 
Bovine Serum Albumin (BSA) concentrations. Finally, cell homogenates with a known 
protein concentration were used for ROS measurements and immunoblotting.  
 
2.5 ROS Level with Lucigenin–Chemiluminescence Assay 
Chemiluminescence is one of the most widely used methods for detecting ROS 
production by mammalian cells and tissues. Lucigenin-chemiluminescence has been 
a popular method for measuring intracellular O2.- production by non-phagocytic cells 
due to the advantages of lucigenin i.e. great cell membrane permeability, minimal 
cellular toxicity, high sensitivity and specific reaction with O2.-.  
 
Intracellular ROS production in cells lysates was measured by using lucigenin-
chemiluminescence assay. Lucigenin buffer containing 800 µM magnesium chloride 
(MgCl2) (Sigma, M8266-100G, 98%) and 1.8 mM calcium chloride (CaCl2) (Sigma, 
C4901-100) in Hank’s balanced salt solution (Gibco, 14175-137) was placed on ice. 
To each tube containing cell pellet, 200 µl of lucigenin buffer was added and sonicated 
using a SONIC Vibra-Cell at 40C. Samples were sonicated for 2 x 10s bursts, with at 
least 20s pauses between bursts. Protein concentration in lysates was quantified using 
the Bradford assay. A lysate volume corresponding to 25 µg protein was made up to 
140 µl with lucigenin buffer per well in a 96-well assay plate. To each well, 20 µl of 1 
mM Nicotinamide Adenine Dinucleotide Phosphate (NADPH) (Sigma, N7785, 
95%) dissolved in lucigenin buffer was added and 40 µl of 25 µM lucigenin solution 
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(Sigma, B49203) was added by using an autodispenser to a final concentration of 5 
µM. Lucigenin-chemiluminescence was then measured in a luminometer (BMG 
Lumistar, Germany).  
 
2.6 ROS Level with Dihydroethidium (DHE) by Flow Cytometry  
Dihydroethidium (DHE) is a cell membrane permeable non-fluorescent compound. It 
is intracellularly oxidised and forms ethidium (a red fluorescent product) which binds 
to DNA and is retained inside the cells. Ethidium fluorescence (Ex: 500-530 nm, Em: 
590-620 nm), can be readily detected by either fluorescence microscopy, flow 
cytometry or high-performance liquid chromatography (HPLC), and has been 
attributed to O2.- trapping inside the cells.  
 
ROS generation in cell suspension was detected using dihydroethidium (DHE) assay 
by a flow cytometer. 1.0 x 106 of single cell suspension in PBS of 500 µl final volume 
was used for this assay. Cells for all conditions in different Eppendorf tubes were 
incubated with 2 µM of DHE and left to stand in the dark for 10 minutes. At the end of 
the incubation period, cells were passed through the pre-set flow cytometry system 
(BD C6 accuri flow cytometer) and 20,000 cells were gated for detection. To determine 
that the source of ROS production is O2.-, tiron, a O2.- scavanger was used as a control. 
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2.7 Osmolality Analysis 
Osmolality is a measure of the number of dissolved substances in a fluidic system. 
The greater of substance dissolved, the higher the osmolality.  
 
To investigate the total osmolality in HPMEC treated medium the osmometer was 
setup and calibrated according to the manufacturer’s instructions prior to detection. 
This machine measures the freezing point depression to determine the total osmolality 
of aqueous solutions. The freezing point is directly proportional to the dissolved parts 
and thus this machine measures osmolality directly. First, 50 µl of supernatant from 
sample was pipetted into a 300 µl Eppendorf tube and it was inserted into the clean 
and dry tip of the probe on the measuring vessel (making sure to avoid air bubbles). 
Next, the measuring vessel (thermistor probe) containing the sample was securely 
lowered down onto the vessel holder and measured by using Osmomat 030 (Gonotec, 
Germany).    
 
2.8 pH level Analysis 
pH analysis is a way to determine an aqueous solution characteristic value whether it is acidic, 
neutral or alkaline.  
 
To observe pH value, supernatant from each sample was measured by using a pH meter 
(Jenway, UK). During harvest phase, supernatant was collected into universal tubes and used 
directly for pH measurement (after the pH meter was calibrated according to the 
manufacturer’s instruction). Each value was noted down and analysed. 
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2.9 Cell Cycle Analysis with Propidium Iodide by Flow Cytometry  
Cell cycle is a process that happens within a cell where cells duplicate and divide their 
cellular content in order to produce two diploid cells. There are five stages involved 
namely senescence stage (G0), first check point phase (G1), synthesis (S), second 
check point phase (G2) and mitosis phase (M). These processes are highly regulated 
and essential to maintain homeostasis (detect and repair genetic damage, prevent 
uncontrolled cell proliferation etc. Errors in cell cycle regulation and its processes may 
lead to cancer development.  
 
To analyse cellular contents in cell suspensions and its cell cycle profile, propidium 
iodide and RNAse A (PI/RNAse A) were used in the process. This is to get rid of the 
RNA and only let PI bind to DNA double strands. 1.0 x 106 of single cell suspension 
was fixed in 70% ethanol at -200C overnight. PI/RNaseA solution was made up 
according to the quantity of samples. In 1 ml of cell cycle analysis solution mixture 
consist of 50 µl of 1 mg/ml PI, 12.5 µl of 0.25 mg/ml (20 mg/ml) RNAse A and 937.5 
µl of PBS. The solution mixture was kept on ice prior to experiment. 
 
Ice cold cells were spun down at 40C, 340 rpm for 5 minutes and the supernatant was 
discarded. Cells then were washed again with PBS once and the supernatant was 
discarded completely. 500 µl of cell cycle analysis solution mixture was added to each 
sample and incubated at 370C for 45 minutes. Cells were spun down and supernatant 
was removed. 1 ml PBS was added to wash the samples and again samples were 
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spun down and supernatant was removed. 300 µl of PBS was added to all the 
samples, vortexed and the samples are ready for detection.  
 
2.10 Cell Viability with MTS Assay 
To determine number of viable cells in proliferation, CellTiter96® Aqueous Non-
Radioactive cell proliferation assay (Promega, UK) was used on HPMEC cells 
stimulated with high glucose in the presence of absence of SCFAs. CellTiter96® 
Aqueous Non-Radioactive cell proliferation assay kit is a colometric assay composed 
of a novel compound, tetrazolium [3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an 
electron coupling reagent (phenazine methosulfate; PMS). MTS is bioreduced by 
dehydrogenase enzymes found in metabolic active cells into a formazan product that 
is soluble in tissue culture medium and measurable at 490 nm absorbance. The 
quantity of formazan product is directly proportional to the number of living cells in 
culture.  
 
To investigate cell viability, HPMEC cells were used and assessed by using 
CellTiter96® Aqueous Non-Radioactive cell proliferation kit on a 96-well tissue culture 
microplate assay. Cells were seeded to reach 85-90% confluence before pre-
incubating with SCFAs and high glucose stimulation for 24 hours with a final volume 
of 100 µl. Then, 20 µl of pre-combined MTS/PMS solution was added directly to the 
wall of each well to avoid cross contamination between samples. Next, the plate was 
incubated for 2 hours at 370C tissue culture incubator. Subsequently, supernatant from 
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each well was removed and 25 µl of 10% DMSO was added into each well to stop the 
reaction before measurement. Finally, absorbance was recorded at 490 nm by using 
a microplate reader. 
 
2.11 Cell Viability with CellTiter–Glo® Luminescence Assay 
There is another method to investigate cell viability which is also a homogeneous 
luminescent based assay known as CellTitre-Glo® Luminescence Cell Viability Assay 
(Promega, UK). This assay is able to determine number of viable cells in culture based 
on quantitation of the ATP present, which is a sign of the metabolically active cells. 
The assay relies on the catalysis of luciferin by proprietary thermostable luciferase 
(Ultra-GloTM Recombinant Luciferase) in the presence of ATP, molecular oxygen and 
Mg2+, which generates a stable luminescent signal while simultaneously inhibiting 
endogenous enzymes released (e.g. ATPases) during cell lysis.   
 
To determine cell viability, HPMEC cells were used and assessed by using CellTitre-
Glo® Luminescence Cell Viability kit on a 96-well tissue culture microplate assay. Cells 
were seeded to reach 85-90% confluence before pre-incubating with SCFAs and high 
glucose stimulation for 24 hours with a final volume of 100 µl. Next, CellTitre-Glo® 
reagent was added in 1: 1 ratio to an equal volume (100 µl) of the cell culture medium 
before mixing with gentle agitation on an orbital shaker to introduce cell lysis. Then, 
the plate was left to incubate at room temperature for 10 minutes to stabilise the 
luminescence signal prior to detection. Finally, the luminescence signal was recorded 
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by using a microplate reader at 490 nmex, 510-570 nmem and a signal was detected at 
1 second for each well. 
 
2.12 Apoptosis Analysis with Caspase–Glo® 3/7 Assay 
Apoptosis is a complex and tightly scripted cell death programme. It is irreversibly 
activated by a group of intracellular proteases and nucleases which are involved in the 
digestion of various components of the cell including the nuclear lamina, parts of the 
cytoskeleton and DNA of the chromosomes. Cells undergoing apoptosis are 
characterised by chromatin condensation, protein and DNA degradation, loss of 
plasma membrane lipid asymmetry and disintegration of the cells into membrane 
bound fragments.  
 
To investigate apoptosis on cells with high glucose induced stress, HPMEC cells were 
used and assessed by using Caspase-Glo® 3/7 reagent (Promega, UK) in a microplate 
assay. Caspase-Glo® 3/7 assay is a homogeneous, luminescent assay that measures 
caspase-3 and caspase-7 activities which play a key role in apoptosis in mammalian 
cells. Cells were seeded onto a gelatine-coated transparent 96-well tissue culture plate 
to reach 85-90% confluence. Next, after pre-incubating cells with NaA and stimulating 
cells with high glucose for 24 hours the tissue culture plate was removed from the 
incubator into a class 2 tissue culture hood for 5 minutes to equilibrate to room 
temperature. Then, 100 µl of pre-mixed Caspase-Glo® 3/7 reagent was added to the 
wall of each well without touching the sample to avoid cross-contamination between 
samples. The plate was then sealed with a sealer and covered with aluminium foil 
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before gentle mixing on a shaker at 300-500 rpm for 30 minutes. Adding the 
luminogenic caspase-3/7 substrate reagent to cells results in cell lysis, followed by 
caspase cleavage of the substrate and generates a luminescent signal produced by 
the luciferase. Luminescence signal is proportional to the amount of caspase activity 
present and this was recorded using a luminometer at 490 nmex, 510-570 nmem and a 
signal was detected at 1 second for each well.  
 
2.13 Immunofluorescence  
Immunofluorescence is a powerful technique that utilises fluorescent-labelled 
antibodies to detect specific target antigens. Investigations on samples either with 
HPMEC cells were done by indirect antibody labelling immunofluorescence using flow 
cytometry and Nikon A1 confocal imaging system respectively. There were two steps 
involved in indirect labelling immunofluorescence, first the primary unlabelled antibody 
binds to the target, after which a fluorophore-labelled secondary antibody (directed 
against the Fc portion of the primary antibody) is used to detect the first antibody. 
Fluorochromes are important dyes for essential diagnostics which work by accepting 
light energy (excitation) from a laser at a given wavelength and re-emit (emission) it at 
a longer wavelength.  
 
2.14 Antigen Detection by Flow cytometry  
Flow-cytometry is a powerful technology that simultaneously allows its user to 
measure and analyse antigens expression and other multiple physical characteristics 
of single particles, in this case cells were used, by labelling them with fluorescent 
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labelled dye or antibodies. Importantly, cells were individually pre-labelled and subject 
to cell sorting by passing through a fluidic stream through a beam of light. The 
properties measured include a cell’s relative size, relative granularity or internal 
complexity and its relative fluorescence intensity. These characteristics are 
determined using an optical-to-electronic coupling system that records how the cell or 
particle scatters incident laser light and emits fluorescence.    
 
HPMEC cells were seeded and treated with high glucose in the presence or absence 
of NaA. After the treatments, cells were processed as described previously (section 
2.1.2). Soon after cell count, 3 x106 of single cell suspension was used and cells were 
fixed with ice cold 2% PFA for 30 minutes at 40C. Samples were spun down and 
supernatants were removed, then 2% BSA/PBS was used to block samples for 10 
minutes with gentle agitation to have an equal mixture between samples and blocking 
mixture. After 10 minutes, supernatant was removed and samples were split into tubes 
according to numbers of antigens desired for detection. Cells were then incubated with 
primary antibodies (mouse Nox2; 1:100, rabbit GPCR43; 1:100) (Santa Cruz) in 2% 
BSA/PBS blocking solution for 30 minutes at room temperature in a dark box. Next, 
the cells were removed of excess antibody by washing three times with PBS (10 
minutes each), followed by incubation with fluorochrome with fluorescein 
isothiocyanate (FITC, Green) or cyanin-3 (Cy3; Red) fluorochrome conjugated 
secondary antibodies (both 1:250 dilution) for 30 minutes at room temperature and 
away from any light exposure. After 30 minutes incubation with secondary antibody, 
excess antibody was removed thoroughly by washing three times with PBS with 10 
minutes each wash. Next, each tube was suspended with 300 µl PBS to form single 
cell suspension after the washing step.  
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Visualisation of indirect labelled fluorescent antigens was examined by using an Accuri 
C6 flow-cytometer equipped with both FITC (excitation/emission: 495/521 nm) and 
Cy3/PE (excitation/emission: 550/570) lasers.   
 
2.15 Antigen Detection by Confocal Microscopy  
Cells were used as samples in this experiment. Harvested samples were snap frozen 
in liquid nitrogen prior to OCT embedment and cryo-sectioning. Next, all samples were 
cut to 5 µm in size using a cryostat at -220C and sectioned samples were transferred 
onto a microscope slide with 3 sections per slide with respect to their experimental 
condition. When samples are adequate, slides were stored at -800C before experiment 
on the next day.  
 
On the next day, to label the samples with fluorescence dye, samples were air dried 
for 15 minutes at room temperature. Next, slides with the samples were fixed in ice 
cold methanol/acetone at -200C for 10 minutes followed by incubation at room 
temperature with 0.25% Triton X-100 in PBS for 15 minutes to permeabilise the 
tissues. After 15 minutes, samples were washed and incubated in blocking buffer (2% 
BSA in PBS) at room temperature in a dark metal humidified chamber for 30 minutes. 
Then, excess liquid on the samples was tipped off and samples were incubated with 
primary antibodies (diluted 1:100) in 2% BSA/PBS for 1 hour at room temperature in 
a dark humidifier chamber. Next, the samples were removed of excess antibody by 
washing three times in PBS (5 minutes each), followed by incubation with secondary 
labelled antibodies conjugated with FITC; Green, or Cy-3; Red fluorochrome for 1 hour 
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at room temperature in a dark humidifier chamber. After 1 hour, 4,6-diamidine-2-
phenylinole chloride (DAPI; Blue) (excitation/emission: 358/461) was added (1 µl/ml in 
PBS) to counterstain the nuclei for 5 minutes. Excess DAPI and secondary antibody 
were removed by washing the cells three times in PBS with 10 minutes each wash, 
followed by dipping slides in distilled water to remove excess salt. The slides were 
then mounted using a coverslip and Mowiol® (10% Mowiol in 25% glycerol with 0.1% 
p-phenylenediamine) as a mounting medium to minimize the fading of fluorochromes 
by the laser during fluorescence detection. 
 
Imaging of indirect labelled fluorescence on specific antigens was examined using a 
Nikon A1 confocal imaging system (Nikon, Japan) equipped with argon UV lamp and 
filters to investigate FITC, Cy3 and DAPI localisation. Samples were captured 
individually and acquired images were saved as N2 format on a Nikon software. 
Imaging exposure was kept constant throughout the capturing process between 
samples. Images were analysed using Nikon own software (Nikon acquired system 
software) for fluorescence intensity and the cellular localisation of the antigens.   
 
2.16 Immuno-blotting  
Immuno-blotting, also known as western blotting, is used to investigate relative protein 
expression and the possible signalling pathway activation in a homogenate protein 
sample. Cell homogenates were prepared by sonication as previously described 
(section 2.1.2) and the protein concentration of each sample was determined using 
the Bradford assay. Samples containing equal protein concentration (30 µg/10 µl) 
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were prepared by adding 3x sample buffer and diluting in an appropriate volume of 
assay buffer (lucigenin or lysis), followed by boiling at 950C for 5 minutes. A complete 
recipe for immuno-blotting is as below. 
 
To prepare for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) separation, Mini-Gels were prepared using the Bio-Rad Mini-protein IITM (Bio-
Rad, UK) according to the manufacturer’s instructions. Importantly, SDS-PAGE 
consists of two phases, a resolving gel of 10% acrylamide (Fisher Scientific) overlaid 
with a stacking gel of 5% acrylamide. 30µg of protein samples were loaded into each 
well in a total volume of 10 µl, alongside a dual protein molecular marker (Lonza). 
Next, the gels were run at 90V for 30 minutes followed by 120V for 90 minutes in ice 
cold 1xSDS running buffer until the loading dye was near to running off the gels. 
Immediately, the separated proteins within the gels were prepared for membrane 
transfer and immuno-blotting.  
 
In order to transfer separated proteins from the gel onto a Millipore® Immobilon-P 
Polyvinylidene Difluoride (PVDF) transfer membrane (Sigma), a Bio-Rad Trans-Blot® 
Semi-Dry Transfer Cell (Bio-Rad), UK) was used. A unit of Bio-Rad Semi-Dry Transfer 
Cell is able to transfer 4 gels at a time. Firstly, filter papers (Whatman, UK) were 
soaked in transfer buffer for 10-15 minutes; PVDF membranes were soaked in 
absolute methanol for 30 seconds followed by 2 minutes in distilled water and left in 
transfer buffer for 10 minutes. Then, the semi dry transfer was laid from bottom (anode) 
up by stacking 4 pieces of transfer buffer soaked filter papers; the PVDF transfer 
membrane; the resolved gel; and another 4 pieces of transfer buffer soaked filter 
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papers. The semi-dry transfer process was run constant at a lower voltage, 15V, for 1 
hour to enable larger molecular weight (>90kDa) protein transfer across from the gel 
onto the membrane. Next, the membranes were blocked with 5% non-fat milk/Tris-
buffered saline-0.1% Tween 20 (TBST) on an orbital shaker for 1 hour at room 
temperature. Then, the membranes were washed using washing buffers before 
proceeding to the next step. Membranes were then incubated with diluted primary 
antibody to their optimal concentrations in 2.5% non-fat milk/PBS overnight at 40C. 
Next morning, the membranes were washed three times in washing buffer (10 minutes 
each time) and immediately incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibody raised against mouse, rabbit or goat antibodies for 2 hours at room 
temperature on a slow orbital shaker. After 2 hours, membranes were washed another 
3 times using PBS (10 minutes each time). To detect the proteins of interest, indirect 
labelling of antigens was investigated by exposing the membrane to Enhanced-
Chemiluminescence Plus (ECLplus) reagent according to the manufacturer’s 
instructions (Bio-Rad, UK) and antigen detection was by a BioSpectrum AC Imaging 
System (UVP, UK). 60 images were captured in 20 minutes of exposure and each 
band was assayed for their optical density (OD) from the resulting image and 
normalised to alpha-tubulin as the loading control.           
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Recipe for western blot buffers 
Stacking gel buffer: 4x Tris.Cl/SDS (pH 6.8, 500ml): 30g Tris-base, 2g SDS, and pH 
to 6.8 with HCl. 
Resolving gel buffer: 4x Tris.Cl/SDS (pH 8.8, 500ml): 90g Tris-base, 2g SDS, and 
pH to 8.8 with HCl. 
3x sample buffer (100ml): 30ml Tris.HCl (pH 6.8), 30ml Glycerol (100%), 6g SDS, 
6% 2-mercaptoethanol (2-ME; added fresh), 40ml dH2O. 
10x running buffer (1 litre): 60g Tris-base, 290g Glycine and 10g SDS.  
1x Transfer buffer (1 litre): 3.75g Tris-base, 18g Glycine and 250ml absolute 
methanol. 
10x TBS washing buffer (1 litre): 30g Tris-base, 80g NaCl, 2g KCl, pH to 7.4. 
10x PBS washing buffer (1 litre): 80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4, 
pH to 7.4. 
 
Mini gel recipe  
10% resolving gel (4 mini-gels): 12ml H2O, 6ml 4x Tris.Cl/SDS (pH 8.8), 6ml 40% 
acrylamide, 12µl N,N,N’,N’-tetramethylethylenediamine (TEMED), 20µl 10% 
ammonium persulfate. 
5% stacking gel (4 mini-gels): 7.5ml H2O, 3ml 4x Tris.Cl/SDS (pH 6.8), 1.5ml 
40%acrylamide, 16µl TEMED and 160µl 10% ammonium persulfate. 
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Table 1: List of antibodies used in Western blotting 
Antibodies Species Dilution Company 
Nox2 Rabbit  1:1000 Santa Cruz  
P47phox Rabbit  1:1000 Santa Cruz 
GPCR43 Rabbit  1:1000 Santa Cruz 
Cyclin D Rabbit  1:4000 Santa Cruz 
Cyclin E Rabbit  1:4000 Santa Cruz 
Cyclin A Rabbit 1:4000 Santa Cruz 
Cyclin B Rabbit  1:4000 Santa Cruz 
PCNA Rabbit 1:4000 Santa Cruz 
P16 Rabbit  1:4000 Santa Cruz 
P53 Rabbit  1:4000 Santa Cruz  
α-tubulin Mouse  1:5000 Sigma  
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2.17 Capillary Formation/ Endothelial Cell Viability by Matrigel  
To investigate cell viability and capillary formation of HPMEC cells, BD Matrigel® 
Basement Membrane Matrix was used in this experiment. BD Matrigel Matrix is a 
solubilised basement membrane preparation extracted from Engelbreth-Holm-Swarm 
(EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins. The main 
composition of BD Matrigel Matrix is laminin, collagen IV, heparin sulphate 
proteoglycans and entactin/nidogen. BD Matrigel Matrix also contains growth factors 
such as TGF-β, epidermal growth factor, insulin-like growth factor, fibroblast growth 
factor, tissue plasminogen activator and other essential growth factors which occur 
naturally in the EHS tumor to promote cell proliferation and capillary formation. This 
basement membrane matrix is effective for attachment and differentiation of both 
normal and transformed anchorage dependent epithiliod and other cells such as 
neurons, hepatocytes and vascular ECs.  
 
To observe HPMEC cell viability and proliferation by its capillary formation, BD 
Matrigel® Basement Membrane Matrix was thawed overnight at 40C and mixed to 
homogeneity. All chambers on the tissue culture slide were coated with a thin layer of 
membrane matrix and allowed to gelatinise at 370C for 3 hours. Then, cells were re-
suspended in high glucose medium and with the presence of SCFAs and seeded on 
the gelatinised cell culture chamber slide. Prior to experiment, chamber slides were 
pre-coated with BD Matrigel® Basement Membrane Matrix (BD Bioscience, UK) with 
thin gel method as per manufacturer guidelines to enable cells to be plated and grow 
on top of the membrane matrix. Then, the chamber slide was left warm at 370C in a 
tissue culture incubator for 30 minutes to stabilise the membrane matrix before 
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seeding the cells into the chamber. After 30 minutes, 0.05x105 cells in the presence 
of cell culture medium were plated on top of the membrane matrix and cells were pre-
incubated with NaA and high glucose stimulation as in previous section (section 2.2 & 
2.3).  
 
After 24 hours of high glucose stimulation in the presence or absence of NaA, capillary 
formation was captured by using an EVOS® Cell Imaging System light microscope 
(Life Technology, UK). Images were then exported to ImageJ anggiogenesis software 
for data analysis.  
 
2.18 Nitric Oxide Bioavailability  
NO is a soluble gas continuously synthesised by the endothelium. It has been found 
to be a mediator of many physiological processes in maintaining normal vascular 
health. Its role is mainly involved in modulation of vascular dilator tone and impairment 
in its synthesis or increased levels in oxidative stress degradation are risk factors for 
the development of endothelial dysfunction that further leads to atherosclerosis, 
hypertension and hypercholesterolemia.  
 
To investigate the level of NO bioavailability, cell supernatants was used and assessed 
in this experiment by Griess Reagent Kit for Nitrite Determination (Invitrogen, UK). In 
this assay, sulfanilic acid convert diazonium salt by reaction with nitrite in an acidic 
solution and this salt is then coupled to N-(1-naphathyl)ethylenediamine to form an 
azo dye which is spectrophotometrically detectable. The Griess reaction can also be 
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used to analyse nitrate through its catalytic reduction to nitrite. First, 130 µl of 
deionised water was added into each well by an auto-pipette. Next, 150 µl of nitrite 
containing sample was added into each well through the wall of each well to avoid 
cross contamination between samples (except the blanks). Subsequently, 20 µl of 
Griess reagent (prepared following the manufacturer’s instructions) was added into 
each well by an auto-pipette. Then the plate was incubated for 30 minutes at room 
temperature to allow reaction to happen. Meanwhile, a photometric reference was 
prepared by mixing 20 µl of Griess reagent and 280 µl of deionised water for 
background reading. Finally, absorbance of each sample was measured at 548 nm 
and reading was cultured at 1 second for each well. 
 
2.19 Statistic Analytical Method 
Statistical analysis for broken capillaries branch experiments was carried out using a 
public domain Java-based image-processing program, ImageJ Angiogenesis 
Analyser. All results were analysed by one-way ANOVA along with Bonferoni post-
Hoc analysis method to determine the confidence of significance value for all the 
results. Data are expressed as the mean of at least three independent experiments 
with standard deviation (SD) and the *p<0.05 was used to indicated a significant 
difference.  
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Chapter 3: Investigation of High Glucose-Induced Oxidative Stress and the Effects 
of SCFAs on Endothelial Cells 
 
3.1 Introduction  
The ECs which line the blood vessels and occur within the heart are an active tissue 
that plays a vital role in maintaining cardiovascular homeostasis which includes 
essential functions such as maintaining vascular tone and tissue perfusion, vascular 
permeability, myocardial function, blood fluidity, anticoagulant activity and 
inflammatory responses (Li and Shah, 2004). Accordingly with appropriate changes in 
order to maintain normal homeostasis, vascular ECs have the ability to release 
(paracrine release) diffusible mediators such as NO, prostacyclin, endothelin-1 (ET-1) 
and growth factors. ECs also express surface proteins such as adhesion molecules 
that interact with other cell types. ECs are also able to alter the activity of enzymes 
such as ACE, which regulates local levels of bioactive angiotensin II and bradykinin 
which relates to blood pressure in the vasculature.  
 
ROS are an important secondary messenger and signalling molecule in order to 
control and regulate essential biological processes in humans especially for the 
endothelium at the cellular level, e.g. for example defence against pathogens in the 
blood, vascular programmed cell death, cell cycle progression and renewal and 
vascular remodelling (Apel and Hirt, 2004). The generation of ROS by the ECs is 
important both physiologically and in the pathogenesis of many cardiovascular 
disorders. ROS generated by ECs includes superoxide (O2.-), hydrogen peroxide 
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(H2O2), peroxynitrite (ONOO-), NO and hydroxyl (.OH) radicals. Over production of 
ROS has emerged as an important pathogenic factor in the development of long term 
complications such as atherosclerosis and nephropathy in patients with diabetes (Li 
and Shah, 2003, Li and Shah, 2004). Changes in the microvasculature have been 
shown to play a significant role in diabetes progression (Katz et al., 2011). Oxidative 
stress involves any condition in which oxidant metabolites (e.g. oxygen radicals) can 
exert their toxic effects because of increased production. Excessive intracellular ROS 
production causes damage to lipids, proteins and alteration in DNA configuration and 
synthesis (Rowe et al., 2008, Li and Shah, 2004).  
 
DM is a common metabolic disease with a high and increasing prevalence worldwide. 
Diabetes is characterised by and is responsible for alterations in micro-and macro-
vascular beds, by inducing changes in neovascular mechanisms and impairing 
vascular homeostasis (Lee et al., 2014).  Dysfunction of the vascular endothelium is 
regarded as an important factor in the pathogenesis of micro- and macro-vascular 
pathogenesis which has led to increasing attention in the study of vascular disease in 
relation to the vascular endothelium (Xu et al., 2005, Hartge et al., 2006). High glucose 
also has been found to reduce cell viability and tube formation as well as promoting 
monocyte adhesion to the endothelium wall (Lee et al., 2014). Organ damage is the 
end stage result of chronic and constant elevation of glucose (hyperglycemia) in the 
blood stream. The heart is particularly affected by diabetes, resulting in 
cardiomyopathic phenotypes that have been well characterised. Vasculature 
pathogenesis or vascular alterations occur both structurally and functionally and have 
been one of the risk factors for stroke and myocardial infarction. Diabetic subjects have 
shown to have stiffened vessel walls in large arteries potentially due to the changes in 
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the composition of the extracellular matrix and paracrine interactions of the matrix with 
the surrounding cells. Sachidanandam et al. have shown the alteration in the 
composition in matrix or cell function and its interaction is known to be affected in 
diabetes (Sachidanandam et al., 2009). However, the mechanisms by which diabetes-
induced endothelial dysfunction happens remains poorly understood. 
 
Importantly, in western society the human population are getting more unhealthy by 
being more inactive (sedentary lifestyle) and incorporating poor diets in their lifestyle 
such as more fast food and ‘unclean eating’ with high levels of fat, salt, sugar, 
carbohydrates, preservatives and colouring in most of their diets. The term ‘we are 
what we eat’ is becoming a reality as a lot of unhealthy eating and being inactive leads 
to the development of metabolically related diseases such as T2DM, obesity, IR and 
in the long run the development of cardiovascular diseases. Worldwide researchers 
have been searching and trying to develop an alternative to overcome this obstacle 
related to the development of metabolic diseases as it is becoming a huge burden to 
the society and the government to handle as this matter is growing bigger yearly. 
Recently, a vast amount of research has found that certain nutritional factors are 
consistently linked to reduction of insulin sensitivity for example low dietary fiber 
intake, high trans fatty acid intake and high saturated fat intake (Parillo and Riccardi, 
2004). Moreover, research by Robertson et al. has shown an interesting fact where 
increasing consumption of resistant starch may modulate and increase insulin 
sensitivity in human studies (Robertson et al., 2005). There are other beneficial 
associations found between high fiber consumption and a reduced risk of irritable 
bowel syndrome, inflammatory bowel disease, colon cancer, cardiovascular disease 
and diabetes (Galisteo et al., 2008). Whole grain foods and legumes have been found 
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to protect against the development of T2DM and improve glycaemic control as well as 
delaying the progression of impaired glucose tolerance to T2DM and improved insulin 
sensitivity (Venn and Mann, 2004, Chandalia et al., 2000). Dietary-related metabolites 
engage ‘metabolite-sensing’ G-protein coupled receptors such as GPCR43 and 
GPCR41. These receptors are expressed on immune cells and some gut epithelial 
cells and generally mediate a direct anti-inflammatory effect (Thorburn et al., 2014). 
Other than having an anti-inflammatory effect on cells, SCFAs also exert multiple 
effects on mammalian energy metabolism. SCFAs are used as an energy source in 
humans. They provide approximately 10% of our daily calorific requirement (den 
Besten et al., 2013). In short, the evidence that whole grain foods and largely insoluble 
forms of dietary fiber derived from cereals protects against T2DM is strong and 
consistent among current studies (Venn and Mann, 2004).   
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3.2 Material and Methodology  
All experiments were done in a controlled manner to minimise any variations that might 
occur during experimental procedures such as tissue culture contamination. Clean and 
specific incubators were used to avoid cross-contamination between samples. 
Furthermore, cells were incubated at a fixed temperature, 370C, and exposed to a 
constant 5% CO2 and 95% O2 within the incubators throughout all experiments. 
Detailed experimental methods can be found in chapter 2. 
 
3.2.1 Glucose Dose Response   
To observe ROS production profile in ECs with high glucose stimulation, a glucose 
dose response experiment was performed on HPMEC cells (as detailed in the 
procedures in chapter 2.3). Glucose dose was started from the basal level at 5 mM 
ranging to 60 mM of concentration and stimulation was for 24 hours. ROS profile in 
ECs was measured by flow cytometry and analysis was done on the C6 flow cytometry 
analysis programme (figure 3.2.1 – next page).  
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Figure 3.2.1: Glucose dose experiment layout.   
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3.2.2 High Glucose Time Course  
To determine the suitable time point for all the experiments in this project, a high 
glucose stimulation time course experiment was performed ranging from 0 hour to 48 
hours. HPMECs were used in this experiment and ROS was detected by DHE flow 
cytometry. Data was analysed using a C6 flow cytometry programme (as detailed in 
the experimental procedure in chapter 2.3) (figure 3.2.2 – next page).  
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Figure 3.2.2: Glucose time course experiment layout. 
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3.2.3 Osmolality Analysis 
To inspect the concentration of the solution under its different conditions, a cultured 
cell culture medium was used. The different conditions varied and the measurements 
include FBS concentrations (0%, 5% and 10%), medium with SCFAs concentration 
(NaA, NaP and NaB), and medium with different glucose concentration (5, 10, 20, 30 
and 40 mM) and medium with high glucose (30 and 40 mM) in the presence of SCFAs. 
The experiment were carried out using an osmometer. For a detailed procedure refer 
to chapter 2.7) (figure 3.2.3 – next page). 
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Figure 3.2.3: Osmolality measurement experimental layout. 
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85 
 
3.2.4 pH Analysis  
To observe pH range in various conditions, a cultured cell medium was used and 
measured by using a pH meter (refer to chapter 2.8 for a detailed procedures). The 
different conditions of the medium has been mentioned previously (3.2.3) (figure 
3.2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.4: pH measurement experimental layout. 
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3.2.5 Morphology/ Structure Analysis 
To inspect the morphology of cultured cells treated with different conditions, at the end 
of cell culture process just before the cells were harvested for related experiments, the 
structure of cells morphology was taken under a light microscope. For more details 
refer to chapter 2.1.3 (figure 3.2.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.5: Observation of cell structure and morphology experimental layout. 
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3.2.6 ROS Detection by NADPH–Dependent Lucigenin–Enhanced Chemiluminescence 
Analysis  
To investigate ROS production in ECs with high glucose and in the presence of 
SCFAs, HPMEC cells were used in this experiment. ROS in cell homogenates was 
measured by using a lucigenin-enhanced chemiluminescence assay. For the detailed 
protocol refer to chapter 2.5 (figure 3.2.6 – next page). 
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Figure 3.2.6: ROS chemiluminescence measurement experimental layout. 
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3.3 Results  
3.3.1 Effects of High Glucose on Endothelial Cell Oxidative Stress Level in the 
Presence of Time and Doses as One of the Risk Factors 
ROS production in ECs is an important factor in cellular pathophysiology of the 
endothelium especially in the development of metabolic diseases. Therefore, to 
investigate the effect that high glucose has on ECs ROS production; HPMECs were 
used and subjected to stimulation with several doses of glucose ranging from 5 mM to 
60 mM for 24 hours. Glucose concentration above basal conditions stimulated higher 
ROS production compared to basal condition (5 mM) in HPMECs detected by flow 
cytometry (figure 3.3.1). 
 
 
 
 
 
 
 
Figure 3.3.1: The effect of various glucose concentrations on endothelial ROS production. 
Detection of O2.- production on HPMEC cell suspension with various glucose doses. HPMEC cells were 
stimulated with several doses of glucose concentration from 5 mM as the control to as high as 60 mM. 
ROS production was measured after 24 hours and event gated was measured for 20,000 cells by flow 
cytometry. n=3, mean ± SD, *p<0.05 for high glucose-stimulated versus control.  
  
    
  
    
  
 
 
 
  
0 
10 
20 
30 
40 
50 
60 
70 
5mM 10mM 20mM 30mM 40mM 50mM 60mM 
* 
* * 
* 
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 ROS 
Concentration (mM) 
90 
 
3.3.2 Effects of Time Course on HPMEC ROS Production 
Metabolic changes of a cell associated with extended exposure to contents such as 
high glucose or excess lipid levels escalate the development of diseases including 
T2DM, obesity and further into other cardiovascular related diseases chronically. 
Prolonged time exposure of glucose on HPMECs increases ECs ROS production. 
Therefore, to investigate the best time point to use as a fixed factor throughout the 
entire project, a time course was performed using HPMECs subjected to high glucose 
30 mM stimulation for a time course of 0 hour to 48 hours. Endothelial ROS production 
was detected by DHE (2 µM) flow cytometry. However, cells stimulated for 12 hours 
and above significantly stimulated ROS production (figure 3.2). 
    
 
 
 
 
 
 
Figure 3.3.2: High glucose treatment increase O2.- production in a time-dependent manner. 
Detection of O2.- production on HPMEC cell suspension at various hours. Cells were stimulated with 
high glucose (30 mM) and measured at 0, 3, 6, 12, 24, 36 and 48 hours by flow cytometry. Event gated 
and measured for 20,000 cells with n=3, mean ± SD, *p<0.05 for high glucose versus unstimulated at 
0 hour.  
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3.3.3 HPMEC ROS Production with High Glucose Compared To Basal Level 
In the vasculature, Nox2 is highly expressed and actively produce ROS in ECs 
throughout any metabolic diseases. Thus, to investigate the effect high glucose has 
on ECs ROS production, HPMECs were used and subjected to stimulation with high 
glucose 30 mM for 24 hours. Under basal conditions, cells have minimal ROS 
production sufficient for normal cell homeostasis detected by NADPH (100 µM)-
dependant lucigenin (5 µM)-enhanced chemiluminesence over a period of 30 minutes. 
Compared to the control (5 mM), 30 mM of high glucose significantly stimulated ROS 
production in HPMECs (figure 3.3.3). 
 
   
Figure 3.3.3: The effect of high glucose on HPMEC cell ROS production. (A) Kinetic reading of O2.- 
production and (B) intracellular of O2.- production in HPMEC cell homogenates stimulated with high 
glucose (30 mM; 24 hours) measured by NADPH (100 µM)-dependent lucigenin (5 µM)-enhanced 
chemiluminescence over 20 minutes. N=3, means ± SD, *p<0.05 for high glucose stimulated versus 
unstimulated.  
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3.3.4 Osmolality Level in Supernatant with Different Experimental Conditions  
Osmolality is an important factor in human blood circulation. Extreme changes in 
osmolality levels can affect and alter normal homeostasis of the human body. To 
investigate osmolality levels on solutions used in this set of experiments, an osmolality 
test was performed using the supernatant from cultured cells. Supernatant with or 
without FBS and in the presence of SCFAs does not change the osmolality level. 
However, there was a slight increase with the addition of glucose in the medium with 
or without SCFAs present in the solution (figure 3.3.4). 
 
 
 
 
 
 
Figure 3.3.4: The effect of glucose and SCFAs on HPMEC cell supernatant osmolality level. 
Detection of total osmolality in various HPMEC treated supernatant sample. Supernatant from various 
treatments was collected at the end of every treatment (after 24 hours) for measurement. Osmolality 
was measured using an osmometer. n=3, means ± SD, *p<0.05 for stimulated versus unstimulated.  
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3.3.5 pH Level in Supernatant with Different Experimental Conditions 
All tissue culture media consist of synthetic mixture of inorganic salts further known as 
physiological or balanced salt solution. Its functions other than to maintain proper pH 
level for cell culture, it is also to maintain ideal osmotic pressure as well as an energy 
source for cultured cells. Normally, optimal medium is buffered at pH between 7.2 and 
7.4.  Most common buffer used in tissue culture medium is sodium bicarbonate. Some 
medium consist of low sodium carbonate (e.g. Hank’s Balanced Salt Solution) and 
some intended to equilibrate with gaseous such as 5% CO2 with a higher level of 
sodium bicarbonate (e.g. Earle’s Balanced Salt Solution). Most medium provided an 
indication such as colour change (e.g. phenol red) to show increase level of pH in the 
culture medium. Apart from sodium bicarbonate, some media uses free base amino 
acids with added pyruvate and glucose instead of galactose as a buffering capacity. 
pH is an interesting factor that can alter normal cellular physiology. A permanent 
challenge for the ECs in the blood vessels when there is an alteration in pH occur in 
the circulation and oxidative stress is another factor that may influence the intracellular 
pH (pHi) and extracellular pH (pHe) in the endothelium. Unsuitable and imbalanced 
pH levels (too acidic or too alkaline) can effect cell proliferation and cause cells to 
undergo cell death. Fluctuation in pH is known to play an important regulatory role 
both intracellularly and extracellularly linking neural, glial and vascular tissue function 
and acting to control enzyme function and ion channel conductance. To investigate 
pH level in solutions, supernatant from cultured cells was used to perform a pH test. 
All of the solutions have a pH ranging between 7 to 8 (figure 3.3.5 – next page).  
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Figure 3.3.5: The effect high glucose and SCFAs on HPMEC cell supernatant pH level. Detection 
of pH level in various HPMEC treated supernatant sample. Supernatant from various treatments was 
collected at the end of every treatment (after 24 hours) for measurement. pH was measured using a pH 
meter. n=3, means ± SD, *p<0.05 for stimulated versus unstimulated.  
 
3.3.6 Cells Morphology Treated with Different Conditions 
ECs in the endothelium are a dynamic cellular organ that controls passage of nutrients 
into tissues, maintaining blood flow and regulating the white blood cells in the 
vasculature. ECs are flat epithelial cells that form a monolayer in the lumen of the all 
blood vessels. Under normal physiological condition, ECs are exposed to blood 
glucose levels between 3.6 – 5.8 mM which are tightly regulated in normal metabolic 
homeostasis processes. Metabolically active ECs produce mediators that affect 
vascular tone, cell adhesion, clotting homeostasis and fibronolysis in a well-controlled 
manner. Normal cell morphology and structure is important for normal cell 
homeostasis and activity. To investigate and observe the differences of ECs structure 
under high glucose conditions, HPMECs were used in this experiment. Cells were pre-
incubated with SCFAs for 1 hour and then subsequently stimulated with high glucose 
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death cells as compared to ECs in normal condition. There are not many difference in 
structure compared to all conditions however, high glucose treated cells show a 
slightly rounded morphology under the light microscope (figure 3.3.6 – next page). 
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Figure 3.3.6: The structure of ECs under different culture conditions. Observation of ECs 
morphology cultured in different conditions. After 24 hours stimulation with high glucose and in the 
absence or presence of NaA, morphological structure of cells was captured under an EVOS light 
microscope. Normal cells and rounded up or dead floating cells were pointed out by using errors. Data 
was collected with n=3 in separate individual experiment. 
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3.3.7 HPMEC ROS Production Stimulated by High Glucose in the Presence of 
SCFAs 
High glucose has been proven in many research studies to increase NADPH-oxidase 
2 enzyme activity and subsequent superoxide production in the vascular endothelium 
which commonly leads to endothelial dysfunction. On the other hand, research has 
found that increased consumption of resistant starch that release SCFAs as bi-
products after bacterial fermentation in the colon have shown to have an anti-
inflammatory property and are able to reduce hyperglycemia, improve IR and prevent 
obesity related complications. However, there is more to discover on the effects of 
SCFAs on cellular level such as its interaction with ECs under high glucose conditions, 
how these bi-products effects ECs ROS levels and cell viability and many more. To 
investigate this property of SCFAs on ECs, HPMECs were used in this experiment. 
Cells were pre-incubated with SCFAs for 1 hour before being stimulated with high 
glucose 30 mM for 24 hours in the presence of SCFAs. Under basal condition, ECs 
ROS were at a minimal level as detected by NADPH (100 µM)-dependent lucigenin (5 
µM)-enhanced chemiluminescence over a period of 30 minutes. However, 24 hours 
high glucose stimulation on ECs significantly increase ROS production as compared 
to the control. Importantly, high glucose stimulated ECs in the presence of SCFAs 
shows reduced level of ROS production as compared to the positive control (30 mM 
glucose) (figure 3.3.7 – next page).  
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Figure 3.3.7: The effect of high glucose-induced oxidative stress and SCFAs on endothelial cell 
ROS production. Detection of intracellular ROS production in HPMEC cell homogenates. (A) kinetic 
reading of O2.- production stimulated  by high glucose (30 mM; 24 hours) and intracellular O2.- production 
by high glucose in the presence of SCFAs (NaA; 5 mM, NaP; 5 mM and NaB; 4 mM) (B). Both were 
measured by NADPH (100 µM)-dependent lucigenin (5 µM)-enhanced chemiluminescence over 30 
minutes and intracellular O2.- production stimulated by high glucose and in the presence of NaA (5 mM) 
was measured by DHE and Tiron through  flow cytometry (C) and their flow cytometry profile (D). Data 
was collected with n=3, mean ± SD, *p<0.05 for high glucose stimulated versus unstimulated. 
High Glucose 
Glucose+NaA 
Minutes 
-100 
0 
100 
200 
300 
400 
500 
  
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
NADPH 
(A) (B) 
(C) (D) 
Control Glucose  NaA Glucose+NaA 
DHE 
Tiron 
I n
 d
 e
 x 
0 
1 
2 
3 
4 
* # 
M
ea
n
 L
ig
h
t 
U
n
it
/2
5
μ
g 
p
ro
te
in
s 
 
 
 
 
  
  
 
Control Glucose +NaA +NaP +NaB 
0 
50 
100 
150 
200 
 
  
* 
# 
# 
# 
M
ea
n
 L
ig
h
t 
U
n
it
/2
5
μ
g 
p
ro
te
in
s 
99 
 
3.4 Discussion    
The present study examined ROS production in response to various doses of glucose 
spanning both the physiologic and pathophysiologic range in T2DM with HPMEC cells 
as an in vitro model. Experiments such as glucose dose response, time course, 
osmolality level and pH balance were performed as the first step for this project to 
investigate their relationship between different solutions and cells physiological 
conditions. This initial step is important to understand and observe changes that may 
occur and the effect that different content of solutions have on cell structure as a whole. 
It is also important to observe whether increase in these parameters have an effect of 
ROS production in ECs.  
 
Our results show that osmolality (300 – 360 mOsm/dl) and pH (7 – 8) are below the 
harmful range and do not affect the cells physical structure (shrinking or swelling) in 
any way. The cell medium (M199) uses a sodium bicarbonate buffering system that 
requires a 5-10% CO2 environment to maintain physiological pH and one of the 
ingredients, phenol red, was used as a useful indicator to look at the changes in the 
pH level where it turns red to yellowish orange colour when the medium is acidic. It is 
very important to maintain a normal and healthy cells to ensure that the results are not 
influenced by other external factors and that the outcome results are solely from the 
compound introduced. Importantly, pH over 8 has been shown to exert toxic effects 
and cell death was observed by researchers (Zetterberg and Engstrom, 1981). 
Moreover, pH can influence various effects on cells for example cellular interaction. 
For example, the interaction between the brain and endothelial cells, also known as 
neurovascular unit that form the blood brain barrier, is very sensitive to pH changes 
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(pH dependent) that link to the brain and at a lowered pH 6.8 and below had shown to 
cause cholinergic neurons to undergo cell death (Humpel, 2011). On the other hand, 
a study from others has shown that higher osmolality (above 500 mOsm/kg) solutions 
caused some phlebitis changes, such as loss of venous ECs, inflammatory cell 
infiltration and oedema (Kuwahara et al., 1998). It was found that high osmolarity also 
caused high blood flow in response to heat while lower osmolarity cause reduced 
blood flow response to heat in skin cells (Petrofsky, 2012). Moreover, it was found that 
bovine aortic endothelial cells exposed to hypertonic media of 330 to 570 mOsm/liter 
for 6 to 30 days caused cell death (Luh et al., 1996). 
 
In this part of the study, the results show that high glucose at 30 mM promotes a 
constant elevation of ROS production in HPMEC cells at 24 hours of stimulation 
detected using lucigenin-enhanced chemiluminescence method while all other factors 
such as osmolality and pH remain constant in all experiments throughout this project. 
It is worth mentioning here that every detection methods has its pros and cons. 
Lucigenin-enhanced chemiluminescence is a commonly used technique for 
measuring intracellular O2.- lucigenin is a cell permeable compound and it is 
reasonably specific for O2.-  detection, thus it is suitable for homogenates and whole 
cells experiments. The signal generated from lucigenin-enhanced chemiluminescence 
is well within linear range of pathological samples even though normal tissues have 
low levels of O2.- (Dikalov et al., 2007). This method is also inexpensive and can be 
performed with equipment fitted with a lumino meter commonly available in the lab. 
The downside of this method is that the validity of this assay has been questioned 
where O2.- production may be artificially overestimated because the lucigenin radical 
can react with oxygen and generate O2.-, it is known as redox cycling (Tarpey and 
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Fridovich, 2001). However, the artefact signal generated using a low level (5 µmol/L) 
of lucigenin is probably insignificant (Dikalov et al., 2007). Normally, to address the 
matter on redox cycling of lucigenin, researchers will do another assay to detect ROS 
in cells. In this project, dihydroethidium (DHE) fluorescence flow cytometry assay was 
used to detect ROS in cells. The interaction of DHE is relatively specific to O2.- to 
produce ethidium bromide that will intercalate with DNA in cells (Tarpey and Fridovich, 
2001). A fluorescence microscope was used to visualised the intensity of the signal 
that represents the level of O2.- present. Nonetheless, the use of DHE is associated 
with several problems such as ethidium bromide, the product of DHE oxidation, 
because it binds to DNA therefore the differences in chromatin density in heterocellular 
organs makes it difficult to image with DHE. Moreover, it was found that unspecific 
oxidation of DHE by O2.- forms another dye known as oxyethidium which has a different 
spectral characteristics from ethidium. The differences between these two compound 
can be detected by using high-performance liquid chromatography (HPLC) to separate 
ethidium from oxyethidium (Brandes and Janiszewski, 2005). Apart from these 
differences, our result is in agreement with previous studies indicating a linear 
relationship between high glucose and ROS production in ECs (Nishikawa et al., 2000, 
Giardino et al., 1996, Shenouda et al., 2011, Bellin et al., 2006). Also, 30 mM of high 
glucose concentration has been chosen to cover the maximum clinical level in 
patients. Thus, this specific dose and time point has been selected as a constant factor 
throughout the whole project. 
 
Hyperglycaemia is one of the hallmarks of DM and it is a major risk factor for 
endothelial dysfunction and vascular complication. Risk factors for cardiovascular 
diseases include T2DM and are characterised by having excess production of ROS in 
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the vasculature. The most important source of ROS in the endothelium is from NADPH 
oxidases. NADPH oxidases are the predominant source of O2.- in human vasculature 
and Nox2 has been shown to be highly expressed in ECs (Sena et al., 2013, Symons, 
2013).   
 
In this era, the society is more inactive and unhealthy diets are consume more in daily 
life and this includes food that consist more of high salt, sugar, fat and carbohydrate, 
thus, this causes the population to be more prone to diabetes and obesity that further 
leads to the development of cardiovascular diseases (CVDs) in the long run. 
Researchers have shown that hyperglecemia and hyperlipidemia have caused an 
increase in ROS production in the vasculature in metabolic diseases (Shen, 2010). 
Our results also show that pre-incubating HPMEC cells with SCFAs are able to 
reduced high glucose-induced ROS production as compared to the positive control. In 
accordance with our results, recent studies has shown that increase in fiber 
consumption exert anti-inflammatory properties as well as being able to increase 
insulin sensitivity, reduce hyperglycemia and obesity related complication (Tedelind et 
al., 2007). However, SCFAs at concentrations above 20 mM are toxic to cells 
(Mirmonsef et al., 2012). 
 
In summary, with the recent experimental derived findings we are able to propose an 
optimistic thought that dietary supplementation with resistant starch has the potential 
to improve metabolic related disorder. However the underlying mechanisms of how 
SCFAs have their effects on cells at the cellular level are still unclear. Thus, we take 
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this further by looking at the effects SCFAs have on cell cycle progression, cell viability 
and apoptosis profile in HPMEC cells.  
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Chapter 4: Effects of High Glucose and SCFAs on Cell Proliferation and Protein 
Expressions 
 
4.1 Introduction  
To achieve and maintain normal homeostasis and neovascularization, ECs have to be 
able to respond to changes, for example, in hemodynamic forces, ambient pO2 and 
local signals with appropriate changes. To hit this target, the endothelium cells have 
to be stable (highly quiescent) but at the same time also able to undergo angiogenesis 
(proliferation) and remodelling (apoptosis) when necessary. To sustain normal 
endothelial cell function and survival, the endothelium requires a constant supply of 
nutrients and growth factors. Lately, several reports found that NADPH oxidase-
induced ROS production may serve as signalling molecules involved in the regulation 
of endothelial cell growth, death and function (Breton-Romero and Lamas, 2014, Irani, 
2000). Endothelial cell function and cell fate are tightly coupled to cellular redox state 
and a well-controlled endogenous ROS generation is absolutely necessary for normal 
endothelial cell proliferation, re-generation/angiogenesis and remodelling through a 
stable cell cycle control system (Trachootham et al., 2008). NADPH oxidase is 
expressed constitutively in ECs and represents a major source of O2.- production in 
the endothelium and vasculature (Gorlach et al., 2000). Under normal physiological 
condition, endothelial cell NADPH oxidase produces a low level of ROS (as a 
secondary messenger) sufficient to regulate cellular signalling (Tickner et al., 2011).  
However, the precise roles of NADPH oxidase enzymes on endothelial cell growth or 
growth arrest (cell cycle regulation) are far from clear. 
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ECs are well known in the literature to express constitutively a major isoform of the 
catalytic subunit of NADPH oxidase enzyme (Nox2), which is a major source of ROS 
in the endothelium in pathological conditions (Li et al., 2007). According to Li et al., 
when cells undergo stress conditions e.g. ischemia, angioplasty, organ transplantation 
or when ECs experience sustained nutrient deprivation (starvation), Nox2 expression 
was upregulated in these cells. The upregulation of the Nox2 subunit was 
accompanied by an increase in O2.- production under nutrient deprivation in human 
dermal microvascular ECs (Li et al., 2007).  
 
All cells arise by division of existing cells as cell reproduction is fundamental to the 
development and function of life. The mammalian cell cycle process is tightly 
controlled by a series of phases (G0/G1 checkpoint, S phase, G2 checkpoint, M 
phase) guarded by systemic regulatory molecules known as cyclins, cyclin-dependent 
kinases (CDKs) and CDK inhibitors (CDKIs) that were put in place to control and obtain 
extreme accuracy during cell cycle progression (Wolf, 2000). 
 
Many reports have shown that high glucose activates and elevates Nox2-induced ROS 
production in ECs in vitro and in vivo studies (Kumar et al., 2015, Kowluru et al., 2014, 
Patel et al., 2013, Sukumar et al., 2013, Ebrahimian et al., 2006). Abnormalities which 
occur functionally and anatomically of the endothelium may represent a pathway to 
increased vascular permeability, reduced cell viability, increased apoptosis as well as 
accelerated atherosclerosis are trademarks of diabetes.  
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4.2 Material and Methodology  
All experiments were done in a controlled manner to minimise any variations that might 
occur during experimental procedures such as tissue culture contamination. Clean and 
specific incubators were used to avoid cross-contamination between samples. 
Furthermore, cells were incubated at a fixed temperature, 370C, and exposed to a 
constant 5% CO2 and 95% O2 within the incubators throughout all experiments. 
Detailed experimental methods can be found in chapter 2. 
 
4.2.1 HPMEC Cell Cycle Profile  
To get a picture of how the cells proliferate, expand and behave under normal and 
extreme conditions, one must look at its cell cycle profile experiment. ECs under the 
normal physiological state are often in the quiescence phase where cells don’t 
proliferate as often as compared to cells in the digestive tract. However, under 
conditions such as oxidative stress, shear pressure, radiation, or exposure to harsh 
chemicals in the bloodstream that ultimately lead to damage to the cell internal 
components or external structure, cells will be lead into a repair mode through cell 
cycle progression provided there are other cell proliferation stimulants and enough 
nutrients for the cells to steadily undergo this process. To investigate the cell cycle 
profile in a normal and a high glucose stimulated condition in the presence or absence 
of SCFAs; HPMEC cells were used in this experiment and detected using a flow 
cytometry method. For a detailed procedure refer to chapter 2.9 (figure 4.2.1 – next 
page).     
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Figure 4.2.1: Cell cycle profile experimental layout. 
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4.2.2 HPMEC Cell Viability Analysis  
The cell viability test is used to evaluate how cells react in the presence of a tested 
compound. Whether the compound is toxic and will cause cells to undergo cell death 
or the compound is safe for cells and does not have an effect on cell proliferation is 
the aim. To investigate whether cells viability is affected with high glucose stimulation 
plus in the presence or absence of SCFAs, HPMEC cells were used for the test. For 
further detail on the procedures refer to chapter 2.10 and 2.11 (figure 4.2.2).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.2: HPMEC cell viability experiment layout. 
Seed cells to confluence  
Pre-incubate with SCFAs  
Stimulate with high glucose  
Add reagent from manufacturer 
Incubate for 2 hours 
Detect on microplate reader 
Data collection 
Cell viability profile experiment 
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4.2.3 HPMEC Apoptosis Analysis 
Apoptosis is a tightly regulated cellular suicide mechanism and it is a normal process 
occurring in living cells. This process is used by cells to repair any damage that occurs 
internally or physically and getting rid of defective cells through the daily harsh 
environment that we are exposed to. Apoptosis or cell death occurs through the 
activation of caspases enzymes (proteases) that further cleave and activate 
downstream effector caspases which in turn execute apoptosis which is characterised 
by nuclear condensation, cell shrinkage, membrane blebbing and DNA fragmentation. 
To investigate whether high glucose and SCFAs have a toxic effect on cells or 
otherwise, HPMEC cells were used in this experiment to get a clearer insight. For 
detailed procedure on this experiment refer to chapter 2.12 (figure 4.2.3 – next page). 
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Figure 4.2.3: high glucose-induced apoptosis experiment layout. 
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4.3 Results 
4.3.1 HPMEC Cell Cycle Profile Stimulated with High Glucose and NaA   
Healthy endothelial cell growth and function starts from its tightly regulated cell cycle 
progression. Provided with sufficient nutrients and growth stimulators, a cell in its 
quiescent state will proceed into cell cycle progression and undergo all the essential 
phases in this process. However, if there are factors such as high oxidative stress, 
lack of nutrients or DNA damage occurring around or within the cell this process will 
not continue and the cell will undergo a quiescence phase, apoptosis or cell death 
pathway instead. Therefore, to investigate the effect that high glucose has on 
endothelial cell cycle progression, HPMECs were subjected to stimulation with high 
glucose at 30 mM for 24 hours in the presence of NaA. High glucose increases the 
synthesis of cell contents in S and cell duplication in the mitosis phase compared to 
the control. On the other hand, cells incubated with NaA have a similar trend in the S 
phase compared to high glucose stimulation. However, NaA incubated cells have a 
similar trend as compared to control. Nevertheless, cells stimulated with high glucose 
in the presence of NaA reduce the S and mitosis phase compared to cells treated with 
high glucose (figure 4.3.1 – next page). 
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Figure 4.3.1: The effect of high glucose and SCFAs on HPMEC cell cycle progression. 
Investigation of cell cycle profile in HPMEC cells pre-incubated with NaA (5 mM; 1 hour) subsequently 
stimulated by high glucose (30 mM; 24 hour) measured by flow cytometry. Each cell cycle stages from 
G0/G1, S to G2/M were assessed. Event gated and measured for 20,000 cells with n=4, mean ± SD, 
*p<0.05 for high glucose versus unstimulated.  
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4.3.2 HPMEC Cell Viability 
Cells in a healthy state are important for normal cell function to maintain essential 
processes in the human body. Cell viability assays are used to look at the organ’s, 
tissue’s or cell’s viability profile resulting from the effect of a test compound or 
stimulants tested in vitro. Multiple research has shown that factors such as oxidative 
damage, hyperglycaemia, and hyperlipidaemia reduce cell viability. However, this 
effect was reduced with addition of antioxidants and oxidative stress inhibitors. 
Therefore, to investigate the effect that high glucose and SCFAs have on endothelial 
cell viability profile; HPMECs were used in this experiment. The cell viability profile 
was reduced about 60% with cells stimulated with high glucose as compared to cells 
incubated with other conditions (figure 4.3.2 A). Meanwhile, by using another cell 
viability method, our result showed about 20% of reduction on cell viability with cells 
stimulated with high glucose as compared to the control (figure 4.3.2 B).  
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B. Cell viability with CellTitre-Glo®  
 
 
 
 
 
 
 
Figure 4.3.2: The effect of high glucose and SCFAs on HPMEC on cell viability. Investigation of 
cell viability profile in HPMEC cells incubated with high glucose (30 mM) and SCFAs (NaA; 5 mM, NaP; 
5 mM and NaB; 4 mM) detected using MTT assay kit (figure A). A second method was carried out 
further to test HPMEC cells viability profile with high glucose and in the absence or presence of SCFAs 
using cellTiter-Glo® luminescence cell viability assay detected by using a microplate reader (figure B). 
Data was collected with n=3, mean ± SD, *p<0.05 for high glucose versus unstimulated. 
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4.3.3 HPMEC Apoptosis Analysis Stimulated with High Glucose and in the Presence or 
Absence of NaA 
Apoptosis or cell death is a normal cell process that is tightly regulated and occurs 
during tissue repair and cell or DNA damage to remove the unwanted cell 
accumulation and prevent defective cells from growing. However, other risk factors 
such as hyperglycaemia, high fat diet and shear stress may also cause cells to 
undergo apoptosis by activation of apoptotic pathways in cells through caspases 
activation such as caspase-3 or caspase-7 pathways or both which drive cells to the 
cell death pathway. To investigate this process, HPMEC cells were used in this 
experiment subjected to high glucose stimulation with the absence or presence of 
SCFAs. In agreement with previous reports, high glucose increases apoptosis 
processes as compared to the control and there are no differences in apoptosis 
progression between cells incubated with NaA alone and NaA in the presence of high 
glucose as compared to the unstimulated cells (figure 4.3.3 – next page).  
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Figure 4.3.3: The effect of high glucose and SCFAs on HPMEC cell apoptosis profile. Investigation 
of apoptosis or cell death profile on HPMEC cells. ECs were stimulated with high glucose 30 mM and 
in the presence or absence of NaA 5 mM for 24 hours measured by a microplate reader. Data was 
measured and collected with n=3, mean ± SD, *p<0.05 for high glucose versus unstimulated.  
 
 
 
 
 
 
 
Control Glucose NaA Glucose+NaA 
0 
20000 
40000 
60000 
80000 
100000 
R
e
la
ti
v
e
 L
ig
h
t 
In
te
n
s
it
y
 
* # 
117 
 
4.4 Discussion  
High glucose increases the drive for EC turnover. However, a constant elevation of 
glucose level in the blood causes ECs to lose their quiescence phenotypic character 
and cells in turn acquire new phenotypes with impaired normal function accompanied 
by ROS production, increased oxidative stress and enhanced permeability of the cell 
layer, and this condition is often regarded as endothelial cell dysfunction (Kern et al., 
2010). 
 
It is in agreement with a study done by Lorenzi at el., where they found high glucose 
caused a decreased cell population in the G0-G1 phase and an increased population 
in the S phase compared to the control sample. This suggests that the replicative delay 
or defects are most likely to occur between DNA synthesis and the mitosis phase 
(Lorenzi et al., 1985). Here, we found that there was an increased suppression in cell 
number and cellular death was definitely seen in cultures stimulated with elevated 
glucose concentrations as compared to control samples and this is in agreement with 
other researchers’ findings (Lorenzi et al., 1985, Quagliaro et al., 2003). Cells 
subjected to high glucose stimulation induce delayed cell replication, impaired local 
injury repair and excess cell death in cultured vascular ECs. This effect was seen in 
an experiment done on HUVEC exposed to 30 mM glucose for short (24, 48 and 72 
hours) and long term (13 +/- 1 days) investigation on the apoptosis profile and it was 
found that after 48 hours and above with high glucose stimulation increased DNA 
fragmentation and increased apoptosis compared to control cultures at 5 mM glucose 
occured. High glucose level mimicking diabetic hyperglycemia resulted in excess cell 
death and decreased replication of human ECs in culture and has led to a conclusion 
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whereby high glucose concentration may be toxic to ECs by inducing DNA damage 
(Lorenzi et al., 1986). However, apoptosis processes on cell culture at 24 hours with 
high glucose was only slightly affected (Baumgartnerparzer et al., 1995, Di Wu et al., 
1999). In contrast, we found that the number of cells undergoing apoptosis was 
significant at 24 hours of culture as compared to control. This suggests that the 
damage to cells under high glucose stimulation may start earlier and it is accompanied 
by oxidative stress production that may further lead to endothelial dysfunction as the 
outcome (Quagliaro et al., 2003).  
 
Elevated glucose levels also induce phenotypic changes in cells that are ongoing 
despite the glucose level returning back to normal levels (Fioretto et al., 1998).  ECs 
exposed to high glucose shows an increase in DNA repair synthesis. These findings 
suggest that under high glucose conditions, excess glucose entry to cells is insulin 
independent for glucose transport and may, directly or indirectly, perturb DNA function. 
Furthermore, it was also suggested that there are possibilities that different individuals 
have different capabilities to repair DNA damage and it is a process that is under 
genetic control. This may represent a mechanism for different individual 
susceptibilities to development of diabetic vascular complications (Lorenzi et al., 
1986). The other possible reason that has been suggested is that high glucose-
induced host DNA damage and lesions-repair mechanisms differ between individuals 
and their susceptibilities to vascular complications of diabetes since DNA lesions can 
be effectively repaired and the repair systems of each individual varies under its 
genetic control (Lorenzi et al., 1986). DNA damage induced by diabetic hyperglycemia 
is sufficient to alter gene expression and viability of cellular systems and leads to a 
host of abnormalities of structure and function at a cellular level (Lorenzi et al., 1986, 
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Pang et al., 2012). Both of our cell viability results on high glucose stimulated cells had 
reduced cells viability about 60% in figure 4.3.2 A and about 20% in figure 4.3.2 B. 
This may be because of the different main compounds in these two different products. 
MTS assay is a simple colometric assay where is it as easy as “add-incubate-
measure” format with single-step reagent addition which enable a homogenous high-
throughput screening to be possible. This assay is non-radioactive, less toxic, water 
soluble and do not require volatile organic solvent to solubilise the formazan product 
(Wang et al., 2010). The disadvantage of MTS method is that viable cells were 
incubated with tetrazolium for a period of time to generate signal and it is possible that 
this would generate artifacts from the chemical interactions among the chemistry 
assay, biochemistry of the cells as well as the compound being tested (Riss et al., 
2004). On the other hand, CellTiter-Glo® luminescence cell viability assay detects 
viable cells in culture based on quantitation of ATP present that indicative of 
metabolically active cells. This assay is more sensitive, accurate and uses as few as 
15 cells/well in a 384-well format or 50 cells/well in a 96-well format. The luminescence 
signal is very stable with a half-life of more than 5 hours and do not need to incubate 
live cells for a period of time. Data can be recorded as fast as 10 minutes after adding 
the reagent and it is less prone to artifacts. This assay do not need to rely on long 
incubation step such as MTS assay. However, the ATP assay sensitivity is limited by 
reproducibility of pipetting replicate samples instead of the result of the assay 
chemistry (Riss et al., 2004). Nonetheless, further studies on the effects that high 
glucose has on cells at its cellular level with other various detection methods are 
warranted. 
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Healthy cells are important and essential to maintain normal homeostasis and body 
function in organisms. In a normal physiological condition, a low level of ROS is 
important to regulate cellular signalling in cells however an excess level of ROS in the 
setting of diabetes is detrimental. Nevertheless, numerous research has been done to 
investigate the clinical outcome that may yield some positive results to systematically 
understand the culprit underlying the pathogenetic process of Nox2-induced ROS 
production and its mechanisms in diabetes. However, this process is still far from clear. 
 
 
 
 
 
 
 
 
 
 
 
121 
 
Chapter 5: Effects of High Glucose on Human Vascular ECs in the Presence or 
Absence of SCFAs 
 
5.1 Introduction  
DM and its  vascular complications represent a serious risk factor for the progression 
and development of cardiovascular diseases such as coronary heart diseases, 
peripheral arterial diseases, hypertension, stroke, cardiomyopathy, nephropathy and 
retinopathy (Yung et al., 2006). To be able to understand the pathogenesis of this 
increased risk will give an insight into the secondary intervention aimed to reduce 
morbidity and mortality in diabetic patients and further aid the development of 
cardiovascular diseases in the long run. Other possible mechanisms for the 
development of diabetic complications include the prothrombotic state, increased level 
of inflammation, hyperglycemia, protein glycation and endothelial dysfunction (Haidara 
et al., 2006). Dysfunction of endothelial cell function has a key role in the initiation of 
cellular events that involve the progression of vascular complications in diabetes and 
other diseases such as hypertension and obesity (Sena et al., 2013, Virdis et al., 
2013). Defects in the production and function of endothelium-derived NO and other 
vasoprotective factors and/or the overproduction of pro-inflammatory and 
vasoconstrictors such as angiotensin II, endothelin-1, of ROS and increased 
production of cyclooxygenase-derived metabolites of arachidonic acid ultimately lead 
to endothelial dysfunction that causes an increase in vascular tone that further 
contributes to the development of macro-, micro-vascular bed and renal damage, 
vascular and cardiac remodelling and hypertension (Mauricio et al., 2013, Wong et al., 
2010). 
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 The possible linking element between many of these phenomena could be, among 
other factors, overproduction of ROS in the vasculature (Haidara et al., 2006, Elahi et 
al., 2009). There are many factors that can activate the endothelial NAPDH oxidase 
enzyme to overproduce ROS and cause subsequent damage in the vasculature. 
These include internal deleterious changes in the form of endoplasmic reticulum (ER) 
stress and genomic stress; DNA damage caused by genotoxic agents, ionizing 
radiation, mitotic spindle damage, hypoxia or ribonucleotide depletion. As well as 
external factors such as high glucose (hyperglycemia), high fat (hyperlipidemia), shear 
stress, proteins and nucleic acids (Jiang et al., 2011). Under physiological conditions, 
vascular ECs possess various actions that are essential for normal homeostasis 
between cells and organs to form a functional system and this is especially important 
to sustain normal endothelium and cardiovascular health. Depending on cell type, 
these functions include cell growth, migration, apoptosis and gene expression as well 
as membrane matrix regulation (Taniyama and Griendling, 2003). ROS at a minimal 
level acts as a second message to regulate cell signalling and maintain normal 
vascular physiology (Morrell, 2008). Many other functions of the ECs are affected by 
ROS, However, when overproduction of ROS overwhelm the endogenous antioxidant 
systems in cells, this condition is to be known as the oxidative stress state. Normal 
physiological actions of ECs, among other functions, production of NO, which 
regulates vasodilation, anticoagulation, leukocyte adhesion, smooth muscle cell 
proliferation and the antioxidative capacity of ECs. Elevated ROS levels causes 
endothelial cell apoptosis, increases monocyte adhesion and plays an essential role 
in angiogenesis. It is well known in the literature that high glucose mimicking DM 
triggers the activation of NADPH oxidase 2 (Nox2) and upregulation of its cytosolic 
subunit, p47phox, which is important for the functional activation of Nox2 to produce 
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ROS  in the endothelium to further contribute to the development of diabetic 
complications (Frey et al., 2009). Furthermore, research found that there was an 
increase in the NADPH oxidase activity and endothelial nitric oxide synthase 3 
(eNOS/NOS3) uncoupling on the saphenous veins and internal mammary arteries of 
diabetic subjects (Guzik et al., 2002). Excess production of vascular endothelial cell 
ROS interferes with eNOS coupling to its cofactor, BH4, that leads to reduce NO 
bioavailability and further contributes to the development of diabetic complications in 
the blood vessels (Haidara et al., 2006). The role of oxidative stress in the 
development of cardiovascular complications in DM at the cellular level is yet to be 
discovered and understood. 
 
Poor diet and a sedentary lifestyle are two of the major factors contributing to the 
development of T2DM in this era. Studies from Salmeron et al. have found that daily 
food intake with low fiber and high glycemic index is positively associated with the 
increased risk of diabetes in men and woman (Salmeron et al., 1997). Various 
research has noticed the beneficial effects of fiber in products such as whole grain, 
oatmeal, bran, nuts, fruits and vegetables in association with lowering the risk of 
diabetes (Hu et al., 2001). Another study has found that animals with naturally 
occurring insulin-dependent DM fed with high fiber significantly lower blood glucose 
concentration in the blood (Kimmel et al., 2000). Moreover, diets containing food rich 
in insoluble and soluble fiber was found to significantly improve glycemic control in 
T2DM patients (McIntosh and Miller, 2001). The beneficial role of fiber has attracted 
high attention among researchers. A number of studies have shown that SCFAs from 
resistant starch and insoluble fiber fermentation by anaerobic gut flora is beneficial in 
protecting against obesity, metabolic disorders and cardiovascular disease (Roelofsen 
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et al., 2010, Jenkins et al., 2000, Johnston et al., 2010). Other research by Anderson 
and colleagues found that oral administration of insoluble oat fiber was able to reduce 
fasting blood glucose, low density lipoprotein cholesterol and apolipoprotein B-100 in 
T2DM patients (Anderson et al., 1991). SCFAs have been known to regulate important 
biological processes in the body for example cell growth, differentiation, proliferation 
and apoptosis (Vinolo et al., 2009). Apart from becoming an energy source for the 
colonocytes they are also able to modulate leukocyte functions for example 
chemotaxis as well as ROS production (Vinolo et al., 2009). This important ability of 
SCFAs could be beneficial to prevent atherosclerosis formation. However, this 
mechanism is far from clear. 
 
Few studies have assessed ROS production and their mechanisms of action with 
SCFAs on ECs in-vitro and in-vivo. This area of research is crucial especially as most 
metabolic diseases have in common the overproduction of ROS and endothelial 
dysfunction. Crucial diet intervention is urgently needed to prevent metabolic diseases 
and cardiovascular diseases naturally and these SCFAs seems very promising in 
decreasing the ROS production in ECs and may prevent endothelial dysfunction. A lot 
more research work has to be done looking at the relationship between the 
mechanisms of SCFAs and redox sensitive pathways as these are essential targets 
for therapeutic discovery to prevent metabolic diseases and cardiovascular diseases. 
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5.2 Materials and Methodology 
All experiments were done in a controlled manner to minimise any variations that might 
occur during experimental procedures such as tissue culture contamination. Clean and 
specific incubators were used to avoid cross-contamination between samples. 
Furthermore, cells were incubated at a fixed temperature, 370C, and ensuring 
exposure to constant 5% CO2 and 95% O2 within the incubators throughout all 
experiments. Detailed experimental methods can be found in chapter 2. 
 
5.2.1 Capillary Formation Assay 
To get a glimpse of the structure of endothelial cell proliferating into capillaries on 
culture, HPMEC cells were seeded on a Matrigel pre-coated chamber microscope 
slide. ECs are the first cells that expose to the contents to the blood and play an 
important role to maintain normal endothelium function in the vasculature. However, 
depending on the contents within the blood (e.g. high glucose, salt, fat or pressure), in 
the extreme or disease setting, this may cause detrimental effects to the ECs lining 
the vasculature. Damaged ECs (endothelial dysfunction) may be the starting point of 
various diseases such as diabetes and obesity that will lead to the progression of other 
cardiovascular diseases in the long run. To observe the effect that substances have 
on the capillary formation by cells, ECs were pre-incubated with SCFAs and 
subsequently stimulated by high glucose for 24 hours. Capillary structures were 
collected using an EVOS light microscope. The details of this procedure can be found 
in chapter 2.17 (figure 5.2.1 – next page). 
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Figure 5.2.1: HPMEC capillary formation with Matrigel experiment layout. 
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5.2.2 High Glucose Nox2 and GPCR43 Expression 
To observe the location of NADPH oxidase 2 (Nox2) protein, GPCR43 receptor and if 
possibly their ability to co-localise with each other, an immunofluorescence staining 
was done to address this area. Immunofluorescence staining is another method to 
qualitatively measure the intensity of labelled antigens i.e. proteins that are expressed 
in a sample. Under the microscope, not only the location of the labelled proteins can 
be detected i.e. cytoplasmic, membrane bound or both, but at the same time the 
physical structure of the cells can be observed for example the cell membrane, 
cytoplasm content and nucleus size for a rough estimation of the cells state and 
condition. To investigate the expression of these proteins located in HPMEC cells in 
the presence or absence of treatments, cells were pre-incubated with SCFAs and 
stimulated with high glucose overnight. Images were acquired by using Nikon A1 
confocal microscope and further details on the procedure are available in chapter 2.15 
(figure 5.2.2 – next page). 
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Figure 5.2.2: Protein expression on HMPEC cells with confocal microscopy experimental 
layout. 
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5.2.3 High glucose-induced cellular signalling pathways 
To investigate the relative protein expression in a given sample and the signalling 
pathway that is involved in the interaction between cells and other compounds, 
immunoblotting or western blot is another method that can be used to look into this 
area. In this method, homogenised cell lysates were loaded equally into each well and 
proteins in the samples were separated using voltage power. Smaller protein 
molecules migrate quicker to the end of the gel as compared to the larger protein 
molecules. Proteins were then transfered onto a membrane and probed with 
antibodies against the proteins of interest. The chemiluminescence signal on the 
relative expression of protein of interest was detected using the UVP imaging system. 
A more detailed procedure can be found in chapter 2.16 (figure 5.2.3 – next page). 
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Figure 5.2.3: Protein expression on HPMEC cells with western blot experimental layout. 
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5.3 Results  
5.3.1 Matrigel Cell Viability and Progression on Matrigel with High Glucose and SCFAs 
To physically observe the proliferation process of normal endothelial (capillary 
formation) and to compare it with the effects of high glucose in the presence of SCFAs, 
cells were cultured on Matrigel with all the required basic nutrients and growth 
stimulators. It is well known from the literature that high glucose-induced oxidative 
stress increased cell death and apoptosis as well as decreased cell viability as 
compared to control subjects. On the other hand, reports have also shown the 
beneficial effects of SCFAs such as exerting an anti-inflammatory effect, enhanced 
proliferation and reduced cellular stress level in human studies. However, the role of 
SCFAs and their mechanism underlying high glucose-induced DM setting, at the 
cellular level especially in ECs, are still in the infant state. Therefore, to try and take a 
step closer to understand the beneficial effects that SCFAs have on endothelial 
proliferation processes under high glucose stimulation, HPMEC cells were used. Cells 
were pre-incubated in SCFAs (NaA; 5 mM and NaP; 5 mM) for 1 hour and cells were 
then subjected to high glucose stimulation in the presence of SCFAs for 24 hours. 
There is no doubt that glucose is also another source of energy fuel for the cells 
however, extremely high levels of glucose causes cellular oxidative stress and 
damage and ultimately leads to cell death and apoptosis. In agreement, high glucose 
stimulated ECs have increases in broken capillaries as compared to the control. On 
the other hand, cells pre-incubated with SCFAs are clearly protected against high 
glucose-induced damage and show more capillary formation as compared to the high 
glucose treated group alone (figure 5.3.1 – next page).  
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A. HPMEC capillary formation under high glucose and SCFAs 
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Figure 5.3.1: The effect of high glucose and SCFAs on HPMEC capillaries formation. HPMEC cell 
proliferation and capillary formation progress with high glucose stimulation and in the presence of 
SCFAs. Cells were seeded and pre-incubated with SCFAs on Matrigel before being stimulated with 
high glucose (30 mM) for 24 hours. Capillary formation structure and cell proliferation images were 
taken under an EVOS light microscope (A) and their data analysed (B). Image A consist of capillaries 
images taken in the present of a bright field background (on the right) and in the present of a dark 
background with low light (on the left). Images were analysed with the angiogenesis analyser by ImageJ 
and data was collected with n=3, mean ± SD, *p<0.05 for high glucose versus unstimulated.  
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5.3.2 HPMEC Nitric Oxide Level under High Glucose and SCFAs Incubation. 
To observe the endothelial NO level and its level in pathological conditions, in this 
case in the diabetic state, and also to see the effects of SCFAs on endothelial NO 
production under high glucose conditions, NO level in the supernatant of treated 
HPMEC samples was detected. Exposure of HPMEC cells to hyperglycemia led to a 
reduction in total of NO level in the supernatant by the ECs. Furthermore, cells pre-
incubated with SCFAs and further stimulated by high glucose show a trend of increase 
in NO production by the ECs, compared to the high glucose group. Treatment of cells 
with SCFAs under high glucose treatment shows an improvement in NO production 
as compared to high glucose group only. However, these differences are not 
significant as more samples are needed to increase the significance or other 
alternative method of nitric oxide detection is required to further investigate this area 
(figure 5.3.2). 
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Figure 5.3.2: The effect of high glucose and SCFAs on HPMEC nitrite level. HPMEC cell NO profile 
in the presence of high glucose and SCFAs incubation. Cells were seeded and pre-incubated with 
SCFAs for 1 hour then subject to direct stimulation with high glucose for 24 hours. Prior to trypsin 
treatment, supernatant from all conditions were collected and frozen in -800C for NO profile experiment 
(B). Beforehand, NO standard curve was measured in accordance to manufacturer’s instructions (A). 
NO level was detected on a 96 well plate by the chemiluminescence plate reader. Data was collected 
with n=3 and mean ± SD. 
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5.3.3 Cellular Signalling Mechanisms in ECs under High Glucose–Induced Oxidative 
Stress and the Effects of SCFAs in this Condition.  
Under normal physiological conditions, ECs express low level of Nox2 activity to 
produce sufficient amount of ROS to modulate and maintain normal cells activity. 
Nevertheless, in the presence of positive stimuli such as high level of glucose or lipids, 
especially in the context of T2DM, these stimuli activate and upregulate Nox2 and its 
cytoplasmic proteins activity. On the other hand, it is still unclear about the interaction 
between SCFAs and their receptor effects on the regulation of downstream cellular 
signalling. Moreover, high glucose stimulation significantly increased NADPH oxidase 
2 (Nox2) expression in ECs as compared to control. However, cells pre-incubated to 
NaA show reduced Nox2 expression as compared to high glucose stimulated cells. 
Nevertheless, GPCR43 receptor expression was slightly increased with glucose and 
a further increase was seen in cells incubated with NaA. At the same time, high 
glucose stimulated cells in the presence or absence of NaA show a possible co-
localisation between Nox2 and GPCR43 protein in this setting  (figure 5.3.3 – next 
page).  
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Figure 5.3.3: The effect of high glucose and SCFAs on HPMEC Nox2 and GPCR43 protein 
expression. Protein expression on HPMEC cells in the presence or absence of SCFAs under high 
glucose stimulation. Cells were seeded on coverslips until confluent and pre-incubated with NaA 5 mM 
for 1 hour and subsequent exposed to high glucose 30 mM stimulation for 24 hours with different 
conditions; control (A), high glucose (B), NaA (C) and high glucose in the presence of NaA (D). Cells 
images were observed with transmitted image filter (1), Nox2; cyanin-3 filter; Cy3, Red (2), GPCR43; 
fluorescein isothiocyanate filter; FITC, green (3), DAPI; blue and merged images (4). Images were 
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analysed with Nikon confocal acquisition software and data was collected with n=3, mean ± SD, *p<0.05 
for high glucose versus unstimulated.  
 
5.3.4 Protein expression under high glucose-induced oxidative stress in the presence 
or absence of SCFAs. 
To investigate the effects that stimulation have on cell signalling pathways implicated 
in areas such as NADPH oxidase 2 (Nox2)-induced oxidative stress and cell 
proliferation pathways such as cell cycle, apoptosis and cell viability, the initial step 
was to look at the proteins that are essentially committed to these pathways. HPMEC 
cells were pre-incubated with SCFAs for 1 hour and cells were then subject to high 
glucose stimulation for 24 hours in the presence or absence of SCFAs. After 24 hours, 
cells stimulated with high glucose showed a significant increase in Nox2 protein 
expression and the expression was significantly reduced in the presence of NaA 
(figure 5.3.3a – A). In diabetic setting, the major complication seen in the vasculature 
was endothelial dysfunction caused by various factors and one of the damages was 
caused by Nox2-induced oxidative stress. Nox2 enzyme activity was found to be 
upregulated and reduction of NO bioavailability by the ECs were commonly seen in 
the literature. Moreover, apoptosis, cell cycle arrest and reduced cell viability upon 
high glucose stimulation on ECs were also common in the findings. P47phox is an 
essential cytoplasmic subunit of Nox2 and it is important for the activation and 
functional work of Nox2 to produce ROS. Under high glucose stimulation P47phox 
expression was significantly upregulated and this expression was reduced in the 
presence of NaA (figure 5.3.3a – B). Furthermore, the SCFAs receptor, GPCR43, 
expression was slightly upregulated in the presence of high glucose. However, in the 
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presence of NaA, GPCR43 protein expression was significantly increased even in the 
presence of high glucose (figure 5.3.3a – C). Although Nox2 and p47phox expression 
were reduced in the presence of NaA, it was found that GPCR43 activation was slightly 
increased with high glucose, on the other hand NaA significantly increased GPCR43 
receptor protein expression. The relation of glucose and GPCR43 receptor is still 
unclear as to how high glucose is upregulating GPCR43 receptor activity. It was 
hypothesised that there was a direct effect of high glucose on GPCR43 receptor 
activation other than through SCFAs activation.  
  
Next, to understand the cell proliferation process in areas such as cell cycle 
progression, cell cycle inhibition and cell proliferation state, cyclins, cyclin dependent 
kinase inhibitor and p53 level were assessed. Cyclins (D; G0/G1 phase, E; G1/S 
phase, A; S/G2 phase and B; G2/M phase) are proteins that are essential in driving 
the cell cycle progression from the early phase to completion in proliferating cells. 
Under the hyperglycemic state, cyclin D was highly expressed as compared to control 
and in the presence of NaA, cyclin D was significantly reduced as compared to high 
glucose stimulated samples (5.3.3b – A). Cyclin E and A were significantly increased 
with high glucose and NaA alone however the combination of high glucose and NaA 
showed a reduction in the expression (figure 5.3.3b – B and C). High glucose and in 
the presence of NaA significantly increased cyclin B expression in comparison to the 
control (figure 5.3.3b – D).  On the other hand, cell cycle arrest occurs when there are 
inhibitory molecules present during the cell cycle process. These molecules such as 
p16INK4a (G0/G1 phase), p21Cip1 (G1 phase), p27Kip1 (S phase) or ultimately p53 can 
inhibit the progression if presence during cell cycle process. In diabetes setting, cells 
were chronically exposed to elevated level of oxidative stress caused by the high level 
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of glucose in the vasculature. Here, p16INK4a expression was significantly increased 
under high glucose stimulation and in the presence of NaA alone. However, the 
expression was reduced in the presence of both high glucose and NaA both (figure 
5.3.3b – F). Chronic exposure to excess level of oxidative stress can cause damage 
to the cell’s DNA as well as conformational and structural changes in proteins and 
oxidation of cytoplasmic contents. Cells will then try to undergo cell cycle progression 
to make repairs. However, the elevated expression of p53 caused cells to be in a state 
of permanent cell cycle arrest or cell death when damage is beyond repair. In 
agreement, under high glucose stimulated cells, p53 expression was significantly 
upregulated as compared to control and the expression was significantly reduced with 
NaA present (figure 5.3.3b – G).  
 
On the other hand, another marker to look at indicative of the progression of cell 
proliferation is proliferating cell nuclear antigen (PCNA). This accessory protein is 
essential for DNA replication that leads to increase in the process of DNA strand 
synthesis. The expression of PCNA under high glucose stimulation and NaA were 
significantly higher as compared to control (figure 5.3.3.b – E).  
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Figure 5.3.3a: The effect of high glucose and SCFAs on NADPH oxidase-2 (Nox2), p47phox, SCFAs 
receptor and GPCR43 protein expression. Protein expression in ECs under high glucose-induced 
oxidative stress for intracellular and membrane bound makers for NADPH oxidase-2 enzyme (A) and 
its crucial cytosolic subunit p47phox (B) and SCFAs receptor; GPCR43 (C) with their respective 
representative image of protein expression. Homogenates from HPMEC cells were pre-incubated with 
SCFAs; NaA (5 mM) for 1 hour and subsequent stimulation with high glucose (30 mM) for 24 hours. 
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Protein expression was detected by immuno – blotting. Data was collected and analysed by UVP 
analysing system with n=3-4, mean ± SD, *p<0.05 for high glucose versus unstimulated. 
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Figure 5.3.3b: The effect of high glucose and SCFAs on cell cycle regulation protein expression. 
Protein expression in ECs under high glucose-induced oxidative stress for intracellular proteins that 
occur during cell cycle progression; cyclin D in G1 phase (A), cyclin E between G1 to S phase (B), cyclin 
A between S to G2 phase (C), and cyclin B between M to G1 phase (D). Subsequently, other 
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intracellular markers for cell proliferation such as PCNA (E) and inhibitors for cell cycle progression 
such as p16 (F) and p53 (G) were looked at with their representative images of protein expression 
respectively. Homogenates from HPMEC cells were pre-incubated with SCFAs; NaA (5 mM) for 1 hour 
and subsequent stimulation with high glucose (30 mM) for 24 hours. Protein expression was detected 
by immuno – blotting. Data was collected and analysed by UVP analysing system with n=3-8, mean ± 
SD, *p<0.05 for high glucose versus unstimulated. 
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5.4 Discussion  
For the first time it is reported that ECs treated with SCFAs at the physiological level 
exert a protective effect on the tube or capillary like structure formation on the 
basement membrane matrix (Matrigel) in the presence of high glucose stimulation. 
Hyperglycemia stimulation has shown significant inhibition of activity in endothelial cell 
proliferation and angiogenesis in vitro. Previous study has shown derangement in tube 
formation with ECs exposed to high glucose mimicking a diabetic model in vitro (Yin 
et al., 2012). Another study from Ingram et al. found that under hyperglycemia and a 
diabetic intrauterine environment reduced clonogenic endothelial cell colony formation 
was seen, suggesting that this cellular phenotype was linked to premature 
senescence, reduced proliferation and impaired tube-forming ability (Ingram et al., 
2008).  
 
On the other hand, other than being the preferred source of energy, SCFAs also 
provide a general trophic effect such as improving regional blood flow, accelerating 
wound healing, modulation of epithelial cells proliferation and differentiation as well as 
development and homeostasis of the immune system especially in the gut (Cook and 
Sellin, 1998). Moreover, SCFAs have been found to have beneficial effects on cells 
such as neutrophils, macrophages and especially for the epithelium cells in the gut. 
Another finding from Frankel WL et al. found that all three SCFAs stimulate and 
modulate colonic epithelial cell proliferation and differentiation in the large and small 
colon in vivo (Frankel et al., 1994). All three SCFAs with its functions are important in 
host physiology. Colonic epithelial cells prefer butyrate over the other two major 
SCFAs (acetate and propionate) as an energy source and consume almost all of it. 
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Whereas, propionate and acetate migrate into the portal blood and the liver 
metabolises propionate and acetate will get metabolised by the peripheral tissues in 
particular smooth muscle cells (Cummings et al., 1987, Cummings and Englyst, 1987). 
The SCFAs, acetate and propionate, have been thought to have a role in glucose 
metabolism. Research from Brighenti et al. found that five healthy individual had 
reduced glucose response by 31.4% after exposure to 6 meals consisting of acetate 
orally. The results suggest that oral acetate and acetic acid from vinegar is sufficient 
to influence glycemic index significantly and the mechanism is related to acidity but 
not gastric emptying (Brighenti et al., 1995). Propionate on the other hand was found 
to be a cholesterol lowering agent and is a gluconeogenic in animal models. In a study 
by Venter CS et al. which investigated the effects of propionate on metabolism in 
humans, they found that propionate increased HDLC and triglyceride level, decreased 
serum fasting glucose level and increased insulin response during a glucose tolerance 
test in 10 healthy female individuals. The results suggest the beneficial effects are 
partially mediated through the effects of propionate on hepatic carbohydrate 
metabolism (Venter et al., 1990). At the cellular level, Siennicka A. found that the 
SCFAs butyrate and propionate have been found to suppress expression of VCAM-1 
and ICAM-1 through inhibition of NF-κβ activation on ox-LDL stimulated ECs. These 
data suggest the important implication that SCFAs have on inflammation as they have 
an anti-inflammatory and anti-atherogenic properties that partially are due to the 
inhibition of NF-κβ activation (Siennicka, 2005). Another previous study from James 
M H. et al found that from the lack of luminal SCFAs as the preferred metabolic 
substrates of colonic epithelium cells leads to the progression of an inflammatory state 
of the colon as seen in diseases such as colitis and inflammatory bowel disease (Harig 
et al., 1989).  
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In the present study, NADPH oxidase containing both Nox2 and p47phox subunit is 
expressed in ECs and contributes significantly to vascular ROS generation in 
response to its positive stimulation. In the present study, the protective effect of SCFAs 
on endothelial cell proliferation and repair under the damage by high glucose-induced 
oxidative stress stimulation is shown. However, the cellular signalling mechanisms on 
how SCFAs have a beneficial effect on diabetic setting is still unknown. That leads to 
the next finding where it was found that under high glucose-induced oxidative stress, 
Nox2 and p47phox levels and activity were significantly upregulated in ECs. These data 
suggest that Nox2 and its subunits are responsible for the production of excess ROS 
in ECs under pathological conditions such as in a diabetes setting. Moreover, data 
from Kumar et al. found that Nox2 and Rac1 activities in the production of ROS were 
significantly upregulated and they found that the excess ROS production by Nox2 
accelerates the damaging effects on mitochondrial homeostasis under high glucose 
and lipid levels in retinal ECs (Kumar et al., 2015). The same finding was found by 
Zhao et al. on HUVEC cells (Zhao et al., 2008). It was also found in this work that there 
is a decrease in ROS production with SCFAs and high glucose stimulation on HPMEC 
cells. This may be due to the effect of SCFAs that are able to decrease p47phox 
phosphorylation in neutrophils thus decreasing the activation of Nox2 and the level of 
ROS production in ECs (Vinolo et al., 2009). On the other hand, elevated level of 
endothelium derived ROS production is often linked to impair and reduced endothelial 
dysfunction–NO dependent–mediated relaxation which is also known as endothelial 
dysfunction which was frequently seen in both cellular and experimental models of 
diabetes and IR (Sukumar et al., 2013, Jarajapu et al., 2011, De Mattia et al., 2003, 
Williams et al., 1996). Furthermore, hyperglycemia in T2DM plays a role in the 
decreased level of NO as high glucose inhibits NOS activity (Tessari et al., 2010). 
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Reduced NO level in the supernatant of cells treated with high glucose was found. 
However, the NO level was increased and improved when cells are pre-treated with 
all three SCFAs before high glucose stimulation. From these data, it is suggested that 
high glucose-induced endothelial dysfunction is through the reduction of bioavailability 
of NO by the ECs and SCFAs are protecting against this damage. However, the 
cellular mechanisms underlying this effect are still unknown.  
 
Moreover, to double check or find other alternative ways to further determine and 
detect NO related markers such as nitrite and nitrate (other than using the 
conventional methods of colorimetric; Griess assay and fluorometric assay; 
diaminonaphthalena assay and diaminofluoroscien-2 assay), another more efficient 
method such as high performance liquid chromatography (HPLC) can be used to 
determine the level of these markers in all biological matrices, with high throughput, 
and with ease. By combining the diazo coupling method and HPLC, the system uses 
reverse phase chromatography to separate nitrite from nitrate, while reducing nitrate 
to nitrite at the same time with cadmium and reduced copper inside the reduction 
column. The detected markers will then mix with Griess reagent inline to get the 
classical diazo compound which is detected by a spectrophotometer. In addition, this 
method allows for easy sample preparation, less cross activity, high detection 
sensitivity, no interference from proteins or coloured species and efficiency along with 
high throughput analysis using an auto-sampler. On the other hand, this method has 
its limitation; there are chemicals or reagents that may not be suitable or compatible 
with the separation or reduction column. For example, an agent such as ferricyanide 
used as a nitrite stabilization solution in whole blood samples is not compatible with 
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the reduction column contains the cadmium and other metals and therefore this will 
not effectively reduce nitrite.  
 
In addition, our results shows that there is a significant increase in the cell cycle 
progression from G0/G1, S to G2/M phase through the increase of cyclin D, E, A and 
B protein expression throughout the whole cell cycle process. These data may suggest 
that there is an increase in ECs utilising the glucose as an energy source and this 
leads to increase in cell cycle progression (Pierce et al., 2012). These data are further 
supported by the increased expression of PCNA protein expression under high 
glucose stimulation in ECs. In addition, another study found that increase in SCFAs 
butyrate production was not harmful or toxic for the normal cell regeneration of the 
intestinal damaged mucosa, since they also found that PCNA, a proliferation marker, 
was increased despite the increase in butyrate production in rats (Comalada et al., 
2006). Furthermore, we found the expression of cyclin D, E and A protein were 
significantly reduced in the presence of SCFAs NaA under high glucose stimulation as 
compared to the high glucose sample. However, all cyclin proteins (cyclin D, E, A and 
B) under high glucose and high glucose with NaA presence were elevated as 
compared to the controls. It was hypothesised that NaA was used as an energy source 
for proliferation process in ECs. Moreover, a study shows that butyrate-induced 
papillae growth and subsequent increase in absorption of SCFAs in the ruminal 
epithelium of goats acts through the increase of cyclin D1 transcription (Malhi et al., 
2013). In regard to these increased protein expressions and the relationships at the 
cellular level in ECs the mechanism is still unknown and more experiment need to be 
done in determining the cellular mechanism underlying this effect of SCFAs. 
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In addition, it was also found that cellular senescence and apoptosis related proteins 
such as tumor suppressor protein p53 and cyclin dependent kinase inhibitor (CDKI) 
p16INKa were significantly upregulated under high glucose-induced oxidative stress in 
ECs. Thus, this explained the damage and inhibition of proliferation caused by high 
glucose on tube or capillary formation by ECs on Matrigel where cell proliferation and 
apoptosis were also seen in other experimental methods (figure 4.3.2 and figure 
4.3.3). Moreover, the same findings were found by Maeda et al. where there was a 
significant increase in the level of expression of p53, p16INKa and p21 proteins as well 
as ROS production under high glucose stimulation on ECs (Maeda et al., 2015). The 
same data from another study suggest that these increased expressions are due to 
high glucose induced apoptosis in ECs   are may be through the increased 
phosporylation of p53 and p38 MAPK activation that leads to downstream signalling 
of apoptosis in cardiac myocyte (Fiordaliso et al., 2001, Wiley and Steinle, 2007). 
Furthermore, P53-induced cell death has been suggested to have its independent 
cellular signalling pathway with GPCR43/propionate treatment on colon cancer cells 
by another group (Tang et al., 2011).  However, other research on SCFAs as a cancer 
treatment has shown that downregulation of p16 protein expression in HCT8 colon 
cells was seen with propionate treatment (Tang et al., 2011). This contradicts the 
finding of researchers who suggested that p16 may not be involved in 
GPCR43/propionate-induced colon cancer cell cycle arrest (Tang et al., 2011).  
 
It is worth to mention that in western blot assay, all the protein concentrations were 
measured by using Bradford assay and the data were quantified against α-tubulin 
protein. This method is acceptable and had been widely published however, it is worth 
to add in the future an additional control for protein concentration against a house 
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keeping marker such as α-actin, β-actin or GAPDH for a double conformation of the 
total protein concentration for each condition is another useful marker. Another area 
that must be pointed out is that with western blot assay, it is a conventional detection 
method and if the assay did not follow a proper technique, could have high 
background, unspecific bindings and undetectable protein band. Meanwhile, level of 
protein expressions do not always reflect the activity levels in cell cycle progression. 
Thus, other alternative methods should be used to double confirm these results for 
example in this case is about the cell cycle progression protein markers. The cell cycle 
progression is driven by CDK/cyclin complexes. The activity of these complexes is 
regulated by inhibitory phosphorylations of threonine and tyrosine residue on CDK 
subunit. Cdc25 phosphatase proteins (Cdc25A, B and C) dephosphorylate these sites 
leading to activation of the kinase (Richon et al., 2000). Alternatively, other method 
such as threonine/serine/tyrosine phosphatase activity assay looking at 
dephosphorylating and activation of phosphatases. For example cdc25 
phosphorylation activates cyclin B-CDK1 complex in G2 phase where this activity is 
directly link by phosphorylation of mitotic cells. Phosphorylation of cdc25 cause 
cyclinB-CDK1 increases its catalytic activity and promote cells to enter into M phase 
(Hoffmann et al., 1993). Thus, this is a good way to investigate and add up data to see 
the real picture in the cell cycle signalling pathway. 
 
Nonetheless, more data are needed to justify the process underlying this effect that 
SCFAs and NaA have on normal ECs as the research uses different types of SCFAs 
and different compounds of SCFAs have different effects on cell proliferation at the 
cellular level and may effect protein expression differently. 
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Chapter 6: General Discussion, Potential Treatment Strategies and Future Work 
 
6.1 General Discussion   
Diabetes has been known as the ‘common’ risk factor for the progression of 
cardiovascular diseases especially the acceleration and worsening of 
atherothrombosis progression through the increase of ROS production in the 
endothelium (Yung et al., 2006). Over 170 million people were diagnosed for diabetes 
and it is responsible for 80% of deaths in diabetic patients from mainly coronary heart 
disease and ischemic stroke. Additionally, this metabolic disease also affects 8% of 
the total population and is expected to increase about 50 to 70% within the next 25 
years (Coccheri, 2007). Oxidative- and reductive- stress, depletion in NO production, 
high glucose–induced endothelial inflammation and insulin or insulin receptor defects 
are the most ‘unique’ characteristics of diabetes and are directly related to the 
metabolic derangement of the disease (Coccheri, 2007). Moreover, investigators 
found that in the T2DM setting, other than hyperglycemia as its marked characteristic 
feature, there were other factors such as IR, oxidative stress and increase in 
inflammation level shown to be associated with the progression of β-cell dysfunction 
and mass (Puddu et al., 2014). Oxidative stress arises from an imbalance between 
the production of ROS and nitrogen species (RNS) and the lack of efficiency of the 
body to remove reactive intermediates and ROS production that comes from various 
sources including NADPH oxidase enzymes, the mitochondrial respiratory chain, 
xanthine oxidase, enzymatic activation of cytochrome p450 and uncoupled NO 
synthase which involves a complex array of cellular processes (Bae et al., 2011). 
Moreover, ROS was initially found in non-phagocytic cells and it is used as a defence 
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mechanism to defeat against host infection (Li and Shah, 2003). However, phagocytic 
ROS production is not just implicated in host defence against infection, it is also linked 
to areas that are related to cardiovascular disease progression such as in the 
development of atherosclerotic plaque (Bae et al., 2009). The results of this thesis are 
in agreement with others where we found an increase in NADPH oxidase-induced 
overproduction of ROS in ECs under high glucose stimulation (figure 3.3.3 and 3.3.7) 
where various other stimuli other than high glucose are able to upregulate ROS 
production. This includes lipids, shear stress, radiation, inflammatory cytokines, 
activation of the renin-angiotensin-aldosterone system and ischemia-reperfusion 
which all able to activate endothelium-derived NADPH oxidase ROS production in the 
vasculature, in particular the Nox2 subunit (Dworakowski et al., 2008, Menden et al., 
2015). In regard of the increase of ROS generation, various cellular signalling proteins 
including NF-κβ, PI3-K, MAPK and P53 show their respective cellular role by either 
going down the cell survival and differentiation route or the apoptosis and cell death 
signalling pathways (Bae et al., 2011).  
 
Nonetheless, ROS is the by-product of aerobic respiration and its over production has 
a detrimental effect on biomolecules including damaging DNA, protein, carbohydrates 
and lipids (Bae et al., 2011, Li and Shah, 2003). The increase in ROS production by 
the endothelial-derived NADPH oxidase enzyme in particular Nox2 under high glucose 
setting has been associated to the decrease in tissue bioavailability of NO through a 
radical reaction that reacts more quickly than the reaction of superoxide with 
superoxide dismutase (SOD) (Kolluru et al., 2012). Overproduction of ROS causes 
oxidative stress that further enhances and facilitates β-cells destruction in the 
pancreas. β-cell have a low level of glutathione peroxidase, superoxide dismutase and 
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catalase activity as an antioxidant defence system (Lenzen et al., 1996). Together with 
high glucose and excess production of ROS, this leads to the further detrimental effect 
of β-cell destruction on T2DM patients such as abnormal insulin production and / or 
cells are resistance to insulin actions that further worsen diabetic linked complications 
(Kolluru et al., 2012). Moreover, under hyperglycemia state NADPH oxidase activity 
and expression are significantly increased in diabetic tissue. Furthermore, 
upregulation of NADPH oxidase Nox2 activity has a linear relationship with increases 
in ROS and VEGF level and the breakdown of the blood retinal barrier during diabetic 
retinopathy (Al-Shabrawey et al., 2008). However, there were no significant cellular 
morphological changes under the light microscope observation between control and 
cells under the high glucose stimulation (figure 3.3.6). The data suggest that the 
abnormal cellular barrier that occurs between cells are marked by the upregulation of 
various cellular adhesion molecules such as VCAM–1, E–selectin and ICAM–1 (Piconi 
et al., 2004). Furthermore, a study from Qualigaro et al. found that high glucose (20 
mM) stimulates overproduction of ROS through activation of NADPH oxidase through 
PKC downstream signalling that leads to increase of cellular apoptosis in HUVEC 
(Quagliaro et al., 2003). Likewise, we found that high glucose significantly increases 
ECs apoptosis and reduced cell viability with a linear relationship to overproduction of 
ROS (figure 4.3.2 and 4.3.3). Additionally, a study from Balteau et al. found that long 
term exposure of rat cardiomyocytes to high glucose induces cell death through the 
increase of ROS production. Moreover, they found Rac1 activates Nox2 and 
translocation of p47phox to the plasma membrane by high glucose. This finding is in 
accordance with our data where we found both Nox2 and p47phox expression were 
upregulated in the presence of high glucose stimulation. Furthermore, Nox2 was 
involved in glucotoxicity under high glucose-induced ROS production. This effect was 
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blocked and confirmed by the use of gp91ds-tat peptide, a specific Nox2 inhibitor, 
which stops high glucose-induced ROS production and prevents glucotoxicity (Balteau 
et al., 2011). These data expressed the importance role of Nox2 under high glucose-
induced metabolic disorder. 
 
Lately, there is a lot of interest in looking at an alternative treatment derived from 
natural products from whole food products such as wheat bran, oat bran, pectin and 
others including plants, flowers, fruits and seeds which have been used to lowering 
glucose level and improve other metabolic disorder-linked complications in animal 
models and human trial studies (Smith and Clinard, 2014, Behall et al., 2006, Qiu et 
al., 2008, Wang et al., 2007). Most of these whole food products, plants, fruits, flowers 
and seeds have in common is the high level of fiber content within them. Thus, fiber 
has been put forward as another major area of interest to search for its potential 
application to treat metabolic disorder related diseases. Most natural food products 
contain fiber and usually it is grouped based on its solubility in water, viscosity, gel–
forming ability and its fermentation rate by the normal flora in the gut. Nonetheless, all 
natural food consists of both soluble and insoluble dietary fiber in variable amounts 
(Weickert and Pfeiffer, 2008). An interesting study by Schulze et al. found that 
increased intake of cereal dietary fiber significantly reduced diabetes risk in most of 
their human studies (Schulze et al., 2007). Similarly, De Munter and colleagues found 
that serving whole grain for two–servings–per–day leads to a 21% reduction in the risk 
of developing type 2 diabetes (de Munter et al., 2007). Meanwhile, Weickert MO et al. 
found that consumption of highly purified insoluble dietary fiber accelerated the acute 
GIP and insulin response and further associated with enhanced postprandial 
carbohydrate management on the following day after consuming a control meal in 
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fourteen women (Weickert et al., 2005). Furthermore, a study by Robertson et al. 
looking at the effects that acute changes of insoluble fiber content in a diet have on 
lipid and carbohydrate handling, found that prior consumption of high–dose resistance 
starch led to a lower postprandial glucose and insulin level in the serum with an 
increase in insulin sensitivity in ten healthy subjects (Robertson et al., 2003). Another 
study conducted by Samra and Anderson found that after insoluble fiber ingestion 
appetite was suppressed, postprandial blood glucose was lower than subjects on 
white bread and low fiber cereal. It was also found that high fiber increased the fullness 
and prevented increase of the blood glucose after a meal in 31 subjects with 2 
separated experiments (Samra and Anderson, 2007). Most of these results show the 
benefits of high fiber diet especially from cereal fiber in most of the human studies. 
However, the mechanisms underlying these effects are still unclear and more tests at 
the cellular level are needed to get a clearer idea on how fiber interacts with the cells, 
tissues and organs in the human body that leads to reducing metabolic disorder and 
its associated complications. Giardina and Inan investigated the effect that SCFAs 
have on cell viability and they found that propionate and butyrate but not acetate are 
able to induce apoptosis in HT-29 colon cells (Giardina and Inan, 1998). In agreement, 
our result show that acetate did not cause significant cell death and reduced cell 
viability however, there was a decreasing trend from acetate, propionate and butyrate 
in the potency to cause cell death in HPMEC cells (figure 4.3.2). Additionally, we also 
found that the presence of acetate protected ECs from high glucose–induced capillary 
damage and apoptosis (figure 5.3.1 and 4.3.2). However, the increasing trend of 
reduced cell viability or increase in cells apoptosis from acetate > propionate > 
butyrate (figure 4.3.2) has been suggested becuase SCFAs and in particular butyrate 
causes cell cycle arrest in HT-29 cells at G1 phase and induced apoptosis by blocking 
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of Bcl-2 protein (Siavoshian et al., 1997, Mandal et al., 1997). This is due to its ability 
to inhibit histone deacetylase (HDAC) and causes transformed cell growth arrest, 
inhibition of angiogenesis and cell death. However, it is dependent on its concentration 
and time of exposure to the histone inhibitors as well as the molecular structure of the 
particular cell (Marks, 2010).  
 
Recently, another interesting piece of research looking at the effect of SCFAs on cystic 
fibrosis airway inflammation and bacterial growth by Ghorbani et al. found that 25 – 50 
mM of SCFAs reduce NO production and nitric oxide synthase (NOS) expression in 
epithelial cells of the airways. However, at a lower concentration, 0.5 – 2.5 mM, SCFAs 
stimulate the release of interleukin 6 (IL-6) and interleukin 8 (IL-8), and granulocyte 
macrophage colony-stimulating factor and granulocyte colony-stimulating factor in 
cystic fibrosis-induced inflammatory epithelial cells. This suggested that SCFAs may 
play an essential role contributing to cystic fibrosis-specific alterations in response to 
airway infection and inflammation (Ghorbani et al., 2015). Furthermore, SCFAs have 
been found to be able to regulate inflammatory cytokine expression and neutrophils 
function in the presence of inflammatory stimuli (Voltolini et al., 2012). In this thesis, it 
was found that SCFAs given in dose of between 4–5 mM have an increased trend on 
NO production under high glucose-induced oxidative stress condition in human 
pulmonary microvascular ECs (HPMEC) (figure 5.3.2). These data may suggest that 
SCFAs at a low concentration may improve NO production under stress setting. 
However, the results showed a decrease in NO production in cells stimulated with high 
glucose but is it not significant as compared to the control and more experiments are 
needed to justify these data. Nevertheless, the clear mechanism behind this needs to 
be investigated further. In addition, Cummings et al. found that the average level of 
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SCFA in the circulation were 375 µmol/L in portal blood, 140 µmol/L in hepatic vein 
blood and 79 µmol/L in peripheral venous blood (Cummings et al., 1987). Plus, acetate 
is particularly interesting as a significant amount of it enters the systemic circulation 
and reaches the peripheral tissues. The level of plasma SCFAs was found to be 
dominated by acetate as compared to other major by-products of fiber fermentation 
(Quagliaro et al., 2003). Nonetheless, the exact levels of SCFAs in gut microcirculation 
are still unknown. However, depending on their potency to modulate adhesion 
molecule gene expression in the cell nucleus however, it was hypothesised that 
concentrations between 1 to 5 mM are able to increase the adhesion molecules protein 
expression in ECs (Miller et al., 2005). However, LPS-induced ICAM-1 mRNA 
expression in amnion explant was significantly reduced after 8 hours of treatment with 
sodium acetate (Voltolini et al., 2012). In a study by Steven and his colleagues on 
tissue injury in inflammatory bowel diseases it was found that SCFAs at their 
physiological relevant concentration modulate cells adhesion molecules gene 
expression in HUVEC. Butyrate at 2.5 mM to 5 mM was found to significantly increase 
expression of ICAM-1 protein and at its mRNA level, and at 5 mM, butyrate significantly 
increased E-select expression level in ECs (Miller et al., 2005). On the other hand, 
SCFAs have been shown to have an anti-inflammatory effect on tissues and organs 
involved in immune responses (Voltolini et al., 2012). There have been some 
contradiction in the data found by researchers. It is suggested that this discrepancy 
may be due to the differences in the cell type used, concentrations employed and 
methodological approach. However, it is convincing that SCFAs and GPCR43 receptor 
are involved in metabolic homeostasis in cells and organs related to metabolic 
disorders.   
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SCFAs is a by-product of fiber fermentation of macrofibrous material by the bacteria 
in the gut that is positively linked to improving the metabolic defects of type 2 diabetes. 
It is well known that decreasing glucose level in the serum, improves the inflammation 
state and IR as well as elevates protective Glucagon-like peptide-1 (GLP-1) secretion 
in the small intestine (Puddu et al., 2014). Also, frequent reports have shown there is 
low grade inflammation with increased level of cytokines such as interleukin 6 (IL-6), 
interleukin 1 (IL-1) and tumor necrosis factor-α (TNF-α) in metabolic disorder such as 
DM and obesity (Zhang et al., 2003, Rajamani and Jialal, 2014, Touati et al., 2015). In 
metabolic disorders, mainly in IR setting, excess lipolysis often occurs and this causes 
an increase of FFA in the circulation. This has become a huge problem to counteract 
because the liver is able to produce cholesterol independently. However, researches 
have shown that oral acetate administration is able to decrease FFA level in the blood 
(Crouse et al., 1968). Another research found that acetate has been shown to increase 
cholesterol synthesis where propionate shown to inhibit cholesterol synthesis. It is 
important to know the ratio of acetate to propionate has been as it may potentially 
reduce serum lipids and possibly CVDs (Wong et al., 2006). Recently, Kimura et al. 
has suggested the activation of the GPCR43 receptor by SCFAs may inhibit lipid 
accumulation and suppress insulin signalling in adipocytes at the same time promoting 
metabolism without incorporating lipids and glucose in peripheral tissues (Kimura et 
al., 2013). This may also suggest that the activation of GPCR43 receptor through 
SCFAs from fiber fermentation by the colonic microbiota may correct metabolic defects 
and increase metabolism efficiently that prevents the progression of metabolic related 
diseases (Watterson et al., 2014). Also, the GPCR43 receptor protein has been found 
to be expressed in immune cells and vascular endothelium in the myometrium and 
epithelium of fetal membranes (Voltolini et al., 2012). Thus, the blood circulating 
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SCFAs have a high potential to interact with its receptor expressed in these cells and 
cause the effects seen in most published research. Besides, changes in the microbiota 
profile in the gut and the composition of SCFAs have also been hypothesised to have 
a direct link to the development of T2DM, IR and obesity (Puddu et al., 2014). In 
addition, another study found that acetate inhibited basal lipolysis in the basal 
epididymal adipocytes in wild-type mice but this effect is absent in GPCR43 knockout 
mice (Zaibi et al., 2010). Also, the elevation of the butyrate level of SCFAs have been 
found to induce suppressive effect on weight gain and IR on high fat diet-fed and obese 
animals (Yadav et al., 2013). Besides, SCFAs-mediated GPCR43 activation has been 
found to suppress insulin signalling in adipose tissue thus leading to inhibition of fat 
accumulation in fat tissue (Ichimura et al., 2014). Furthermore, Laurent C et al. found 
that the SCFAs acetate and propionate decreased circulating fasting plasma free fatty 
acids in healthy volunteers (Laurent et al., 1995). Also, GPCR43 has been found to 
stimulate suppression of fat accumulation in adipose tissue and promote GLP-1 
secretion in the colon and improve IR. These data suggested that GPCR43 regulates 
adipose tissue insulin signalling by sensing the level of SCFAs from the fermentation 
of fiber from the gut normal flora to regulate fat accumulation and maintain body energy 
and metabolism (Ichimura et al., 2014). Additionally, GPCR43 receptor knockout 
exerts exacerbated and unresolved inflammation in colitis, arthritis and asthma 
subjects even after treatment with SCFAs (Voltolini et al., 2012). Thus, from all these 
data, GPCR43 through SCFAs-induced activation have been thought to regulate 
energy metabolism and inflammation processes as GPCR43 is expressed in both 
metabolic and immune cells (Ichimura et al., 2014).   
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By now, it is well known that ROS is an important cell signalling mediator and has the 
ability to modulate various cellular processes. A fully functional NADPH oxidase 
enzyme consists of multiple subunits that leads to the production of ROS. Significantly, 
ROS is especially important in areas involved in important processes such as cell cycle 
progression that leads to either apoptosis or proliferation / angiogenesis. Lately, low 
fiber is also associated with another metabolic disorder known as obesity where it is 
also linked to factors such as reduced physical activity and excess energy intake 
similar to those for T2DM. Most importantly, DM which is often associated with IR and 
is often linked to diet-induced obesity is commonly involved with an altered endothelial 
cell phenotype and overproduction of ROS that commonly results in endothelial 
dysfunction that further worsens diabetic-linked complications. In metabolic diseases 
such as T2DM and diet-induced obesity it is often reported that free fatty acids in the 
plasma level are frequently increased.  Further resulting in IR and excess lipid 
accumulation or deposition. Recently, there has been a reasonable amount of 
research looking at the connection between ROS on cell growth and proliferation in 
the literature. However, the link between SCFAs on NADPH oxidase-induced cellular 
stress, tissue repair, angiogenesis, growth and proliferation under high glucose 
stimulation mimicking type 2 diabetes is still far from clear. Thus, it is urgent to 
elucidate effective therapeutic targets and intervention strategies to treat metabolic 
disorder-linked complications. 
 
Our current results show high glucose induced detrimental effects on the endothelium 
cells including increased NADPH oxidase–dependent ROS production, cell cycle 
arrest and proliferation deficiency with reduced cell viability and increased apoptosis 
on cells. However, for the first time this thesis shows that by pre–incubating cells with 
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SCFAs under high glucose stimulation, these effects are seen to reverse with reduced 
intracellular NADPH oxidase–dependent ROS production, improved cell proliferation 
ability and the maintenance of cell viability, NO level and degree of apoptosis back to 
basal level. Nevertheless, most results from researchers have only shown the multiple 
benefit of SCFAs in improving serum glycemic index, insulin sensitivity and reducing 
inflammation in human and animal models but not at the cellular level. Even though 
the actual mechanism underlying these positive effects of SCFAs on high glucose 
detrimental consequences is still unclear, further study is needed in the future to 
isolate the key downstream mechanisms for various benefits of SCFAs for the 
treatment of metabolic diseases. In short, SCFAs and their receptor, GPCR43, have 
potential therapeutic value for the treatment of diabetes-linked metabolic disorders.  
 
Researches has been trying to find the best way to make full use of SCFAs and their 
receptors (GPCR41/ GPCR43) as targets for treating diseases associated with 
inflammation, cancer, metabolic disorders and reducing cardiovascular disease 
events. However, questions such as safety of the drugs, interaction between drugs 
and the long term side effects are still unclear as most studies are under short periods 
of time. The bioactive molecules of short chain fatty acids have the potential as 
therapeutic a gents in chemotherapy for cancer patients. Nevertheless, because of the 
number of carbon chains they possess, they are able to induce cell death through 
apoptosis in a range of cancer cells, careful thought and effort must be laid out on 
aspects such as; the concentration, the potency they have to cause cell death, type of 
SCFAs to be used (or in combination between the 3 SCFAs) and the length of 
exposure to SCFAs on the subjects, to make SCFAs a therapeutic agent for targeting 
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metabolic diseases. Furthermore, their properties are able to cause cell cycle arrest 
and activation of pro-apoptotic genes in cells (Fauser et al., 2011).  
 
Last but not the least, there are some limitations in the methods in this project. It is 
worth noting that all methods come with some limitations and disadvantages. For 
example, in the method lucigenin-enhanced chemiluminescence for ROS detection, 
the lucigenin compound itself able to self-generate O2.- through oxidation with the 
oxygen (O2) in the air around it that leads to overestimation of the total O2.- generated 
in the sample (Lee et al., 2012, Dikalov et al., 2007). Thus, this gives rise to questions 
as to how sensitive is this assay? Also, how much is the right concentration to 
represent the normal basal signal for ROS in normal cells? Therefore, to tackle these 
problems, an alternative method was used such as the DHE fluorescence for the 
detection of intracellular ROS. However, this method comes with different issues such 
as sensitivity and the accuracy of this method as O2.- react with DHE generates 
ethidium and 2-hydroxyethidium, whereas the product ethidium was thought to arise 
from various reactions in cells that reflect the total redox status in cells (Lee et al., 
2012, Dikalov et al., 2007). However, due to 2-hydroxyethidium having a different 
molecular weight to DHE and ethidium, there is an alternative method to separate 
these compound and find the true levels of each compound, HPLC can be used to 
separate these compounds and accurately detect and quantify the products that 
represent the total intracellular O2.- generation in cells (Lee et al., 2012, Dikalov et al., 
2007).  
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Within this thesis, indirect immunofluorescence–labelled antibodies was used to 
detect the proteins in endothelial cells such as Nox2 and GPCR43. Other than it can 
provide a glimpses of the location of the proteins of interest, intensity of the protein 
signal as well as if there is any co-localisation between multiple proteins nonetheless, 
issue with this method is the nonspecific background fluorescence signal. This may 
be due to autofluorescence where unstained tissue components is in the same 
wavelength as that fluorescence labels or it may be caused by the nonspecific staining 
of the unbound fluorescein dye that binds to unconjugated serum proteins, together 
with the presence of unwanted conjugated antibodies and overcoupling of 
immunoglobulins (Schenk and Churukian, 1974). To try and get a clearer picture of 
the protein expression levels in cells, immunoblotting was used to double confirm the 
previous method. Western blot is a traditional method commonly used to detect and 
quantify the levels of the protein of interest. A period of time was needed to complete 
this assay (about 3 days to detect a protein of interest). There are multiple steps 
involved in this detection method and unspecific bindings were common when the 
immunoblot membrane did not go through the blocking step properly. Sometimes, 
proteins did not transfer fully on to the membrane caused by the insufficient voltage or 
the presence of some air bubbles or the proteins got trapped by the filaments of the 
gel during loading and thus the protein levels varies and smudged membranes during 
detection. Meanwhile, a compound known as azide often use as an antibody’s 
preservative by the manufacturers can also effect the protein detection by inhibiting 
the enzyme activity (between HRP and its substrate). Additionally, acrylamide is a 
toxic compound which being used as one of the ingredients for the gels. Thus there 
are also safety issue while performing this method. Nonetheless, with proper controls 
all the procedures can be done within safety limits.  
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6.2 Potential Treatment Strategies  
In metabolic diseases such as DM and diet-induced obesity, it is frequently reported 
that these diseases show prominent characteristics such as increased serum glucose 
(hyperglycemia), lipolysis (breakdown of fat cells), circulation free fatty acids (FFAs) 
either by lipolysis or fatty diets, low-grade serum inflammation markers and decreased 
insulin sensitivity, insulin production or both (Lee et al., 2008). There are many 
therapeutic strategies that have been suggested to treat or improve diabetes and its 
complications such as gene therapy, islet transplantation, stem cell therapy, anti-
inflammatory, immunosuppressive and anti-hyperglycemic drugs (Rivera-Mancia et 
al., 2015). 
 
Scientists are still out there looking to find the right treatment that can treat and prevent 
metabolic syndrome with as little side effects as possible. Up to now, there are various 
treatments available to lower glucose concentration in the body on the market that 
target several organs and this includes the liver, pancreas, intestine, hypothalamus in 
the brain and kidney (Inzucchi et al., 2015). Moreover, the drugs available exert 
various advantages and downsides because of the side effects they possess. A 
glucose lowering drug, metformin, is the most common drug used today to treat 
patients with T2DM. Its primary physiological effect is to reduce internal glucose 
production by the liver that leads to reduce glucose secretion into the blood circulation. 
It also increases insulin sensitivity and enhances glucose uptake through the 
phosphorylation of GLUT-enhancer factor as well as increases the oxidation of fatty 
acids and decreases glucose absorption by the gastrointestinal tract (Olokoba et al., 
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2012). Depending on the patients, the correct amount of metformin does not cause 
hypoglycaemia and at the same time it has been shown to reduce cardiovascular 
disease (CVD) events in the UK Perspective Diabetes Study (UKPDS) and it is low in 
cost as one of its advantages (Inzucchi et al., 2015). Another well-known glucose 
lowering agent, insulin, has been divided into several groups such as rapid-acting, 
short-acting, intermediate-acting, basal insulin and premixed (with several types 
together) analogs and the main cellular mechanism of this group is to target and 
activate insulin receptors. The main physiological action is to increase glucose 
disposal in the circulation and reduce hepatic glucose production. The good news is 
that insulin analogs have a universal response and have unlimited efficacy with a 
positive response in reducing microvascular risk in a study. The downside of these 
insulin analogs includes weight gain and hypoglycaemia in diabetic patients. The 
analogs are required to be injected subcutaneously and training is needed before the 
patients can use this safely at home. Often, some of the patients are reluctant to accept 
the treatment and this may vary the outcome of this treatment (Olokoba et al., 2012, 
Inzucchi et al., 2015). 
 
Recently, researchers have suggested a new theory explaining the “Metabolic 
memory” and “legacy effect” that have been use to describe the prolonged benefits of 
good blood glucose control, the former is now recognised as a phenomenon related 
to the prolonged harm produced mainly by hyperglycemia (Aschner and Ruiz, 2012). 
Vascular memory is an extended concept of lipid lowering and antihypertensive 
treatment and even life-style modification and also known as metabolic memory. 
According to this new concept, not only immediate and short-term but long-term effect 
of the metabolic and cardiovascular risk milieu is of great importance. Consequently, 
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early and intensive lifestyle interventions, treatment of hyperglycemia, lipid 
abnormalities and hypertension can result in beneficial effects on cardiovascular 
outcomes even in the long run. On the other hand, failing in target-oriented treatment 
from early detection of abnormalities can be associated with life threatening 
cardiovascular events subsequently(Jermendy, 2012).   
 
Other than that, there is a rapidly growing interest in finding compounds that are 
natural, cheap, abundant and with less side effects while acting as an agonist or 
antagonist to treat and prevent chronic metabolic disorders such as T2DM and diet-
induced obesity as they lead to the progression of cardiovascular diseases in the long 
run. There are many natural products that are plant-derived herbs that have been 
implicated to treat diabetes and plenty of these products mostly in combination have 
been known for lowering blood glucose and complications associated with diabetes. 
Herbal products such as bitter melon, budock, cinnamon, dandelion, fenugreek, 
tumeric ginseng, gymnema, ivy gourd, onion and psyllium have been used in treating 
diabetes. Other food products for example wheat bran, guar gum and pectin are also 
known for their benefits in treating metabolic disorders (Bazzano, 2008, Satija and Hu, 
2012). Most of these natural products are from natural plants, flower, fruit and seeds, 
and most of them have in common, other than their nutritional vitamins and minerals 
value, fiber as their main property (Smith and Clinard, 2014).  
 
A recent report has listed the effects of these natural products in lowering glucose level 
in animal models and human trials. Natural products from plants, flowers and fruits 
including burdock root and its fruit, bitter melon, cinnamon, dandelion, fenugreek, 
169 
 
onion and pysllium per 100g consist of 3.3g, 1.9g, 53g, 3.5, 25g, 1.7g, 88g fiber 
respectively 
(http://ndb.nal.usda.gov/ndb/foods),(http://www.nutritionexpress.com/home+page/top
+nav/health+concerns/tabs/colon/fitness+labs+psyllium+husks+12+ounces.aspx). 
Different fiber contents are found in individual plants, flowers and fruits, fiber 
fermentation from different source yields different molar ratios between the three major 
SCFAs; acetate, propionate and butyrate. For example, fiber sourced from original 
material produces higher butyrate as compared to the other two SCFAs (61:19:20). 
On the other hand, fermentation of stimulated cell wall fraction (combination of 
cellulose, hemicellulose and pectic substances in propotions represented in the cell 
wall) yields higher acetate and propionate but less butyrate production (65:24:11) as 
compared to the results of the original material fermentation. The source of these 
fibers come from corn, oat bran and wheat bran with a total dietary fiber of 64.3g, 
11.1g and 50.4g/100g of dry matter (Bourquin et al., 1992). 
 
Aside from treating metabolic disorder patients with fiber as an alternative idea, the 
only problem that will arise from this is allergy or intolerance to these whole food 
products as well as substances that should be avoided when taken together with these 
foods. For example burdock has varying level of pectin complex (soluble dietary fiber) 
and some patients were found to have an allergy towards pectin and this herb should 
not be given to patients with allergies towards other herbs such as daisies, marigolds 
and chrysanthemums. This herb also has a risk of bleeding in animal studies thus it is 
not wise to administer with an anti-coagulant or an anti-platelet agent (Smith and 
Clinard, 2014).  
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The best strategy is to use fermented fiber by products – SCFAs as an alternative to 
prevent problems such as allergies, intolerance and risk of interaction with other 
medications. Scientists have been trying to develop treatment strategies using SCFAs 
in many ways. For its anti-inflammation property, it has been formulated into enemas 
(acetate; 60 mM, propionate; 30 mM and butyrate; 40 mM) and a study found SCFAs 
accelerated the healing process in patients with chronic radiation proctitis (Pinto et al., 
1999). Another study used SCFAs as a topical treatment of 100 ml enemas (acetate; 
80 mmol/L, propionate; 30 mmol/L, butyrate; 40 mmol/L), twice daily and found 
significant improvements in patients with distal ulcerative colitis (Vernia et al., 1995). 
Moreover, SCFAs have been incorporated and designed in engineering new tissue for 
treating osteoarthritis in cartilage and they were found to stimulate new tissue 
production and reduced inflammation in interleukin 1β (IL-1β) – induced chondrocytes 
(Coburn et al., 2013). Most research has looked into the application of SCFAs in 
cancer and inflammatory bowel diseases and only a few have looked into using SCFAs 
in treating metabolic disorders. More versatile ways should be inventigated into using 
SCFAs from delivering them into experimental subjects (tablet, liquid, powder injection 
and so on), looking at the metabolisms of SCFAs in organs and their impact at the 
cellular level as SCFAs have a very promising future to treat metabolic disorders and 
reduce CDV events. 
 
Recently, researchers have been trying to target SCFAs receptors as another 
treatment strategy for metabolic linked diseases with knock-out (KO) or 
overexpression of SCFAs receptors in animal models. Some found that GPCR43 KO 
mice have reduced glucagon like peptide 1 (GLP-1) and impaired glucose tolerance 
(Ichimura et al., 2014). Others, found GPCR41 KO mice have these effects in mice 
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(Samuel et al., 2008). Some found that GPCR 41 is responsible for energy and 
metabolic homeostasis and others contradicted this and suggested GPCR43 agonist 
as a novel insulin-sensitizing drug for treating type 2 diabetes (Ichimura et al., 2014). 
Although there seems to be a contradiction on which receptors are responsible for 
metabolic control and significant impact in treating metabolic diseases, more 
experimental data is needed to confirm the correct target.  
 
In short, there are no feasible drugs consisting of SCFAs that derive from natural 
products on the market for the treatment and management of metabolic disorders. The 
urgent potential for therapy with SCFAs derived substitutes is needed to reduce the 
incidence of metabolic–induced cardiovascular diseases as the disease rate is 
expanding rapidly every year.  
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6.3 Possible Future Work 
In type 2 diabetes, hyperglycemia, IR, oxidative stress, endothelial dysfunction and 
increased inflammation are the main characteristics that are often associated with the 
progressive deterioration of organs in the body including the pancreas, liver, kidney, 
eye and the blood vessels. This research has discovered the role of SCFAs have on 
high glucose-induced Nox2-derived oxidative stress in ECs under diabetes conditions 
in vitro but this has only really touched on a small area that commonly related between 
oxidative stress, NO level, cell proliferation and apoptosis, cell cycle and angiogenesis 
as well as the SCFAs receptor, GPCR43 in diabetes setting in the vascular ECs.  
 
More work has to be done in this area and the next step will be to further clarify the 
role of SCFAs in the vascular endothelium by investigating the effect that SCFAs have 
on endothelial nitric oxide synthase (eNOS) activity in the ECs as well as using another 
method to find the true value of NO level in the supernatant from the treated cells. This 
is to further support our data that NO level is depleted with high glucose stimulation 
through elevated oxidative in cells that dysregulate the production of NO in ECs. 
Meanwhile, to get a more accurate level of O2.- production level in cells with or without 
high glucose stimulation in the presence or absence of SCFAs treatment, HPLC 
separation method can be used to separate the products of DHE oxidation accurately. 
This is to look at the real value of O2.- signal generated in any pathological conditions. 
 
In addition, to further evaluate the true mechanism of cell cycle progression and its 
activity, other than performing western blot assay and cell cycle analysis with 
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propidium iodide and RNAse A, a phosphatase activity assay can be used to look at 
enzyme that dephosphorylate or activate CDK/cyclin complex such as looking at the 
activity of the cdc25 protein. This is to understand if the activity of these enzyme 
correlate with the western blot results or otherwise. Furthermore, other methods that 
based on colour change as an indicator such as enzyme linked immunosorbent assay 
(ELISA) as well as In-Cell WesternTM by Licor that can detect and quantitatively 
measure in situ protein signal in cells cultured on a microplate. These extra detection 
methods can further support to the data from previous experiments.  
 
To extend this field further, it will be interesting to look at the effects of SCFAs have 
on endothelial cell adhesion molecule markers under high glucose-induced oxidative 
stress such as vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion 
molecule-1 (ICAM-1) and endothelial-leukocyte adhesion molecule-1 (E-selectin). 
Also, whether these SCFAs effect endothelial cellular signalling mechanism and 
downstream pathways as well as insulin receptor and its signalling pathway both in 
diabetes setting. Furthermore, if SCFAs are beneficial against oxidative stress in ECS, 
it would be interesting to investigate whether these natural compounds are a 
scavenger or an inhibitor in reducing ROS in ECs by performing an inhibitory and 
scavenging assay. Besides, it is worth to discover NADPH oxidase 2 (Nox2) related 
subunits (intracellular and membrane bound) expression and the effect that SCFAs 
have under hyperglycemic setting. This may bring a new insight whether SCFAs may 
have the ability to inhibit Nox2 subunits and prevent its activation to generate 
intracellular ROS in ECs. Additionally, it is also interesting to discover the effects of 
subcutaneous SCFAs injection on ROS production in organs in a complete 
metabolically active system through animal models. Lastly, it would be great to view 
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the expression and co-localisation of another SCFAs receptor, GPCR41, on ECs and 
its possible function in ECs. 
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Appendix 
 
Table 2: List of materials and reagents. 
Materials Supplier Catalogue Number 
Acetonitrile (100%) Fisher Scientific A/0626/17 
Acrylamide  Fisher Scientific BPE1410-1 
Ammonium persulphate Sigma Aldrich A9164 
Ampicillin  Fisher Scientific  BPE1760-5 
β-mercaptoethanol Sigma Aldrich M7154 
Bio-Rad Bradford Protein Dye Bio-Rad 500-0006 
BSA Sigma Aldrich A2153 
Calcium Chloride Sigma Aldrich C5670 
DHE Invitrogen  D11347 
DMEM (Normal Glucose) Sigma Aldrich D5546 
DMSO Sigma Aldrich D2650 
DNA loading dye Promega  NA 
DAPI Sigma Aldrich D9542 
ECLPlus reagent GE Healthcare  NA 
EDTA Fisher Scientific  D/0700/53 
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Eppendorf tube (0.5/1.5 ml)   
ECGS Sigma Aldrich E2759 
Ethanol (100%) Fisher Scientific  NA 
FBS Sigma Aldrich F2442 
Gelatin  Sigma Aldrich G1393 
Glycine  Fisher Scientific  G/0800/60 
Hanks’ Buffered Salt Solution Gibco, Thermofisher  14175-137 
Heparin Sigma Aldrich H0135 
L-Glutamine  Sigma Aldrich G3126 
Lucigenin Sigma Aldrich B49203 
M199 medium Sigma Aldrich M4530 
Magnesium chloride  Sigma Aldrich M8266 
Membrane filter (0.22 µm) Milipore  NA 
Methanol  Fisher Scientific  NA 
Mowiol Sigma Aldrich 81381 
NADPH Sigma Aldrich N7785 
Non-fat milk Marvel NA 
PBS Sigma Aldrich P4417 
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Paraformaldehyde Sigma Aldrich P6148 
Protease inhibitor cocktail  Sigma Aldrich P8340 
PVDF Sigma Aldrich P2813 
Propidium iodide Sigma Aldrich P4170 
Protein marker  Lonza 50550 
RNAse A Invitrogen  12091-021 
Sodium chloride  Fisher Scientific  S/3120/65 
Sodium dodecylsulphate Sigma Aldrich 71725 
Sodium fluoride  Sigma Aldrich S7920 
Sodium orthovanadate Sigma Aldrich S6508 
Sodium pyrophosphate  Sigma Aldrich P8010 
Streptomycin/Penicillin (10X) Sigma Aldrich P7539 
TEMED Sigma Aldrich 87689 
Tiron  Sigma Aldrich 89460 
Triton X-100 Sigma Aldrich X100 
Tris-acetate  Sigma Aldrich T8280 
Trypan blue  Sigma Aldrich T8154 
Trypsin-EDTA Sigma Aldrich T3924 
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Tween-20 Fisher Scientific  BPE337 
 
 
 
 
Table 3: List of instruments. 
Instrument  Supplier  Model  
Accuri C6 flow-cytometry BD Bioscience  Accuri C6 
Boi-Rad Mini-protein II Bio-Rad - 
Bio-Rad Semi-dry transfer cell Bio-Rad - 
Biospectrum AC imaging system UVP - 
Centrifuge (bench top) ThermoFisher Pico17 
Cryo-freesing box Nalgene 5100-0001 
Cyclone vortex  Nikel Electrical  CM-1 
Haemocytometer  Neubauer  BrightLight  
Homogeniser  Polytron  PT DA03/2EC 
Laminar Flow tissue culture hood Gelaire  BSB-4A 
Lumistar Galaxy plate reader  BMG LabTech Galaxy 
Microplate reader  PerkinElmer  Victor-3 
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NanoDrop ND-1000 
spectrophotometer 
ThermoFisher  N-1000 
Ultra-sonic processor  Vibra-cell - 
Water bath  Nikel Electrical  Static  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
